Activation of bioluminescence by structural complementation
Bioluminescent complexes formed by non-luminescent peptides and polypeptides address the sensitivity issues in molecular interaction detection, offering improved monitoring of protein-protein interactions and other molecular associations.
Patent Information
- Application Number
- JP2024124929
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-03-15
- Filing Date
- 2024-07-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2034-03-13
AI Technical Summary
Existing methods for detecting molecular interactions under physiological conditions lack the necessary sensitivity and specificity, particularly for protein-protein interactions, due to the low sensitivity of current luminescent probes.
The development of bioluminescent complexes composed of non-luminescent peptides and polypeptides that emit light upon association, utilizing structural complementarity to form a bioluminescent signal, allowing for the detection of molecular interactions through the formation of these complexes.
This approach provides high sensitivity and specificity in detecting molecular interactions, enabling the monitoring of protein-protein interactions and other molecular associations with enhanced detection capabilities.
Smart Images

Figure 2024167207000069 
Figure 2024167207000070 
Figure 2024167207000071
Abstract
Description
[Technical Field]
[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 61 / 791,549, filed March 15, 2013, which is incorporated herein by reference in its entirety.
[0002] (Technical field) Provided herein are compositions and methods for constructing bioluminescent conjugates from two or more non-luminescent (e.g., substantially non-luminescent) peptide and / or polypeptide units, specifically, where bioluminescent activity is conferred to a non-luminescent polypeptide by structural complementarity with another, complementary, non-luminescent peptide. [Background technology]
[0003] Biological processes depend on covalent and non-covalent interactions between molecules, macromolecules, and molecular complexes. To understand such processes and develop techniques and compounds to manipulate them for research, clinical, and other practical applications, it is necessary to have tools to detect and monitor these interactions. In particular, studying these interactions under physiological conditions (e.g., at normal expression levels to monitor protein interactions) requires high sensitivity. Summary of the Invention
[0004] The present invention relates to compositions comprising complementary non-luminescent amino acid chains (e.g., substantially non-luminescent peptides and / or polypeptides that are not fragments of pre-existing proteins), complexes thereof, and methods for generating a detectable bioluminescent signal upon association of the non-luminescent amino acid chains (e.g., peptides and / or polypeptides). In some embodiments, the present invention provides two or more non-luminescent or substantially non-luminescent peptides and / or polypeptides that, when combined together, assemble to form a bioluminescent complex. In some embodiments, a pair of substantially non-luminescent peptide and / or polypeptide units assemble to form a bioluminescent complex. In other embodiments, three or more substantially non-luminescent peptide and / or polypeptide units assemble to form a bioluminescent complex (e.g., a ternary complex, a tertiary complex, etc.). Provided herein are techniques for detecting interactions between molecular entities (e.g., proteins, nucleic acids, carbohydrates, small molecules (e.g., small molecule libraries)) by correlating such interactions with the formation of a bioluminescent complex of otherwise non-luminescent (e.g., substantially non-luminescent) amino acid chains.
[0005] In some embodiments, the assembled couple catalyzes a chemical reaction of an appropriate substrate to a high-energy state, resulting in the emission of light. In some embodiments, the bioluminescent complex exhibits luminescence in the presence of a substrate (e.g., coelenterazine, furimazine, etc.).
[0006] While the embodiments described herein primarily describe and refer to complementary, non-luminescent amino acid chains that form bioluminescent complexes, it should be noted that the technology of the present invention is equally applicable to other detectable attributes (e.g., other enzymatic activity, formation of fluorophores, formation of chromophores, etc.). The embodiments described herein relating to luminescence should also be considered to apply to complementary, substantially non-enzymatically active amino acid chains (e.g., peptides and / or polypeptides that are not fragments of pre-existing proteins) that separately lack a specific detectable activity (e.g., enzymatic activity), or to substantially non-enzymatically active subunits of polypeptides, complexes thereof, and methods that result in detectable activity (e.g., enzymatic activity) upon association with complementary, substantially non-enzymatically active amino acid chains (e.g., peptides and / or polypeptides). Furthermore, embodiments described herein that refer to non-luminescent peptides and / or polypeptides, in some embodiments, apply to substantially non-luminescent peptides and / or polypeptides.
[0007] The present invention is further directed to assays for detecting molecular interactions between molecules of interest by correlating the interaction of a pair of non-luminescent peptides / polypeptides with the interaction (e.g., transient association, stable association, complex formation, etc.) of the molecules of interest. In such embodiments, a pair of non-luminescent elements is tethered (e.g., fused) to the molecules of interest, and molecular interaction of the molecules of interest results in the assembly of a bioluminescent complex. If the molecules of interest engage in a sufficiently stable interaction, a bioluminescent complex forms and a bioluminescent signal is generated. If the molecules of interest cannot engage in a sufficiently stable interaction, a bioluminescent complex does not form or forms only weakly, and the bioluminescent signal is undetectable or substantially reduced (e.g., substantially undetectable, essentially undetectable, etc.). In some embodiments, the magnitude of the detectable bioluminescent signal is proportional (e.g., directly proportional) to the amount, strength, favorability, and / or stability of the molecular interaction between the molecules of interest.
[0008] In some embodiments, the invention provides peptides comprising an amino acid sequence having less than 100% (e.g., 20%...30%...40%...50%...60%...70%...80% or more) sequence identity to SEQ ID NO:2, wherein a detectable bioluminescent signal is produced when the peptide is contacted with a polypeptide consisting of SEQ ID NO: 440. In some embodiments, the invention provides peptides comprising an amino acid sequence having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO:2, wherein a detectable bioluminescent signal is produced when the peptide is contacted with a polypeptide consisting of SEQ ID NO:440. In some embodiments, a detectable bioluminescent signal is generated when the peptide is contacted with a polypeptide having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO: 440. In certain embodiments, a detectable bioluminescent signal is generated or substantially increased when the peptide associates with a polypeptide comprising or consisting of SEQ ID NO: 440 or a portion thereof. In preferred embodiments, the peptide exhibits altered (e.g., enhanced) one or more traits compared to the peptide of SEQ ID NO: 2, the traits being selected from affinity for a polypeptide consisting of SEQ ID NO: 440, expression, intracellular solubility, intracellular stability, and bioluminescent activity when combined with a polypeptide consisting of SEQ ID NO: 440. Without being limited to these sequences, the peptide amino acid sequence may be selected from the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365. In some embodiments, a fusion polypeptide is provided that includes (a) the aforementioned peptide and (b) a first interacting polypeptide that forms a complex with a second interacting polypeptide when the first interacting polypeptide and the second interacting polypeptide are contacted.In certain embodiments, a bioluminescent complex is provided comprising: (a) a first fusion polypeptide as described above; and (b) a second fusion polypeptide comprising (i) a second interacting polypeptide and (ii) a complementary polypeptide that emits a detectable bioluminescent signal when associated with a peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:2, wherein the first fusion polypeptide and the second fusion polypeptide are associated, and the complementary polypeptide is associated with a peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:2.
[0009] In some embodiments, the invention provides a polypeptide comprising an amino acid sequence having less than 100% sequence identity to SEQ ID NO: 440, wherein a detectable bioluminescent signal is produced when the polypeptide is contacted with a peptide consisting of SEQ ID NO: 2. In some embodiments, the invention provides a polypeptide comprising an amino acid sequence having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO: 440, wherein a detectable bioluminescent signal is produced when the polypeptide is contacted with a peptide consisting of SEQ ID NO: 2. In some embodiments, a detectable bioluminescent signal is generated when the polypeptide is contacted with a peptide having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO:2. In some embodiments, the polypeptide exhibits altered (e.g., enhanced) one or more traits compared to the peptide of SEQ ID NO:440, the traits being selected from affinity for the peptide of SEQ ID NO:2, expression, intracellular solubility, intracellular stability, and bioluminescent activity when combined with the peptide of SEQ ID NO:2. Without being limited to these sequences, the polypeptide amino acid sequence may be selected from one of the amino acid sequences of SEQ ID NOs:441-2156. In some embodiments, a detectable bioluminescent signal is generated when the polypeptide associates with the peptide of SEQ ID NO:2. In some embodiments, a fusion polypeptide is provided that includes (a) the aforementioned polypeptide and (b) a first interacting polypeptide that forms a complex with a second interacting polypeptide when the first interacting polypeptide and the second interacting polypeptide are contacted.In certain embodiments, a detectable bioluminescent signal is generated from (a) the first fusion polypeptide described above, and (b) (i) a second interacting polypeptide, and (ii) a polypeptide comprising an amino acid sequence having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO: 440 when the association between the two is formed. and a second fusion polypeptide comprising a complementary peptide to be released, wherein the first fusion polypeptide and the second fusion polypeptide are associated with each other, and the complementary peptide is associated with a polypeptide comprising an amino acid sequence having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO: 440.
[0010] In some embodiments, the present invention provides nucleic acids (e.g., DNA, RNA, etc.), oligonucleotides, vectors, etc. encoding any of the peptides, polypeptides, fusion proteins, etc. described herein. In some embodiments, nucleic acids are provided that include or consist of one of the nucleic acid sequences of SEQ ID NOs: 3-438 and 2162-2365 (encoding non-luminescent peptides) and / or SEQ ID NOs: 441-2156 (encoding non-luminescent polypeptides). In some embodiments, other nucleic acid sequences are provided that encode the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365 and / or SEQ ID NOs: 441-2156.
[0011] In certain embodiments, the present invention provides a bioluminescent conjugate comprising: (a) a peptide comprising a peptide amino acid sequence having less than 100% sequence identity (e.g., >99%, <95%, <90%, <80%, <70%, <60%, <50%, etc.) to SEQ ID NO:2; and (b) a polypeptide comprising a polypeptide amino acid sequence having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO:440, wherein the bioluminescent conjugate exhibits detectable luminescence. In certain embodiments, the present invention provides a bioluminescent conjugate comprising: (a) a peptide comprising a peptide amino acid sequence having less than 100% and more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO:2; and (b) a polypeptide comprising a polypeptide amino acid sequence having less than 100% and more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to SEQ ID NO:440, wherein the bioluminescent conjugate exhibits detectable luminescence. Although not limited to a particular sequence, in some embodiments, the peptide amino acid sequence is selected from one of the amino acid sequences provided in SEQ ID NOs: 3-438 and 2162-2365.
[0012] In various embodiments, a bioluminescent complex is provided that includes (a) a first amino acid sequence that is not a fragment of a pre-existing protein, and (b) a second amino acid sequence that is not a fragment of a pre-existing protein, wherein the bioluminescent complex exhibits detectable luminescence and the first amino acid sequence and the second amino acid sequence are associated. Some such bioluminescent complexes further include (c) a third amino acid sequence comprising a first member of an interacting pair, the third amino acid sequence being covalently linked to the first amino acid sequence, and (d) a fourth amino acid sequence comprising a second member of the interacting pair, the fourth amino acid sequence being covalently linked to the second amino acid sequence. In certain embodiments, in the absence of interaction between the first and second members of the interacting pair, the interaction between the first and second amino acid sequences (e.g., non-covalent interactions (e.g., hydrogen bonds, ionic bonds, van der Waals attractions, hydrophobic interactions, etc.), covalent interactions (e.g., disulfide bonds), etc.) does not significantly associate the first and second amino acid sequences. In some embodiments, the first polypeptide chain comprises a first amino acid sequence and a third amino acid sequence, and the second polypeptide chain comprises a second amino acid sequence and a fourth amino acid sequence, In some embodiments, the first polypeptide chain and the second polypeptide chain are expressed intracellularly.
[0013] In some embodiments, the invention provides bioluminescent complexes that include (a) a pair of non-luminescent elements, where each non-luminescent element is not a fragment of an existing protein, and (b) an interacting pair, where each interacting element of the interacting pair is covalently bound to one of the non-luminescent elements.
[0014] Various embodiments described herein include, for example, (a) attaching a first amino acid sequence to a third amino acid sequence and a second amino acid sequence to a fourth amino acid sequence, wherein the third and fourth amino acid sequences are not fragments of a pre-existing protein, the complex of the third and fourth amino acid sequences emits a detectable bioluminescent signal (e.g., substantially increased bioluminescence compared to the polypeptide chain, respectively), the interaction (e.g., non-covalent) between the third and fourth amino acid sequences is insufficient or only weakly forms a complex of the third and fourth amino acid sequences in the absence of further stabilizing and / or aggregating conditions, and the first amino acid sequence (b) placing the first, second, third, and fourth amino acid sequences of step (a) under conditions that allow interaction between the first amino acid sequence and the second amino acid sequence to occur; and (c) detecting a bioluminescent signal emitted by the complex of the third and fourth amino acid sequences, wherein detection of the bioluminescent signal indicates an interaction between the first amino acid sequence and the second amino acid sequence. In some embodiments, attaching the first amino acid sequence to the third amino acid sequence and the second amino acid sequence to the fourth amino acid sequence comprises forming a first fusion protein comprising the first amino acid sequence and the third amino acid sequence, and forming a second fusion protein comprising the second amino acid sequence and the fourth amino acid sequence. In some embodiments, the first fusion protein and the second fusion protein further comprise linkers between the first and third amino acid sequences and between the second and fourth amino acid sequences, respectively. In certain embodiments, the first fusion protein is expressed from a first nucleic acid sequence encoding the first and third amino acid sequences, and the second fusion protein is expressed from a second nucleic acid sequence encoding the second and fourth amino acid sequences. In some embodiments, a single vector comprises the first nucleic acid sequence and the second nucleic acid sequence.In other embodiments, the first nucleic acid sequence and the second nucleic acid sequence are on separate vectors. In certain embodiments, the (a) "attaching" and (b) "disposing" steps comprise expressing the first and second fusion proteins in the cell.
[0015]
[0003] Methods for forming, producing, creating, and / or optimizing a pair of non-luminescent elements are provided, including: (a) aligning the sequences of three or more related proteins; (b) determining a consensus sequence for the related proteins; (c) providing first and second fragments of a protein related to the three or more proteins (or providing first and second fragments of one of the three or more proteins), where the fragments are substantially non-luminescent individually but exhibit luminescence when the fragments interact; (d) mutating each of the first and second fragments at one or more positions, where the mutation changes the sequence of the fragment to more closely resemble the corresponding portion of the consensus sequence (e.g., the mutation results in a pair of non-luminescent elements that are not fragments of an existing protein); and (e) testing the pair of non-luminescent elements for absence of luminescence (e.g., essential absence, substantial absence, etc.) when unassociated, and for luminescence when the non-luminescent pair associates into a bioluminescent complex. Examples of such processes are described in Examples 1-5. In some embodiments, the non-luminescent element exhibits one or more enhanced traits compared to the first and second fragments, the traits being selected from increased affinity for reconstitution, decreased affinity for reconstitution, enhanced expression, increased intracellular solubility, increased intracellular stability, and increased intensity of reconstituted luminescence.
[0016] In some embodiments, the invention provides a detection reagent comprising: (a) a polypeptide comprising an amino acid sequence having less than 100% but more than 40% sequence identity to SEQ ID NO: 440, wherein a detectable bioluminescent signal is produced when the polypeptide is contacted with a peptide consisting of SEQ ID NO: 2; and (b) a substrate for a bioluminescent complex produced by the polypeptide and the peptide consisting of SEQ ID NO: 2. In some embodiments, the invention provides a detection reagent comprising: (a) a peptide comprising an amino acid sequence having less than 100% sequence identity to SEQ ID NO: 2, wherein a detectable bioluminescent signal is produced when the peptide is contacted with a polypeptide consisting of SEQ ID NO: 440; and (b) a substrate for a bioluminescent complex produced by the peptide and the polypeptide consisting of SEQ ID NO: 440. In some embodiments, the invention provides a detection reagent comprising: (a) a peptide comprising an amino acid sequence having less than 100% but more than 40% sequence identity to SEQ ID NO: 2, wherein a detectable bioluminescent signal is produced when the peptide is contacted with a polypeptide consisting of SEQ ID NO: 440; and (b) a substrate for a bioluminescent complex produced by the peptide and the polypeptide consisting of SEQ ID NO: 440. [Brief explanation of the drawings]
[0017] [Figure 1] 1 shows a graph depicting the effect of various variants of the GVTGWRLCKRISA (SEQ ID NO: 236) peptide on the luminescence resulting from complementation with SEQ ID NO: 440. [Figure 2] 1 shows a graph depicting the effect of various variants of SEQ ID NO: 440 polypeptide on the luminescence resulting from complementation with GVTGWRLCKRISA (SEQ ID NO: 236) or GVTGWRLFKRISA (SEQ ID NO: 108) peptides. [Figure 3] Figure 3A shows the luminescence (RLU) detected for each non-luminescent polypeptide (NLpoly) mutant containing a single glycine to alanine substitution, and Figure 3B shows the fold increase in luminescence compared to the wild type. [Figure 4]Figure 4A shows the luminescence (RLU) detected for each NLpoly mutant containing multiple glycine to alanine substitutions, and Figure 4B shows the fold increase in luminescence compared to the wild type. [Figure 5] Graphs depicting luminescence (RLU) detected in HT-NL peptide fusions are shown. [Figure 6] A graph showing the luminescence (RLU) detected in HT-NLpep fusions is shown. [Figure 7] Graphs depicting luminescence (RLU) detected in NL peptide-HT fusions are shown. [Figure 8] The luminescence (RLU) generated by the luminescent complex after freeze-thaw cycling of the non-luminescent peptide (NLpep) is shown. [Figure 9] Concentration-normalized peptide activity and the TMR gel used to determine relative concentrations are shown. [Figure 10] Graphs of the luminescence of various mutants of residue R11 of NLpoly-5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 11] Graphs of the luminescence of various mutants of residue A15 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 12] Graphs of the luminescence of various mutants of residue L18 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 13] Graphs of the luminescence of various mutants of residue F31 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 14] Graphs of the luminescence of various mutants of residue V58 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 15] Graphs of the luminescence of various mutants of residue A67 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 16] Graphs of the luminescence of various mutants of residue M106 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 17] Graphs of the luminescence of various mutants of residue L149 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 18] Graphs of the luminescence of various mutants of residue V157 of NLpoly 5A2 in the presence of NLpep53 (top) and in the absence of complementary peptide (bottom) are shown. [Figure 19] 1 shows a graph of the luminescence of NLpep-HT fusions. [Figure 20] 1 shows a graph of the luminescence of NLpep-HT fusions and a TMR gel showing their relative expression levels. [Figure 21] 1 shows a graph of the luminescence of NLpep-HT fusions. [Figure 22] Graphs of the luminescence of NLpoly5A2 (top) and NLpoly5A2+R11E (bottom) in the presence of various NLpeps are shown. [Figure 23] 1 shows a graph of the luminescence of NLpep-HT fusions. [Figure 24] Graphs of luminescence from NLpoly1-13 with NLpep53 (top) and without complementary peptide (bottom) are shown. [Figure 25] Graphs of the luminescence of various NLpolys when used with NLpep53 in NANOGLO or DMEM buffer and furimazine or coelenterazine substrates are shown. [Figure 26] Graph comparing luminescence in the presence of different furimazine to coelenterazine ratios for various NLpoly and NLpep53. [Figure 27] Graph comparing luminescence in the presence of different furimazine to coelenterazine ratios for various NLpoly and NLpep53. [Figure 28]1 shows a graph comparing the luminescence of various NLpoly and NLpep53 in HEK293 cell lysates in the presence of furimazine and coelenterazine. [Figure 29] 1 shows a graph of the luminescence of various combinations of NLpoly and NLpep pairs in DMEM buffer containing furimazine. [Figure 30] 1 shows a graph of signal / background emission for various combinations of NLpoly and NLpep pairs in DMEM buffer containing furimazine. [Figure 31] 1 shows graphs of luminescence and substrate specificity of various NLpoly mutants with NLpep69 using either furimazine or coelenterazine as substrate. [Figure 32] A comparison of the luminescence and substrate specificity of different NLpoly variants with NLpep69 is shown under either soluble (lower graph) or live cell (upper graph) conditions using either furimazine or coelenterazine as substrate. [Figure 33] A comparison of the luminescence and substrate specificity of NLpoly variants with NLpep78 is shown under either soluble (lower graph) or live cell (upper graph) conditions using either furimazine or coelenterazine as substrate. [Figure 34] A comparison of the luminescence and substrate specificity of different NLpoly variants with NLpep79 is shown under either soluble (lower graph) or live cell (upper graph) conditions, using either furimazine or coelenterazine as substrate. [Figure 35] Graphs of luminescence of NLpep78-HT (top) and NLpep79-HT (bottom) fusions in the presence of various NLpolys are shown. [Figure 36] 2 shows a graph of the luminescence of various NLpoly in the absence of NLpep. [Figure 37] Graphs of luminescence of NLpep78-HT (top) and NLpep79-HT (bottom) fusions in the presence of various NLpoly using either furimazine or coelenterazine substrates are shown. [Figure 38] 1 shows a graph of the luminescence of NLpep78-HT using various NLpolys expressed in CHO and HeLa cells. [Figure 39] Graphs of original and normalized luminescence from NLpoly fused to firefly luciferase expressed in HEK293, Hela, and CHO cell lysates are shown. [Figure 40] Graphs of original and normalized luminescence from NLpoly fused to click beetle red luciferase expressed in HEK293, Hela, and CHO cell lysates are shown. [Figure 41] 1 shows a graph of luminescence of complementation in live cells using either NLpoly wild type or 5P. [Figure 42] Graphs of luminescence from cell-free complementation of NLpep78-HT fusions (top) and NLpep79-HT fusions (bottom) with various NLpolynucleotides are shown. [Figure 43] Binding affinity graphs are shown for various combinations of NLpep and NLpoly expressed in HeLa, HEK293, and CHO cell lysates. [Figure 44] Binding affinity graphs are shown for various combinations of NLpep and NLpoly in PBS or NANOGLO buffer. [Figure 45] 1 shows a graph of the binding affinity of NLpoly5P expressed in HeLa, HEK293, or CHO cell lysates to NLpep9 or NLpep53. [Figure 46] 1 shows a graph of the luminescence of various amounts of NLpoly in the absence of NLpep. [Figure 47] A graph of the background luminescence of various NLpoly mutants is shown. [Figure 48] A graph of the background luminescence of various NLpoly mutants is shown. [Figure 49] SDS-PAGE gel of total lysate and soluble fragments of several NLpoly mutants is shown. [Figure 50](a) SDS-PAGE gel of total lysate and soluble fragments of NLpoly mutants, and (b) background luminescence of NLpoly mutants. [Figure 51] Graphs of the luminescence produced by several NLpoly mutants when complemented with 10 nM (right) or 100 nM (left) NLpep78 are shown. [Figure 52] 1 shows a graph showing background luminescence in E. coli lysates of various NLpoly mutants. [Figure 53] 1 shows a graph depicting luminescence in E. coli lysates of various NLpoly mutants complemented with NLpep78. [Figure 54] 1 shows a graph depicting luminescence in E. coli lysates of various NLpoly mutants complemented with NLpep79. [Figure 55] Graphs of signal versus background for various NLpoly variants complemented with NLpep78 or NLpep79 and normalized to NLpoly5P are shown. [Figure 56] Graphs showing the background, luminescence from NLpep79 (right) or NLpep78 (left), and signal-to-noise ratios of various NLpoly mutants are shown. [Figure 57] SDS-PAGE gel of total lysates and soluble fragments of various NLpoly5P mutants is shown. [Figure 58] (A) Amounts of total lysate and soluble fragments of NLpoly5P and NLpoly I107L, (B) luminescence generated by NLpoly5P or NLpoly I107L without NLpep or with NLpep78 or NLpep79, and (C) improved signal-to-background of NLpoly I107L compared to NLpoly5P. [Figure 59] Graphs of luminescence of various NLpoly mutants are shown (A) without complementary peptide, (B) with NLpep78-HT, and (C) with NLpep79-HT. [Figure 60]Graphs of luminescence of various NLpoly mutants are shown (A) without complementary peptide, (B) with NLpep78-HT, and (C) with NLpep79-HT. [Figure 61] Graphs of luminescence of various NLpoly mutants are shown (A) without complementary peptide, (B) with NLpep78-HT, and (C) with NLpep79-HT. [Figure 62] Graphs of luminescence of various NLpoly mutants are shown (A) without complementary peptide, (B) with NLpep78-HT, and (C) with NLpep79-HT. [Figure 63] Binding affinities of extended NLpoly variants (addition of amino acids at the C-terminus) and truncated NLpep (deletion of amino acids at the N-terminus) are shown. [Figure 64] 1 shows a graph of the binding affinity of various NLpoly mutants to NLpep78. [Figure 65] Binding and Vmax of NLpep80 and NLpep87 to 5P expressed in mammalian cells (CHO, HEK293T, and HeLa) are shown. [Figure 66] Binding and Vmax of NLpep80 and NLpep87 to NLpoly5P expressed in E. coli are shown. [Figure 67] Graph of the luminescence of shortened NLpoly and extended NLpep is shown. [Figure 68] The Kd and Vmax of NLpoly5P in HeLa lysate with various complemented NLpeps are shown. [Figure 69] 1 shows a graph of the binding affinity of several NLpoly mutants to NLpep81. [Figure 70] 1 shows a graph of the binding affinity of several NLpoly mutants to NLpep82. [Figure 71] 1 shows a graph of the binding affinity of several NLpoly mutants to NLpep78. [Figure 72] 1 shows a graph of the Michaelis constants of several NLpoly mutants with NLpep78. [Figure 73] Graph of luminescence from tertiary complementation of two NLpeps and NLpoly5P-B9 is shown. [Figure 74] 1 shows a graph of luminescence from titration of NLpoly5P with NLpep88-HT. [Figure 75] Images of the subcellular localization of various NLpep fusions with HaloTag (HT) are shown. [Figure 76] Images of the subcellular localization of NLpoly(wild type) and NLpoly(5P) are shown. [Figure 77] We demonstrate the ability to detect proteins of interest conjugated to NLPep by complementation after separation by SDS-PAGE and transfer to a PVDF membrane. [Figure 78] A graph of the relative luminescence signal from various NLpoly variants compared to NLpoly5P is shown (in the absence of NLpep). [Figure 79] A graph of the relative luminescence signal to background from various NLpolys compared to NLpoly5P is shown (in the absence of NLpep). [Figure 80] The dissociation constants of NLpeps consisting of either one or two repeat units of NLpep78 are compared. [Figure 81] The affinity between NLpoly5A2 and NLpep86 is shown. [Figure 82] Graphs of luminescence from NLpoly mutants without NLpep, with NLpep78, and with NLpep79 are shown. [Figure 83] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 84] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 85] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 86] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 87] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 88] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 89] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 90] The dissociation constants and Vmax values of NLpoly5A2, 5P, 8S, and 11S when 96 mutants of NLpep were used are shown. [Figure 91] Shown are protein gel images of total lysates of NLpoly mutants and the soluble fraction of the same lysates. [Figure 92] Shown are protein gel images of total lysates of NLpoly variants and soluble fractions of the same lysates, as well as a table containing the dissociation constants of the same variants. [Figure 93] 1 shows the substrate specificity of NLpoly5P and 11S when NLpep79 is used, demonstrating that NLpoly11S has superior specificity for furimazine than 5P. [Figure 94] 1 shows an image of a protein gel following affinity purification of NLpoly8S by binding to NLpep78. [Figure 95] Contains a table of the association and dissociation rate constants for the binding of NLpoly WT or 11S to NLpepWT, 78, or 79. [Figure 96] The Km values of various pairs of NLpoly / NLpep are shown. [Figure 97] The dissociation constants of NLpoly11S / NLpep79 at subsaturating and saturating concentrations of furimazine are compared. [Figure 98]The Km values of NLpoly5A2 when using NLpepWT, 78, and 79 are compared. [Figure 99] The emission of NLpoly from various stages in the evolution process in the absence of NLpep is shown. [Figure 100] The luminescence from E. coli-derived NLpoly was improved over the evolutionary process, with an overall improvement of approximately 105 (from NLpolyWT:NLpepWT to NLpoly11S:NLpep80). [Figure 101] The improvement in luminescence from NLpoly expressed in HeLa over the evolutionary process was shown, with an overall improvement of approximately 105 (NLpolyWT:NLpepWT to NLpoly11S:NLpep80). [Figure 102] The improvement in luminescence from NLpoly expressed in HEK293 over the evolutionary process was shown, with an overall improvement of approximately 104 (NLpolyWT:NLpepWT to NLpoly11S:NLpep80). [Figure 103] The dissociation constants are shown, demonstrating an approximately 104-fold improvement in binding affinity from NLpolyWT:NLpepWT to NLpoly11S:NLpep86. [Figure 104] Shown are protein gel images of total lysates of NLpoly mutants from different stages of the evolutionary process and the soluble fractions of the same lysates. [Figure 105] The luminescence of various NLpolys in the absence of NLpep and in the presence of NLpep78 and NLpep79 is shown. [Figure 106] The luminescence of various NLpolys in the absence of NLpep and in the presence of NLpep78 and NLpep79 is shown. [Figure 107] The luminescence of various NLpolys in the absence of NLpep and in the presence of NLpep78 and NLpep79 is shown. [Figure 108]Figure 1 shows a comparison of luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 after 15 minutes of treatment with rapamycin or vehicle. Fold induction refers to the signal generated in the presence of rapamycin compared to the signal generated with vehicle. [Figure 109] A comparison of the luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 after 60 min treatment with rapamycin or vehicle is shown. [Figure 110] A comparison of the luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 after 120 min treatment with rapamycin or vehicle is shown. [Figure 111] Figure 1 shows a comparison of luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 after 120 min of treatment with rapamycin or vehicle. All eight possible combinations of FRB and FKBP fused to NLpoly / NLpep were tested, using less total DNA. [Figure 112] A comparison of the luminescence generated by FRB or FKBP fusions expressed in the absence of binding partner is shown. [Figure 113] A comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 / 87 DNA is shown. [Figure 114] A comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P or FKBP-NLpep80 / 87 DNA in the absence of binding partner is shown. [Figure 115] Figure 11 shows a comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 / 87 DNA. This example differs from Figure 113 in that lower levels of DNA were used. [Figure 116]Figure 11 shows a comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P or FKBP-NLpep80 / 87 DNA in the absence of binding partner. This differs from Figure 114 in that lower levels of DNA were used. [Figure 117] A comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 DNA after treatment with rapamycin for different lengths of time is shown. [Figure 118] A comparison of the luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep87 DNA after treatment with rapamycin for different lengths of time is shown. [Figure 119] A comparison of the luminescence generated by cells expressing different combinations of FRB-NLpoly5P and FKBP-NLpep80 / 87 / 95 / 96 / 97 is shown. Assays were performed in both 2-day and 3-day formats. [Figure 120] A comparison of the luminescence generated by cells expressing different combinations of FRB-NLpoly5A2 and FKBP-NLpep80 / 87 / 95 / 96 / 97 is shown. Assays were performed in both 2-day and 3-day formats. [Figure 121] A comparison of the luminescence generated by cells expressing different combinations of FRB-NLpoly5A2 or FRB-NLpoly11S and FKBP-NLpep101 / 104 / 105 / 106 / 107 / 108 / 109 / 110 is shown. [Figure 122] A comparison of the luminescence generated by cells transfected with different combinations of FRB-NLpoly5A2 or FRB-NLpoly11S and FKBP-NLpep87 / 96 / 98 / 99 / 100 / 101 / 102 / 103 is shown. [Figure 123] A comparison of the luminescence generated by cells transfected with different levels of FRB-NLpoly11S and FKBP-NLpep87 / 101 / 102 / 107 DNA is shown. [Figure 124]A comparison of the luminescence generated by cells transfected with different levels of FRB-NLpoly5A2 and FKBP-NLpep87 / 101 / 102 / 107 DNA is shown. [Figure 125] 1 shows a rapamycin dose-response curve showing luminescence of cells expressing FRB-NLpoly5 and PFKBP-NLpep80 / 87 DNA. [Figure 126] 1 shows a rapamycin dose-response curve showing the luminescence of cells expressing FRB-NLpoly5A2 or FRB-NLpoly11S and FKBP-NLpep87 / 101 DNA. [Figure 127] A comparison of the luminescence produced by cells expressing FRB-11S and FKBP-101 and treated with the substrates PBI-4377 or furimazine is shown. [Figure 128] A rapamycin time course of cells expressing FRB-NLpoly11S / 5A2 and FKBP-NLpep87 / 101 performed in the presence or absence of rapamycin (rapamycin was added manually). [Figure 129] A rapamycin time course of cells expressing FRB-NLpoly11S / 5A2 and FKBP-NLpep87 / 101 performed in the presence or absence of rapamycin is shown (rapamycin was added by syringe). [Figure 130] Luminescence generated by FRB-NLpoly11S and FKBP-NLpep101 measured on two different luminometers is shown. [Figure 131] 10 provides images showing luminescence of cells expressing FRB-NLpoly11S and FKBP-NLpep101 at various time points after rapamycin treatment. [Figure 132] 1 provides a graph showing quantification by Image J of the signal produced by individual cells expressing FRB-NLpoly11S and FKBP-NLpep101 at various time points after rapamycin treatment. [Figure 133] Comparison of luminescence in different cell lines expressing FRB-NLpoly11S and FKBP-NLpep101. [Figure 134] A comparison of the luminescence generated by cells expressing FRB-NLpoly11S and FKBP-NLpep101 after treatment with the rapamycin-competitive inhibitor FK506 is shown. [Figure 135] Shown is the luminescence generated by cells expressing FRB-NLpoly11S and FKBP-NLpep101 after treatment with the rapamycin-competitive inhibitor FK506 (left), and the percentage of luminescence remaining after treatment with FK506 (right). [Figure 136] Shown is the luminescence generated by cells transfected with different combinations of V2R-NLpoly5A2 or V2R-NLpoly11S and NLpep87 / 101-ARRB2 in the presence or absence of the V2R agonist AVP. [Figure 137] A time course of AVP treatment is shown showing the luminescence generated by cells transfected with V2R-NLpoly11S and NLpep87 / 101-ARRB2 after treatment with AVP (AVP was added manually). [Figure 138] A time course of AVP treatment is shown showing the luminescence generated by cells transfected with different combinations of V2R-NLpoly5A2 or V2R-NLpoly11S and NLpep87 / 101-ARRB2 after treatment with AVP (AVP was added by syringe). [Figure 139] A time course of AVP treatment at 37° C. is shown showing the luminescence generated by cells expressing different configurations of V2R and ARRB2 fused to NLpoly11S and NLpep101 after treatment with AVP. [Figure 140] A comparison of luminescence in different cell lines expressing V2R-NLpep11S and NLpep101-ARRB2 is shown. [Figure 141] Shown are 60X images showing luminescence of cells expressing V2R-NLpoly11S and NLpep101-ARRB2 at various time points after AVP treatment. [Figure 142]Shown are 150X images showing luminescence of cells expressing V2R-NLpoly11S and NLpep101-ARRB2 at various time points after AVP treatment. [Figure 143] Shown are protein gel images of total lysates of NLpoly mutants and the soluble fraction of the same lysates. [Figure 144] Dissociation constants are shown for NLpoly5P and combinations of mutations at positions 31, 46, 75, 76, and 93 of NLpoly5P. [Figure 145] An example of detecting the activity of post-translational modifying enzymes using NLpep and aminopeptidase is shown for transferase. [Figure 146] An example of detecting the activity of post-translationally modified enzymes using NLpep and methyl-specific antibodies is shown for hydrolases. [Figure 147] Includes wavelength scans of NLpepWT conjugated to TMR or NLpolyWT complemented with either NLpepWT. [Figure 148] Includes wavelength scanning of NanoLuc fused to HaloTag (NL-HT) and NLpoly 5A2 complemented with NLPepWT with four additional amino acids (DEVD) and conjugated to non-chloro TOM (NCT). [Figure 149] A schematic ternary interaction is shown in which energy transfer via NLpoly and NLpep can also be used to measure three interacting molecules. In the diagram, interaction between an NLpoly-labeled GPCR and an NLpep-labeled GPCR-interacting protein forms a bioluminescent complex, allowing measurement of the binary interaction. Energy transfer occurs when a small molecule GPCR ligand bearing a fluorescent moiety suitable for energy transfer interacts with this system. Thus, binary protein-protein interactions and drug-protein-protein ternary interactions can be measured in the same experiment. [Figure 150]Graphs and tables showing the binding affinity of NLpoly11S to synthetic NLPep78 and NLPep78 at the N- or C-terminus of the fusion partner (HaloTag). [Figure 151] Graphs and tables showing the binding affinity of NLpoly11S to synthetic NLPep79 and NLPep79 at the N- or C-terminus of the fusion partner (HaloTag). [Figure 152] Graphs showing the normalized fluorescence intensity of NLpoly11S with NLPep86 or PBI-4877 are shown. [Figure 153] Graphs showing the normalized fluorescence intensity of NLpoly11S with NLPep86 or PBI-5434 are shown. [Fig. 154] Graphs showing the normalized fluorescence intensity of NLpoly11S with NLPep86 or PBI-5436 are shown. [Figure 155] 1 shows a graph depicting the furimazine binding affinity in affinity buffer of complexes between NLpoly11S and NLpep86, 78, 99, 101, 104, 128, and 114. [Figure 156] 1 shows a graph depicting the furimazine binding affinity of complexes of NLpoly11S with NLpep86, 78, 99, 101, 104, 128, and 114 in NanoGlo assay buffer. [Figure 157] Graphs showing the change in affinity (NLpoly156 / NLPep1 and NLpoly11S / NLPep1) with increasing concentrations of furimazine substrate are shown. [Figure 158] Graphs showing the change in affinity (NLpoly156 / NLPep1 and NLpoly11S / NLPep1) with increasing concentrations of NLPep1 are shown. [Figure 159] 1 shows a graph depicting the Vmax and Bmax of NLPoly156, NLPoly11S, and NanoLuc® luciferase (Nluc) with NLPep1. [Figure 160]Graphs showing RLU as a function of NLPep concentration are shown for NLPoly11S and NLPeps 86, 78, 79, 99, 101, 104, 114, 128 and wild type. [Figure 161] 1 shows a Western blot depicting the expression levels of NLPoly156 and NLPoly11S in HEK293T cells compared to full-length NanoLuc® luciferase. [Figure 162] 1 shows a graph depicting a comparison of the affinity of β-lactamase SME and its inhibitor BLIPY50A when used as unfused proteins or fused to NLPoly11S and NLPep114. [Figure 163] A comparison of the luminescence produced by cells expressing different combinations of FRB-NLpoly11S and FKBP-NLpep101 / 111-136 is shown. [Fig. 164] A comparison of the luminescence produced by cells expressing different combinations of FRB-NLpoly11S and FKBP-NLpep114 and 137-143 is shown. [Figure 165] Rapamycin dose-response curves for cells expressing FRB-NLpoly11S and FKBP-NLpep78 / 79 / 99 / 101 / 104 / 114 / 128 are shown. [Figure 166] Response of cells expressing FRB-NLpoly11S and FKBP-78 / 79 / 99 / 101 / 104 / 114 / 128 to the rapamycin-competitive inhibitor FK506 is shown. [Figure 167] A comparison of the luminescence generated by cells transfected with different ratios of FRB-NLpoly11S and FKBP-NLpep114 is shown. [Figure 168] 1 shows a comparison of the luminescence generated by cells expressing the NLpoly11S / NLpep114 fusion of FRB / FKBP in different orientations and with different linker lengths. [Figure 169] Graphs depicting (A) dose-specific and (B) time-specific inhibition of FRB-NLpoly11S / FKBP-NLpep114 or split firefly complementation signals by rapamycin. [Figure 170] Graphs depicting (A) dose-specific and (B) time-specific induction of FRB-NLpoly11S / FKBP-NLpep114 or split firefly complementation signals by FK506. [Figure 171] Western blots showing similar expression levels of FKBP-NLpep114 and FKBP-Fluc(394-544) at equal levels of transfected DNA are shown. [Figure 172] Graphs depicting (A) dose-specific and (B) time-specific inhibition of NLpoly11S-BRD4 and histone H3.3-NLpep114 interactions by IBET-151. [Fig. 173] 1 shows a graph depicting the dose-dependent increase in RAS / CRAF, BRAF / BRAF, and CRAF / BRAF dimer formation in response to the BRAF inhibitor GDC0879. [Fig. 174] Graphs showing RLU as a function of NLPep concentration are shown for NLpoly11S as well as NLpep86, wild type, and NLpep114. [Figure 175] 1 shows a schematic of an assay using a luminescent pair of high affinity peptides as intracellular protein tags and a luminescent pair of polypeptides as detection reagents. [Figure 176] 1 shows a graph depicting the linear range of affinity for NLpoly11S and MLpep86. [Figure 177] This image shows the sensitivity of 11S to detect proteins tagged with high-affinity NLPep. The figure also compares detection using NLPep / NLPoly with detection using fluorescently labeled HaloTag. [Figure 178] 1 shows a graph showing the stability of NLpoly11S. [Figure 179] 1 shows a graph depicting the linear range of affinity for NLpoly11S and NLpep78. [Figure 180]An outline of the NLpep sequence is shown. High affinity (naturally occurring) peptides are peptides (NLpeps) that bind to NLpoly11S with high affinity. Dark / quenching peptides are peptides (NLpeps) that can reduce the level of light produced or detected by NLpoly11S. [Figure 181] A schematic representation of the structural complementarity concept is shown (Panels A and B) where LSP and SSP (i.e., NLpoly and NLpep) are brought together to generate a bioluminescent signal. Disruption of the protein interaction (i.e., X and Y) separates the LSP and SSP, resulting in reduced luminescence (Panel C). [Figure 182A] Figure 182A shows two options (A, B) for manipulating structural complementarity: loss of signal when a protein interaction occurs between X and Y, and gain of signal when the interaction between X and Y is disrupted. Option A represents intermolecular structural complementarity. Option B represents intramolecular structural complementarity. [Figure 182B] Figure 182B shows a list of genetic constructs that may be suitable for intramolecular structural complementation. [Figure 183] (A) Inhibition of binding by various dark peptides NLpoly11S and NLpep114, and (B) dose-dependent inhibition by Lys-162 and Gln-162 peptides. [Figure 184] Panel A shows that inhibition by Q-162 and A-162 is dose-dependent. Panel B shows that A-162 is only slightly dose-dependent at best, while Q-162 generates a signal by itself in a dose-dependent manner. [Figure 185] 10 shows a graph depicting the dose response of dark peptides with CP Nluc. [Figure 186] 10 is a graph showing the time course of dark peptides when CP Nluc is used. [Figure 187]1 shows dose-dependent inhibition by the dark peptide of luminescence generated by FRB-NLpoly11S alone and between FRB-NLpoly11S and FKBP-NLpep114 in the presence and absence of rapamycin. [Figure 188] 1 shows the dose-dependent inhibition by the dark peptide of luminescence generated by either FRB-NanoLuc(311) or NanoLuc-FRB(307) in the presence and absence of rapamycin (RLU). [Figure 189] Shown is the dose-dependent inhibition by dark peptide of luminescence generated by either FRB-NanoLuc(311) or NanoLuc-FRB(307) in the presence and absence of rapamycin (normalized to the dark no peptide control; 100%). [Figure 190] When fused to FKBP, the dark peptide can compete with both low-affinity (114) and high-affinity (80) peptides (also FKBP fusions), thereby reducing the overall luminescence produced and detected in live cells. [Figure 191] 1 shows a comparison of the signals between Fluc- and NLpep86-based assays for intracellular levels of Fluc. [Figure 192] 1 shows a graph depicting the utility of tandemly linked NLpep in complementing Npoly11S. [Figure 193] 1 shows a graph demonstrating that the NLpoly and NLpep components do not interfere with the intracellular degradation of the reporter protein FlucP. [Figure 194] 1 shows a schematic diagram depicting an extracellular protease activity assay. [Figure 195] 1 shows a schematic diagram of an assay for measuring enzyme activity using ProNLpep. [Figure 196] 1 shows a schematic representation of an assay for screening antibodies, proteins, peptides, or transporters that mediate cell internalization. [Figure 197] 1 shows a schematic diagram of the post-translational modification transferase assay. [Figure 198] 1 shows a schematic diagram of the post-translational modification hydrolase assay. [Figure 199] 1 shows a graph correlating activity of the tyrosine kinase SRC with luminescence compared to background in a post-translational modification assay. [Figure 200] 1 shows a graph depicting the spontaneous complementation of three different forms of NLpoly11S with 12 synthetic peptides. [Figure 201] 1 shows a schematic representation of a homogeneous immunoassay format using fusions of NLpep and NLpoly with distinct binding moieties A and B. [Figure 202] (A) Graphs showing that background luminescence from NLpoly11S decreases when complexed with GWALFKK and dabcyl-GWALFKK, and (B) NLpep86 forms a complex with NLpoly11S in the presence of GWALFKK and dabcyl-GWALFKK. [Figure 203] Graphs showing that (A) VTGWALFEEIL (Trp 11mer) and VTGYALFEEIL (Tyr 11mer) induce luminescence above background (NLpoly11S alone, no peptide control), and that the N-terminal dabsyl forms of each provide significant quenching of this signal, and (B) NLpep86 forms a complex with NLpoly11S in the presence of the dabsyl forms of the Trp 11mer and Tyr 11mer. DETAILED DESCRIPTION OF THE INVENTION
[0018] definition As used herein, the term "substantially" means that the recited characteristic, parameter, and / or value need not be achieved exactly, but that deviations or variations, including, for example, tolerances, measurement errors, measurement accuracy limits, and other factors known in the art, may occur in amounts that do not interfere with the effect of the characteristic intended to be provided. A substantially absent characteristic or property (e.g., substantially non-luminescent) can be a characteristic that is within the noise, below background, below the detection capability of the assay used, or a small number (e.g., <1%, <0.1%, <0.01%, <0.001%, <0.00001%, <0.000001%, <0.0000001%) of the characteristic of interest (e.g., the luminescence intensity of a bioluminescent protein or bioluminescent complex).
[0019] As used herein, the term "bioluminescence" refers to the production and emission of light by a chemical reaction catalyzed or enabled by an enzyme, protein, protein complex, or other biological molecule (e.g., a bioluminescent complex). In typical embodiments, a substrate of a bioluminescent entity (e.g., a bioluminescent protein or bioluminescent complex) is converted by the bioluminescent entity into an unstable form: the substrate then emits light.
[0020] As used herein, the term "complementarity" refers to the characteristic of two or more structural elements (e.g., peptides, polypeptides, nucleic acids, small molecules, etc.) that can hybridize, dimerize, or otherwise form a complex with one another. For example, "complementary peptides and polypeptides" can assemble to form a complex. Complementary elements may require assistance to form a complex (e.g., from interacting elements), such as by positioning the elements in a conformation suitable for complementarity, colocalizing the complementary elements, lowering the interaction energy for complementarity, etc.
[0021] As used herein, the term "complex" refers to an assembly or aggregation of molecules (e.g., peptides, polypeptides, etc.) that are in direct and / or indirect contact with one another. In one embodiment, "contact" or more specifically "direct contact" means that two or more molecules are in sufficient proximity that non-covalent attractive interactions, such as van der Waals attractions, hydrogen bonds, ionic bonds, and hydrophobic interactions, dominate the interaction of the molecules. In such embodiments, a complex of molecules (e.g., peptides and polypeptides) forms under assay conditions such that the complex is thermodynamically favored (e.g., compared to the unaggregated or uncomplexed states of its constituent molecules). As used herein, unless otherwise specified, the term "complex" refers to an assembly of two or more molecules (e.g., peptides, polypeptides, or combinations thereof).
[0022] As used herein, the term "non-luminescent" refers to an entity (e.g., a peptide, polypeptide, complex, protein, etc.) that exhibits the characteristic of not emitting a detectable amount of light in the visible spectrum (e.g., in the presence of a substrate). For example, an entity may be referred to as non-luminescent if it exhibits no detectable luminescence in a given assay. As used herein, the term "non-luminescent" is synonymous with the term "substantially non-luminescent." For example, a non-luminescent polypeptide (NLpoly) is substantially non-luminescent, e.g., 10-fold or more (e.g., 100-fold, 200-fold, 500-fold, 1×10) compared to a complex of the NLpoly and its non-luminescent complementary peptide. 3 times 1×10 4 times 1×10 5 times 1×10 6 times 1×10 7 In some embodiments, an entity is "non-luminescent" if any light emission is small enough so as not to produce background that interferes with a particular assay.
[0023] As used herein, the terms "non-luminescent peptide" (e.g., NLpep) and "non-luminescent polypeptide" (e.g., NLpoly) refer to a peptide or polypeptide that exhibits substantially no luminescence (e.g., in the presence of a substrate), or an amount that is below the noise, or 10-fold or more (e.g., 100-fold, 200-fold, 500-fold, 1×10) when compared to a signal of interest (e.g., a luminescent conjugate) using a typical instrument (e.g., a luminometer) under standard conditions (e.g., physiological conditions, assay conditions, etc.). 3 times 1×10 4 times 1×10 5 times 1×10 6 times 1×10 7 The term "bioluminescent complex" refers to peptides and polypeptides that exhibit an amount (e.g., 1 / 2 times) of light emitted by the non-luminescent peptides and polypeptides. In some embodiments, such non-luminescent peptides and polypeptides assemble according to the criteria described herein to form a bioluminescent complex. As used herein, a "non-luminescent element" is a non-luminescent peptide or a non-luminescent polypeptide. The term "bioluminescent complex" refers to a complex formed by the assembly of two or more non-luminescent peptides and / or non-luminescent polypeptides. A bioluminescent complex catalyzes or allows the conversion of the substrate of the bioluminescent complex to an unstable form; the substrate then emits light. When uncomplexed, the two non-luminescent elements that form a bioluminescent complex may be referred to as a "non-luminescent pair." When a bioluminescent complex is formed by three or more non-luminescent peptides and / or non-luminescent polypeptides, the uncomplexed components of the bioluminescent complex may be referred to as "non-luminescent groups."
[0024] As used herein, the term "interacting element" refers to a moiety that assists in bringing together a pair of non-luminescent elements or groups to form a bioluminescent complex. In a typical embodiment, a pair of interacting elements (also known as an "interacting pair") is attached to a pair of non-luminescent elements (e.g., a non-luminescent peptide / polypeptide pair), and an attractive interaction between the two interacting elements promotes the formation of a bioluminescent complex; the present invention is not limited to such a mechanism, and understanding of the mechanism is not necessary to practice the present invention. The interacting element may promote the formation of a bioluminescent complex by any suitable mechanism (e.g., bringing the non-luminescent pair / groups into close proximity, positioning the non-luminescent pair / group in a suitable conformation for stable interaction, reducing the activation energy for complex formation, a combination thereof, etc.). The interacting element can be a protein, polypeptide, peptide, small molecule, cofactor, nucleic acid, lipid, carbohydrate, antibody, etc. The interacting pair may consist of two identical interacting elements (i.e., a homogeneous pair) or two different interacting elements (i.e., a heterogeneous pair). In the case of a homogeneous pair, the interacting members may be the same type of moiety (e.g., a polypeptide) or two different types of moieties (e.g., a polypeptide and a small molecule). In some embodiments in which complex formation by an interacting pair is examined, the interacting pair may be referred to as a "target pair" or "pair of interest," and the individual interacting members are referred to as "target members" (e.g., "target peptide," "target polypeptide," etc.) or "members of interest" (e.g., "peptide of interest," "polypeptide of interest," etc.).
[0025] As used herein, the term "pre-existing protein" refers to an amino acid sequence that physically existed before a particular event or date. A "peptide that is not a fragment of a pre-existing protein" is a short chain of amino acids that is not a fragment or subsequence of a protein (e.g., synthetic or naturally occurring) that physically existed before the design and / or synthesis of the peptide.
[0026] As used herein, the term "fragment" refers to a peptide or polypeptide that results from the excision or "fragmentation" of a larger whole entity (e.g., a protein, polypeptide, enzyme, etc.), or that has been prepared to have the same sequence as such. A fragment is thus a subsequence of the whole entity (e.g., protein, polypeptide, enzyme, etc.) from which it is made and / or engineered. A peptide or polypeptide that is not a subsequence of an existing whole protein is not a fragment (e.g., not a fragment of an existing protein). A peptide or polypeptide that is "not a fragment of an existing bioluminescent protein" is an amino acid chain that (1) physically exists prior to the design and / or synthesis of the peptide or polypeptide, and (2) is not a subsequence of a protein (e.g., natural or synthetic) that exhibits appreciable bioluminescent activity.
[0027] As used herein, the term "subsequence" refers to a peptide or polypeptide that has 100% sequence identity with another, larger peptide or polypeptide. A subsequence is an exact sequence match with a portion of a larger amino acid chain.
[0028] As used herein, the term "sequence identity" refers to the degree to which two polymer sequences (e.g., peptides, polypeptides, nucleic acids, etc.) have the same sequence composition of monomer subunits. The term "sequence similarity" refers to the degree to which two polymer sequences (e.g., peptides, polypeptides, nucleic acids, etc.) have similar polymer sequences. For example, similar amino acids are those that share the same biophysical characteristics and can be classified into families such as acidic (e.g., aspartic acid, glutamic acid), basic (e.g., lysine, arginine, histidine), nonpolar (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). "Percent sequence identity" (or "percent sequence similarity") is calculated by: (1) comparing two optimally aligned sequences over a comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window); (2) determining the number of positions containing identical (or similar) monomers (e.g., the same amino acid occurs in both sequences, a similar amino acid occurs in both sequences) to obtain the number of matching positions; (3) dividing the number of matching positions by the total number of positions in the comparison window (e.g., the length of the longer sequence, the length of the shorter sequence, a specified window); and (4) multiplying the result by 100 to obtain the percent sequence identity or sequence similarity. For example, if peptides A and B are both 20 amino acids long and have identical amino acids except for one position, peptide A and peptide B have 95% sequence identity. If the amino acids at non-identical positions share the same biophysical characteristics (e.g., both are acidic), peptide A and peptide B have 100% sequence similarity. As another example, if peptide C is 20 amino acids long and peptide D is 15 amino acids long, and 14 of the 15 amino acids in peptide D are identical to some amino acids in peptide C, then peptides C and D have 70% sequence identity, but peptide D has 93.3% sequence identity with the optimal comparison window of peptide C.For purposes of calculating "percent sequence identity" (or "percent sequence similarity") herein, any gap in the aligned sequences is treated as a mismatch at that position.
[0029] As used herein, the term "physiological conditions" encompasses any conditions that are compatible with living cells, such as defined aqueous conditions of temperature, pH, salinity, chemical composition, and the like.
[0030] As used herein, the term "sample" is used in a broad sense. In one sense, this term is meant to include specimens or culture media obtained from any source, as well as biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass liquids, solids, tissues, and gases. Biological samples include blood products such as plasma and serum. A sample may also refer to a cell lysate or purified forms of the peptides and / or polypeptides described herein. A cell lysate may include cells lysed with a lysing agent or a lysate such as rabbit reticulocyte or wheat germ lysate. A sample may also include a cell-free expression system. Environmental samples include environmental materials such as surface material, soil, water, crystals, and industrial samples. However, these examples should not be construed as limiting the types of samples applicable to the present invention.
[0031] As used herein, unless otherwise specified, the terms "peptide" and "polypeptide" refer to a polymeric compound of two or more amino acids joined through a backbone by peptide amide bonds (--C(O)NH--). The term "peptide" typically refers to short amino acid polymers (e.g., chains having fewer than 25 amino acids), while the term "polypeptide" typically refers to longer amino acid polymers (e.g., chains having more than 25 amino acids).
[0032] Detailed Description In particular, the study of protein interactions under physiological conditions and / or at physiological expression levels requires high sensitivity. In certain embodiments described herein, protein interactions with small molecules, nucleic acids, other proteins, etc. are detected based on the association of two non-luminescent components that assemble to form a bioluminescent complex capable of generating a detectable signal (e.g., luminescence). The formation of the bioluminescent complex is dependent on the protein interaction being monitored.
[0033] Provided herein are compositions and methods for constructing bioluminescent conjugates from two or more non-luminescent peptide and / or polypeptide units (e.g., non-luminescent pairs). In some embodiments, the non-luminescent peptide and / or polypeptide unit is not a fragment of an existing protein (e.g., is not a complementary sequence of a known polypeptide sequence). Specifically, structural complementarity with the non-luminescent peptide confers bioluminescent activity to the non-luminescent polypeptide.
[0034] In some embodiments, provided herein are non-luminescent pairs (e.g., protein-protein, protein-DNA, protein-RNA interactions, RNA-DNA, protein-small molecule, RNA-small molecule, etc.) for use in detecting and monitoring molecular interactions. Also provided herein are complementary panels of interchangeable non-luminescent elements (e.g., peptides and polypeptides) with variable affinities and emissions upon formation of various bioluminescent complexes (e.g., high affinity / high luminescence pairs, medium affinity / high luminescence pairs, low affinity / moderate luminescence pairs, etc.). Utilizing different combinations of non-luminescent elements provides a flexible system containing a variety of pairs ranging in affinity, luminescence, and other variable characteristics. This flexibility allows for fine-tuning of molecular interaction detection / monitoring to suit the specific molecule(s) of interest, expanding the range of molecular interactions that can be monitored to include very high or low affinity interactions. Additionally, provided herein are methods by which non-luminescent pairs (or groups) and panels of non-luminescent pairs (or groups) can be developed and tested.
[0035] In some embodiments, the interaction between the peptide / polypeptide members of a non-luminescent pair alone is insufficient to form a bioluminescent complex and generate a resulting bioluminescent signal. However, when an interacting element is attached to each peptide / polypeptide member of the non-luminescent pair, the interaction of the interacting pair (e.g., to form an interacting complex) promotes the formation of a bioluminescent complex. In such embodiments, the bioluminescent signal from the bioluminescent complex (or the ability to generate such a signal in the presence of a substrate) serves as a reporter for the formation of the interacting complex. Once the interacting complex is formed, a bioluminescent complex is then formed, and the bioluminescent signal is detected / measured / monitored (e.g., in the presence of a substrate). If the interacting complex cannot form (e.g., due to unfavorable conditions, unstable interactions between interacting elements, or incompatible interacting elements), the bioluminescent complex does not form and no bioluminescent signal is generated.
[0036] In certain embodiments, the interaction pair includes two molecules of interest (e.g., proteins of interest). For example, assays can be performed to detect the interaction of two molecules of interest by tethering each member of a non-emissive pair to another member. If the molecules of interest interact (e.g., transiently interact, stably interact, etc.), the non-emissive pair is brought into close proximity in the appropriate conformation, a bioluminescent complex is formed (and a bioluminescent signal is generated / detected (in the presence of substrate)). If there is no interaction between the molecules of interest (e.g., no complex formation, even a transient interaction, etc.), the non-emissive pair does not interact sufficiently, and no or only a weak bioluminescent signal is generated. Such embodiments can be used to examine the effect of inhibitors on complex formation, the effect of mutations on complex formation, the effect of conditions (e.g., temperature, pH, etc.) on complex formation, the interaction of small molecules (e.g., potentially therapeutic) with target molecules, etc.
[0037] Different non-luminescent pairs may require different strengths, durations, and / or stabilities of the interaction complex to result in the formation of a bioluminescent complex. In some embodiments, a stable interaction complex is required to produce a detectable bioluminescent signal. In other embodiments, even a weak or transient interaction complex results in the formation of a bioluminescent complex. In some embodiments, the strength or extent of the interaction complex is directly proportional to the intensity of the resulting bioluminescent signal. Some non-luminescent pairs have dissociation constants (e.g., K d Other non-luminescent pairs produce a detectable signal when combined with an interaction complex having a low millimolar concentration (e.g., K > 100 mM) to produce a bioluminescent complex with a detectable signal. d <100 mM), micromolar (e.g., K d <1 mM), nanomolar concentrations (e.g., K d <1 μM), or even picomolar concentrations (e.g., K d The interaction requires an interaction pair with a dissociation constant of <1 nM.
[0038] In some embodiments, one or more of the non-luminescent peptides / polypeptides are not fragments of an existing protein. In some embodiments, one or more of the non-luminescent peptides / polypeptides are not fragments of an existing bioluminescent protein. In some embodiments, none / none of the non-luminescent peptides / polypeptides are fragments of an existing protein. In some embodiments, none / none of the non-luminescent peptides / polypeptides are fragments of an existing bioluminescent protein. In some embodiments, none of the non-luminescent peptides or polypeptides that assemble to form a bioluminescent complex are fragments of an existing protein. In some embodiments, the non-luminescent elements used in embodiments of the present invention are not subsequences of existing proteins. In some embodiments, the non-luminescent pairs used herein do not comprise complementary subsequences of existing proteins.
[0039] In some embodiments, the non-luminescent peptides / polypeptides are substantially non-luminescent by themselves. In certain embodiments, when placed under appropriate conditions (e.g., physiological conditions), the non-luminescent peptides / polypeptides interact to form a bioluminescent complex that generates a bioluminescent signal in the presence of a substrate. In other embodiments, without the addition of one or more interacting elements (e.g., complementary interacting elements attached to constituent non-luminescent peptides and polypeptides), the non-luminescent peptides / polypeptides are unable to form a bioluminescent complex or only weakly form a complex. In such embodiments, the non-luminescent peptides / polypeptides are substantially non-luminescent in the presence of each other alone, but generate significant detectable luminescence when aggregated, associated, oriented, or otherwise combined by the interacting elements. In some embodiments, without the addition of one or more interacting elements (e.g., complementary interacting elements attached to constituent peptides and polypeptides), the peptides and / or polypeptides that assemble into a bioluminescent complex generate low levels of luminescence in the presence of each other, but generate a significant increase in detectable luminescence when aggregated, associated, oriented, or otherwise combined by the interacting elements.
[0040] In some embodiments, the compositions and methods described herein include one or more interacting elements. In typical embodiments, the interacting elements are moieties (e.g., peptides, polypeptides, proteins, small molecules, nucleic acids, lipids, carbohydrates, etc.) that are attached to peptides and / or polypeptides to assemble into a bioluminescent complex. The interacting elements promote the formation of a bioluminescent complex by any suitable mechanism, including interacting with one or both non-luminescent elements, inducing a conformational change in a non-luminescent element, interacting with another interacting element (e.g., an interacting element attached to another non-luminescent element), bringing the non-luminescent elements into proximity, orienting the non-luminescent elements for proper interaction, etc.
[0041] In some embodiments, one or more interacting elements are added to a solution containing the non-luminescent elements but are not attached to the non-luminescent elements. In such embodiments, the interacting element(s) interact with the non-luminescent elements to induce the formation of a bioluminescent complex or to create conditions favorable for the formation of a bioluminescent complex. In other embodiments, a single interacting element is attached to a member of a non-luminescent pair. In such embodiments, a single interacting element interacts with one or both of the non-luminescent elements to create an interaction favorable for the formation of a bioluminescent complex. In an exemplary embodiment of the invention, one interacting element is attached to each member of a non-luminescent pair. The favorable interaction between the interacting elements promotes the interaction between the non-luminescent elements. The interacting pair may interact stably, interact transiently, form a complex, etc. The interaction of the interacting pair promotes the interaction of the non-luminescent elements (and the formation of a bioluminescent complex) by any suitable mechanism, including, but not limited to, bringing the non-luminescent pair members into proximity, properly orienting the non-luminescent pair members away from the interaction, reducing covalent forces acting against the interaction of the non-luminescent pair, etc.
[0042] In some embodiments, an interaction pair includes any two chemical moieties that promote the interaction of the associated non-emissive pair. An interaction pair may consist of, for example, two complementary nucleic acids, two polypeptides capable of dimerization (e.g., homodimers, heterodimers, etc.), a protein and a ligand, a protein and a small molecule, an antibody and an epitope, a reactive pair of small molecules, etc. Any suitable pair of interacting molecules can be used as an interaction pair.
[0043] In some embodiments, an interaction pair comprises two molecules of interest (e.g., proteins of interest) or target molecules. In some embodiments, the compositions and methods described herein provide useful assays (e.g., in vitro, in vivo, in situ, whole animal, etc.) for examining interactions between pairs of target molecules.
[0044] In certain embodiments, a pair of interacting elements, each attached to one of the non-luminescent elements, interact with each other, thereby promoting the formation of a bioluminescent complex. In some embodiments, the presence of a ligand, substrate, cofactor, or additional interacting element (e.g., not attached to the non-luminescent element) is necessary to induce interaction between the interacting elements, promoting the formation of a bioluminescent complex. In some embodiments, detection of a signal from a bioluminescent complex indicates the presence of a ligand, substrate, cofactor, or additional interacting element, or conditions that allow interaction with the interacting element.
[0045] In some embodiments, a pair of interacting elements and a pair of non-luminescent elements are all present in a single amino acid chain (e.g., (interacting element 1)-NLpep-(interacting element 2)-NLpoly, NLpoly-(interacting element 1)-NLpep--(interacting element 2), NLpoly-(interacting element 1)-(interacting element 2)-NLpep, etc.). In some embodiments in which a pair of interacting elements and a pair of non-luminescent elements are all present in a single amino acid chain, a ligand, substrate, cofactor, or additional interacting element is required for the interacting pair to form an interaction complex and promote the formation of a bioluminescent complex.
[0046] In certain embodiments, the interactive element and the non-luminescent element are attached, fused, linked, connected, etc. In typical embodiments, a first non-luminescent element and a first interactive element are attached to one another, and a second non-luminescent element and a second interactive element are attached to one another. Attachment of the signal element and the interactive element may be achieved by any suitable mechanism, chemistry, linker, etc. The interactive and non-luminescent elements are typically attached by a covalent connection, although non-covalent linkage of the two elements is also provided. In some embodiments, the signal element and the interactive element are directly connected, while in other embodiments, they are connected by a linker.
[0047] In some embodiments where the interacting element is a peptide or polypeptide, the signal element and the interacting element are contained within a single amino acid chain. In some embodiments, the single amino acid chain comprises, consists of, or consists essentially of a non-luminescent element and an interacting element. In some embodiments, the single amino acid chain comprises, consists of, or consists essentially of a non-luminescent element, an interacting element, and optionally one or more N-terminal sequences, C-terminal sequences, regulatory elements (e.g., promoters, translation initiation sites, etc.), and linker sequences. In some embodiments, the signal element and the interacting element are contained within a fusion polypeptide. While the signal element and the interacting element (and any other amino acid segments included in the fusion) can be expressed separately, in other embodiments, a fusion protein is expressed that comprises or consists of both the interacting sequence and the signal sequence.
[0048] In some embodiments, a first fusion protein comprising a first non-luminescent element and a first interacting element and a second fusion protein comprising a second non-luminescent element and a second interacting element are expressed in the same cell. In such embodiments, the first and second fusion proteins are purified and / or isolated from the cell, or the interaction of the fusion proteins is assayed in the cell. In other embodiments, the first and second fusion proteins are expressed in separate cells and combined for signal detection (e.g., after purification and / or isolation, or after fusion of cells or portions of cells, or by transferring the fusion proteins from one cell to another, or by secreting one or more fusion proteins into the extracellular medium). In some embodiments, one or more fusion proteins are expressed in a cell lysate (e.g., rabbit reticulocyte lysate) or a cell-free system. In some embodiments, one or more fusion proteins are expressed from the genome of a virus or other cellular pathogen.
[0049] In certain embodiments, nucleic acids, DNA, RNA, vectors, etc. are provided that encode the peptides, polypeptides, fusion polypeptides, fusion proteins, etc. of the invention. Such nucleic acids and vectors may be used for expression, transformation, transfection, injection, etc.
[0050] In some embodiments, the non-luminescent element and the interacting element are connected by a linker. In some embodiments, the linker connects the signaling element and the interacting element while providing a desired amount of space / distance between them. In some embodiments, the linker allows both the signaling element and the interacting element to simultaneously form their respective pairs (e.g., non-luminescent pair and interacting pair). In some embodiments, the linker assists the interacting element in facilitating the formation of the interaction of the non-luminescent pair. In some embodiments, once the interacting pair is formed, the linker connecting each non-luminescent element to its respective interacting element positions the non-luminescent elements at the appropriate distance and conformation to form a bioluminescent complex. In some embodiments, the interacting element and the non-luminescent element are held in close proximity by the linker (e.g., <4 monomer units). In some embodiments, the linker provides a desired amount of distance (e.g., 1, 2, 3, 4, 5, 6... 10... 20, or more monomer units) between the signal element and the interacting element (e.g., to prevent undesired interactions between the signal element and the interacting element, for steric considerations, to allow proper orientation of the non-emissive element when the interacting complex is formed, to allow propagation of complex formation from the interacting complex to the non-emissive element, etc.). In certain embodiments, the linker provides an appropriate attachment chemistry between the signal element and the interacting element. The linker may also improve the synthetic process for making the signal element and the interacting element (e.g., allowing them to be synthesized as a single unit, allowing post-synthetic connection of the two elements, etc.).
[0051] In some embodiments, the linker is any suitable chemical moiety that can link, connect, or tether the non-luminescent element to the interacting element. In some embodiments, the linker is a polymer of one or more repeating or non-repeating monomer units (e.g., nucleic acids, amino acids, carbon-containing polymers, carbon chains, etc.). When the non-luminescent element and the interacting element are part of a fusion protein, the linker (if present) is typically an amino acid chain. When the non-luminescent element and the interacting element are tethered together after expression of the individual elements, the linker may include any chemical moiety having functional (or reactive) groups at either end that react with functional groups on the signaling element and the interacting element, respectively. Any suitable moiety that can tether the signaling element and the interacting element can be used as a linker.
[0052] A wide variety of linkers can be used. In some embodiments, the linker is a single covalent bond. In some embodiments, the linker comprises a linear or branched, cyclic or heterocyclic, saturated or unsaturated structure having 1 to 20 non-hydrogen atoms (e.g., C, N, P, O, and S), and is composed of any combination of alkyl, ether, thioether, imine, carboxylic acid, amine, ester, carboxamide, sulfonamide, hydrazide linkages, and aromatic or heteroaromatic linkages. In some embodiments, the linker is longer than 20 non-hydrogen atoms (e.g., 21 non-hydrogen atoms, 25 non-hydrogen atoms, 30 non-hydrogen atoms, 40 non-hydrogen atoms, 50 non-hydrogen atoms, 100 non-hydrogen atoms, etc.). In some embodiments, the linker comprises 1 to 50 non-hydrogen atoms (in addition to hydrogen atoms) selected from the group of C, N, P, O, and S (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 non-hydrogen atoms).
[0053] The present invention is not limited by the type of linker that can be used. The signal element and the interaction element can be linked either directly (e.g., a linker consisting of a single covalent bond) or via a suitable linker. The present invention is not limited to any particular linker group. A variety of linker groups are contemplated, and suitable linkers include, but are not limited to, alkyl groups, methylene carbon chains, ethers, polyethers, alkylamide linkers, peptide linkers, modified peptide linkers, poly(ethylene glycol) (PEG) linkers, streptavidin-biotin or avidin-biotin linkers, polyamino acids (e.g., polylysine), functionalized PEGs, polysaccharides, glycosaminoglycans, dendritic polymers (WO 93 / 06868 and Tomalia et al., Angew. Chem. Int. Ed. Engl. 29:138-175 (1990); incorporated herein by reference in their entireties), PEG-chelator polymers (WO 94 / 08629, WO 94 / 09056, and WO 96 / 26754; incorporated herein by reference in their entireties), oligonucleotide linkers, phospholipid derivatives, alkenyl chains, alkynyl chains, disulfides, or combinations thereof. In some embodiments, the linker is cleavable (e.g., enzymatically (e.g., a TEV protease site), chemically, photoinducibly, etc.
[0054] In some embodiments, substantially non-luminescent peptides and polypeptides are provided that have less than 100% sequence identity and / or similarity to any portion of an existing luciferase (e.g., firefly luciferase, Renilla luciferase, Pterygosperm luciferase, or the highly sensitive Pterygosperm luciferases described in U.S. Patent Application Publication Nos. 2010 / 0281552 and 2012 / 0174242, which are incorporated by reference in their entireties). Certain embodiments of the invention involve the formation of bioluminescent complexes of non-luminescent peptides and polypeptides that have less than 100% sequence identity to all or a portion (e.g., for peptides, 8 or more amino acids, less than about 25 amino acids) of SEQ ID NO:2157 (e.g., the complete NANOLUC sequence). Certain embodiments of the invention involve the formation of bioluminescent complexes of non-luminescent peptides and polypeptides that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity to all or a portion (e.g., for peptides, 8 or more amino acids, less than about 25 amino acids) of SEQ ID NO:2157 (e.g., the complete NANOLUC sequence). In some embodiments, non-luminescent peptides and polypeptides (e.g., peptides and polypeptides that interact to form bioluminescent complexes) that have less than 100% sequence similarity to a portion (e.g., for peptides, 8 or more amino acids, less than about 25 amino acids) of SEQ ID NO:2157 are provided. In some embodiments, non-luminescent peptides and polypeptides (e.g., peptides and polypeptides that interact to form bioluminescent complexes) are provided that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence similarity to a portion of SEQ ID NO: 2157 (e.g., for peptides, 8 or more amino acids, less than about 25 amino acids).Non-luminescent peptides are provided that have less than 100% sequence identity and / or similarity to about 25 amino acids or a smaller portion of SEQ ID NO: 2157, and when combined under appropriate conditions (e.g., stabilized by an interaction pair) with a polypeptide having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity and / or similarity to another portion of SEQ ID NO: 2157, such peptides form a bioluminescent complex. Non-luminescent peptides are provided that have less than 100% sequence identity and / or similarity to about 25 amino acids or a smaller portion of SEQ ID NO: 2157, and when combined under appropriate conditions (e.g., stabilized by an interaction pair) with a polypeptide having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity and / or similarity to another portion of SEQ ID NO: 2157, such peptides form a bioluminescent complex. Non-luminescent peptides are provided that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity and / or similarity to about 25 amino acids or a smaller portion of SEQ ID NO:2157, such peptides form bioluminescent complexes when combined under appropriate conditions (e.g., stabilized by an interaction pair) with a polypeptide having less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity and / or similarity to another portion of SEQ ID NO:2157.Similarly, non-luminescent polypeptides are provided that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity or similarity to a portion of SEQ ID NO:2157, such polypeptides forming a bioluminescent complex when combined under appropriate conditions (e.g., stabilized by an interaction pair) with a peptide having less than 100% but optionally more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity and / or similarity to another portion of SEQ ID NO:2157. In some embodiments, non-luminescent peptides are provided that have less than 100% sequence identity or similarity to SEQ ID NO: 2. In some embodiments, non-luminescent peptides are provided that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity or similarity to SEQ ID NO: 2. In some embodiments, non-luminescent polypeptides are provided that have less than 100% sequence identity or similarity to SEQ ID NO: 440. In some embodiments, non-luminescent polypeptides are provided that have less than 100% but more than 40% (e.g., >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, >98%, >99%) sequence identity or similarity to SEQ ID NO:440.
[0055] In some embodiments, non-luminescent peptides used in embodiments of the invention include peptides having one or more amino acid substitutions, deletions, or additions relative to GVTGWRLCKRISA (SEQ ID NO: 236). In some embodiments, the invention provides peptides comprising one or more of the amino acid sequences of Table 1 and / or nucleic acids comprising the nucleic acid sequences of Table 1 (encoding the peptide sequences of Table 1). Table 1. Peptide sequences JPEG2024167207000001.jpg249169 JPEG2024167207000002.jpg239166 JPEG2024167207000003.jpg249166 JPEG2024167207000004.jpg249166 JPEG2024167207000005.jpg249166 JPEG2024167207000006.jpg249166 JPEG2024167207000007.jpg249166 JPEG2024167207000008.jpg249166 JPEG2024167207000009.jpg249166 JPEG2024167207000010.jpg249166 JPEG2024167207000011.jpg249166 JPEG2024167207000012.jpg249166 JPEG2024167207000013.jpg249166 JPEG2024167207000014.jpg249166 JPEG2024167207000015.jpg249166 JPEG2024167207000016.jpg249166 JPEG2024167207000017.jpg249166 JPEG2024167207000018.jpg249166 JPEG2024167207000019.jpg249166 JPEG2024167207000020.jpg249166 JPEG2024167207000021.jpg249166 JPEG2024167207000022.jpg249166 JPEG2024167207000023.jpg249166 JPEG2024167207000024.jpg249166 JPEG2024167207000025.jpg249166 JPEG2024167207000026.jpg249166 JPEG2024167207000027.jpg249166 JPEG2024167207000028.jpg239166
[0056] In certain embodiments, a peptide in Table 1 is provided. In some embodiments, the peptide comprises a single amino acid difference from GVTGWRLCKRISA (SEQ ID NO:236) and / or any of the peptides listed in Table 1. In some embodiments, the peptide comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid differences from GVTGWRLCKRISA (SEQ ID NO:236) and / or any of the peptides listed in Table 1. In some embodiments, a peptide is provided that comprises one of the amino acid sequences of SEQ ID NOs:3-438 and 2162-2365. In some embodiments, a peptide is provided that comprises one of the amino acid sequences of SEQ ID NOs:3-438 and 2162-2365 that includes one or more additions, substitutions, and / or deletions. In some embodiments, the peptide or portion thereof comprises greater than 70% sequence identity (e.g., 71%, 75%, 80%, 85%, 90%, 95%, 99%) with one or more of the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365. In some embodiments, a nucleic acid comprising one of the nucleic acids encoding the sequences of SEQ ID NOs: 3-438 and 2162-2365 is provided. In some embodiments, a nucleic acid comprising one of the nucleic acid sequences of SEQ ID NOs: 3-438 and 2162-2365 comprising one or more additions, substitutions, and / or deletions is provided. In some embodiments, the nucleic acid or portion thereof comprises greater than 70% sequence identity (e.g., 71%, 75%, 80%, 85%, 90%, 95%, 99%) with one or more of the nucleic acid sequences of SEQ ID NOs: 3-438 and 2162-2365. In some embodiments, nucleic acids are provided that encode one of the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365. In some embodiments, nucleic acids are provided that encode one of the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365 that include one or more additions, substitutions, and / or deletions. In some embodiments, nucleic acids are provided that encode amino acids having greater than 70% sequence identity (e.g., 71%, 75%, 80%, 85%, 90%, 95%, 99%) to one or more of the amino acid sequences of SEQ ID NOs: 3-438 and 2162-2365.
[0057] In certain embodiments, nucleic acids of Table 1 are provided. In some embodiments, nucleic acids encoding peptides of Table 1 are provided. In some embodiments, nucleic acids of the invention encode peptides comprising a single amino acid difference from MGVTGWRLCERILA (SEQ ID NO:2) and / or any of the peptides listed in Table 1. In some embodiments, nucleic acids encode peptides comprising two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid differences from MGVTGWRLCERILA (SEQ ID NO:2) and / or any of the peptides listed in Table 1. In some embodiments, nucleic acids comprising the sequence of one of the nucleic acids of Table 1 are provided. In some embodiments, nucleic acids comprising the sequence of one of the nucleic acids of Table 1 comprising one or more additions, substitutions, and / or deletions are provided. In some embodiments, a nucleic acid or portion thereof comprises greater than 70% sequence identity (e.g., 71%, 75%, 80%, 85%, 90%, 95%, 99%) with one or more of the nucleic acids of Table 1.
[0058] In some embodiments, non-luminescent polypeptides used in embodiments of the invention include peptides having one or more amino acid substitutions, deletions, or additions relative to SEQ ID NO: 440. In some embodiments, the invention provides polypeptides comprising one or more of the amino acid sequences of Table 2 and / or nucleic acids comprising the nucleic acid sequences of Table 2 (encoding the polypeptide sequences of Table 2). Table 2. Polypeptide sequences JPEG2024167207000029.jpg239167 JPEG2024167207000030.jpg244166 JPEG2024167207000031.jpg244166 JPEG2024167207000032.jpg244166 JPEG2024167207000033.jpg244166 JPEG2024167207000034.jpg244166 JPEG2024167207000035.jpg244166 JPEG2024167207000036.jpg244166 JPEG2024167207000037.jpg249169 JPEG2024167207000038.jpg244167 JPEG2024167207000039.jpg213167 JPEG2024167207000040.jpg213167 JPEG2024167207000041.jpg213167 JPEG2024167207000042.jpg213167 JPEG2024167207000043.jpg223167 JPEG2024167207000044.jpg249167 JPEG2024167207000045.jpg234166 JPEG2024167207000046.jpg139165
[0059] The polypeptides and encoding nucleic acid sequences in Table 2 (SEQ ID NOS: 441-1298) all contain an N-terminal Met residue (amino acid) or an ATG start codon (nucleic acid). In some embodiments, the polypeptides and encoding nucleic acid sequences in Table 2 are provided without an N-terminal Met residue or an ATG start codon (SEQ ID NOS: 1299-2156).
[0060] In certain embodiments, a polypeptide is provided that comprises one of the amino acid polymers of SEQ ID NOs: 441-2156. In some embodiments, the polypeptide comprises a single amino acid difference from SEQ ID NO: 440. In some embodiments, the polypeptide comprises two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30...35...40...45...50 or more) amino acid differences from SEQ ID NO: 440 and / or any of the amino acid polymers of SEQ ID NOs: 441-2156. In some embodiments, a polypeptide is provided that comprises the sequence of one of the amino acid polymers of SEQ ID NOs: 441-2156, comprising one or more additions, substitutions, and / or deletions. In some embodiments, the polypeptide or portion thereof comprises greater than 70% sequence identity (e.g., >71%, >75%, >80%, >85%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, or >99%) to one or more of the amino acid polymers of SEQ ID NOs:441-2156.
[0061] In certain embodiments, nucleic acids of Table 2 are provided. In some embodiments, nucleic acids encoding polypeptides of Table 2 are provided. In some embodiments, nucleic acids of the invention encode polypeptides comprising a single amino acid difference from SEQ ID NO:440 and / or any of the amino acid polymers of SEQ ID NOs:441-2156. In some embodiments, nucleic acids encode polypeptides comprising two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30...35...40...45...50 or more) amino acid differences from SEQ ID NO:440 and / or any of the polypeptides listed in Table 2. In some embodiments, nucleic acids comprising the sequence of one of the nucleic acid polymers of SEQ ID NOs:441-2156 are provided. In some embodiments, a nucleic acid is provided that comprises the sequence of one of the nucleic acid polymers of SEQ ID NOs: 441-2156, including one or more additions, substitutions, and / or deletions. In some embodiments, the nucleic acid, or a portion thereof, comprises greater than 70% sequence identity (e.g., >71%, >75%, >80%, >85%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, or >99%) with one or more of the nucleic acid polymers of SEQ ID NOs: 441-2156. In some embodiments, a nucleic acid or portion thereof encodes a polypeptide comprising greater than 70% sequence identity (e.g., >71%, >75%, >80%, >85%, >90%, >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, or >99%) to one or more of the amino acid polymers of SEQ ID NOs: 441-2156. In some embodiments, nucleic acids encoding one of the polypeptides of SEQ ID NOs: 441-2156 are provided. In some embodiments, nucleic acids encoding one of the polypeptides of SEQ ID NOs: 441-2156 that comprise one or more additions, substitutions, and / or deletions are provided.
[0062] In some embodiments, the non-luminescent peptide or polypeptide and / or interacting element comprises a synthetic peptide, a peptide containing one or more unnatural amino acids, a peptidomimetic, a conjugated synthetic peptide (e.g., conjugated to a functional group (e.g., a fluorophore, a luminescent substrate, etc.)).
[0063] The present invention provides compositions and methods useful in a variety of fields, including basic research, medical research, molecular diagnostics, etc. The reagents and assays described herein are not limited to any particular use, and any useful use should be considered within the scope of the present invention; the following are exemplary assays, kits, fields, experimental settings, etc., utilizing the invention claimed herein.
[0064] Typical applications utilizing embodiments of the present invention involve monitoring / detecting protein dimerization (e.g., heterodimers, homodimers), protein-protein interactions, protein-RNA interactions, protein-DNA interactions, nucleic acid hybridization, protein-small molecule interactions, or any other combination of molecular entities. A first entity of interest is attached to a first member of a non-emissive pair, and a second entity of interest is attached to a second member of the non-emissive pair. Interaction of the first and second entities is inferred if a detectable signal is produced under specific assay conditions. Such assays are useful for monitoring molecular interactions under any suitable conditions (e.g., in vitro, in vivo, in situ, whole animal, etc.), for example, drug discovery, elucidating molecular pathways, studying equilibrium or kinetic aspects of complex assembly, high-throughput screening, proximity sensors, etc.
[0065] In some embodiments, non-emissive pairs with known characteristics (e.g., spectral properties, mutual affinity of the pair) are used to elucidate the affinity or understand the interaction of an interacting pair of interest. In other embodiments, well-characterized interacting pairs are used to determine the characteristics (e.g., spectral properties, mutual affinity of the pair) of the non-emissive pair.
[0066] The embodiments described herein can be used in drug screening and / or drug development. For example, the interaction of a target protein of interest (e.g., a therapeutic protein) with a small molecule drug or an entire library of small molecules is monitored under one or more appropriate conditions (e.g., physiological conditions, disease conditions, etc.). In other embodiments, the ability of a small molecule drug or an entire library of small molecules to enhance or inhibit the interaction between two entities (e.g., receptor and ligand, protein-protein, etc.) is assayed. In some embodiments, drug screening applications are performed in a high-throughput format to allow for the detection of binding of tens of thousands of different molecules to a target or to examine the effect of those molecules on the binding of other entities.
[0067] In some embodiments, the present invention provides for the detection of molecular interactions within living organisms (e.g., bacteria, yeast, eukaryotes, mammals, primates, humans, etc.) and / or cells. In some embodiments, fusion proteins comprising signal and interacting (target) polypeptides are co-expressed in cells or whole organisms, and the signal is detected and correlated with the formation of an interaction complex. In some embodiments, cells are transiently and / or stably transformed or transfected with vector(s) encoding non-luminescent element(s), interacting element(s), fusion proteins (e.g., comprising a signal element and an interacting element), etc. In some embodiments, transgenic organisms are generated that encode the fusion proteins necessary to perform the assays described herein. In other embodiments, whole organisms are injected with vectors. In some embodiments, transgenic animals or cells (e.g., expressing fusion proteins) are used to monitor the biodistribution of small molecules or biologics tethered (e.g., conjugated or genetically fused) to NL peptide sequences, which form complexes in subcellular compartments and / or tissues where they are concentrated.
[0068] In some embodiments, the peptide (e.g., non-luminescent peptide) portion of the luminescent complex is used as a protein tag (e.g., intracellularly). In such embodiments, the polypeptide (e.g., non-luminescent polypeptide) portion of the luminescent complex (e.g., capable of forming a luminescent complex with a non-luminescent peptide) is applied to cells (e.g., as part of a reagent) to detect / quantitate the presence of a protein tagged with the non-luminescent peptide. For example, a protein of interest is fused to a high-affinity NLpep (e.g., NLpep86). The NLpep is then transfected into cells of interest, and a reagent containing NanoGlo+NLpoly11S is then added to the cells and medium, and luminescence is detected. This assay scheme is shown in Figure 175. In some embodiments, small peptides are used to tag proteins. In some embodiments, the non-luminescent polypeptides used in such systems are sufficiently stable to exist in an appropriate buffer for extended periods of time (e.g., in the presence of a furimazine substrate). In certain embodiments, the non-luminescent polypeptide has minimal detectable luminescence in the absence of a complementary peptide (e.g., even in the presence of a furimazine substrate). In some embodiments, buffer conditions optimized to meet the criteria required for protein tagging are used. High-affinity naturally occurring polypeptides and peptides are useful in such systems, for example, in immunoassays, detection of viral particles, studying protein dynamics in living cells, etc. In some embodiments, such systems provide extremely small protein tags (e.g., 11 amino acids) that offer high-sensitivity detection, stability (e.g., especially under denaturing conditions), and / or a wide dynamic range.
[0069] The compositions and methods provided herein, and any techniques or technologies based thereon, find use in a variety of applications and fields; a non-limiting list of exemplary applications follows: Antibody-free Western blot: For example, a protein of interest is fused (e.g., by genetic engineering) to a non-luminescent peptide and expressed by any suitable means. The proteins are separated (e.g., by PAGE) and transferred to a membrane. The membrane is then washed with a complementary non-luminescent polypeptide (e.g., to form a luminescent complex), and the membrane is loaded with furimazine (PBI-3939) and placed on an imager (e.g., using a CCD camera) to detect the protein of interest (e.g., by the emission of the luminescent complex). "LucCytochemistry": For example, a protein of interest is expressed fused to a non-luminescent peptide or polypeptide and then detected with a complementary non-luminescent polypeptide or peptide in a manner similar to immunocytochemistry. Protein localization assay: For example, a non-luminescent polypeptide or polypeptides are tagged (e.g., by genetic engineering) with a localization signal and expressed in cells (e.g., an added nuclear localization signal results in expression of the non-luminescent polypeptide in the nucleus). A complementary non-luminescent peptide or polypeptide is fused (e.g., by genetic engineering) to a protein of interest and expressed in cells containing the non-luminescent polypeptide or peptide. If the protein of interest is localized in the same subcellular compartment (e.g., the nucleus) as the non-luminescent polypeptide with the localization signal, luminescence is generated. Protein stability assays: For example, a protein of interest is fused (e.g., by genetic engineering) to a non-luminescent peptide or polypeptide and incubated under one or more conditions of interest. A complementary non-luminescent polypeptide or peptide is added (e.g., at various time points) and luminescence is used to quantify the amount of protein of interest (e.g., as a surrogate for stability). Protein detection / quantification: For example, a protein of interest is fused (e.g., by genetic engineering) to a non-luminescent peptide or polypeptide, expressed and / or manipulated by any method, and then a complementary non-luminescent polypeptide or peptide is added to detect and / or quantify the protein of interest. Protein purification: For example, a protein of interest is fused (e.g., by genetic engineering) to a non-luminescent peptide or polypeptide and expressed by any method. The protein mixture is passed over a complementary non-luminescent polypeptide or peptide immobilized (e.g., on beads, a column, a chip, etc.), washed with an appropriate buffer, and eluted (e.g., with a buffer of high ionic strength or low pH). A mutant form of the non-luminescent peptide or polypeptide that does not activate the luminescence of the complementary non-luminescent peptide or polypeptide can be used to elute the protein of interest. Pull-down: for example, using an immobilized complementary non-luminescent polypeptide to isolate a protein of interest (and interacting proteins) that has been fused (e.g., by genetic engineering) to a non-luminescent peptide. G protein-coupled receptor (GPCR) internalization assay: For example, a non-luminescent peptide or polypeptide is fused (e.g., by genetic engineering) to a GPCR of interest and expressed on the surface of cells. A complementary non-luminescent polypeptide or peptide is added to the cell culture medium and used to detect the GPCR on the cell surface. A decrease in luminescence is observed upon addition of a ligand to stimulate GPCR internalization. Membrane integrity assay for cell viability: For example, if the cell membrane of a cell expressing a non-luminescent polypeptide is compromised, the non-luminescent peptide will enter the membrane (e.g., a peptide that would not otherwise be able to cross the cell membrane), thereby forming a luminescent complex and producing light. Detection of 5-hydroxymethylcytosine: For example, cysteine is added to a non-luminescent peptide and incubated with DNA and a methyltransferase. The methyltransferase catalyzes the addition of a thiol (cysteine) only to the 5-hydroxymethylated cytosine residues. Unincorporated peptides are then separated from the DNA (using any method possible), a non-luminescent polypeptide is added, and the peptide conjugated to the DNA is detected. Detection of formylcytosine: Similar to the detection of 5-hydroxymethylcytosine described above, this detection method uses a chemistry that is specifically reactive towards formylcytosine. Viral incorporation: A nucleic acid encoding a non-luminescent peptide or polypeptide is incorporated into the viral genome, resulting in constitutive expression of the complementary non-luminescent polypeptide or peptide in target cells. Upon infection of the target cell and expression of the non-luminescent peptide, a bioluminescent complex forms and a signal is detected (e.g., in the presence of a substrate). Chemical labeling of proteins: A non-luminescent peptide is fused or tethered to a reactive group (e.g., biotin, succinimidyl ester, maleimide, etc.). Attachment of the reactive group to a protein of interest (e.g., an antibody) tags the protein of interest with the non-luminescent peptide. Because the peptide is small, it does not affect the functionality of the protein of interest. A complementary non-luminescent polypeptide is added to the system; upon binding of the polypeptide to the peptide, a luminescent complex is generated. Protease assay: For example, a peptide sequence recognized by a protease of interest can be attached to an NLPep in a manner that avoids bioluminescence when exposed to the NLPoly. Methods for doing this include adding a quencher to the protease recognition sequence or attaching the protease recognition site to the NLPep so that complementation is prevented. This system is a highly sensitive protease assay because when the protease is activated to cleave the recognition site, the ability of the NLPoly to complement the NLPep and emit luminescence is restored. RNA detection Characterization of biomolecular linkers: Linkers attached to biomolecules, such as antibodies, can be evaluated for their stability under a range of conditions by attaching an NLPep to the molecule via the linker of interest. Over time, the addition of NLPoly and furimazine and quantification of the generated bioluminescence can monitor the degradation of the linker to produce free NLPep. Mutation assays: for example, point mutations, frameshift mutations, etc. introduced in vitro or in vivo result in a gain or loss of signal from a complementary pair. Such assays can be used, for example, to test compounds for mutagenicity. Target binding of peptide inhibitors: Use of low affinity NLpep conjugated peptides (expressed in cells) to monitor target binding of peptide inhibitors. NLpep tethers to the target of interest. Binding results in a decrease in signal from the luminescent conjugate. Signal-acquisition type protease biosensor: A protease cleavage site is expressed between NLpoly and a dark peptide (NLpep) (low affinity). Upon cleavage, the dark peptide is released, and the high-affinity NLpep can complement NLpoly. Gain-of-function protease assay: The sequence of NLpep is engineered proximal to the cleavage site of a full-length substrate of a protease (e.g., caspase, ADAM, etc.). As long as the substrate remains intact and the peptide is "buried," it remains sterically sequestered. Both the engineered protease substrate and NLpoly (e.g., NLpoly11S) are co-transfected into a target cell line. Induction of protease activity induces luciferase activity, leading to cleavage of the substrate and exposure of an activator peptide on the N- or C-terminus of one of the fragments. This principle can be extended to detect conformational changes and / or protein modifications. Quantification of intracellular analytes using recombinant intracellular antibodies: An antibody fragment is expressed intracellularly as a fusion with NLpoly or NLpep. The complementary subunit is genetically fused to the analyte of interest. If the analyte is present, the antibody binds and a luminescent complex is formed. This application extends to intracellular PTM (e.g., phosphorylation) biosensors that bind the analyte when the intracellular antibody is phosphorylated (or otherwise bound by a modified specific Ab). The above uses of the compositions and methods of the present invention are not limiting and can be modified in any suitable manner while still remaining within the scope of the present invention.
[0070] The present invention also provides methods for the design and / or optimization of non-emissive pairs / groups and bioluminescent conjugates formed therefrom. Any suitable method for the design of non-emissive pairs / groups and / or panels thereof consistent with the embodiments described herein is within the scope of the present invention.
[0071] In certain embodiments, the non-luminescent pairs / groups are de novo designed to lack luminescence individually and exhibit luminescence upon association, in such embodiments, the strength of the interaction between the non-luminescent elements is insufficient to generate a bioluminescent signal in the absence of the interacting elements to promote the formation of a bioluminescent complex.
[0072] In other embodiments, non-luminescent elements and / or non-luminescent pairs are rationally designed, e.g., using a bioluminescent protein (e.g., SEQ ID NO: 2157) as a starting point. For example, such a method may include: (a) aligning the sequences of three or more related proteins; (b) determining a consensus sequence of the related proteins; (c) providing first and second fragments of a bioluminescent protein related to the protein for which the consensus sequence was determined, wherein the fragments are substantially non-luminescent individually but exhibit luminescence when the fragments interact; (d) mutating (e.g., in vitro, in silico, etc.) each of the first and second fragments at one or more positions, wherein the mutation alters the sequence of the fragment to more closely resemble the corresponding portion of the consensus sequence, where the mutation results in a non-luminescent pair that is not a fragment of a pre-existing protein; and (e) testing the non-luminescent pair for absence of luminescence when unassociated and for luminescence when the non-luminescent pair associates. In other embodiments, a first and second fragment of one of the proteins used in determining the consensus sequence are provided, mutated, and tested.
[0073] In some embodiments, the peptide of the luminescent pair is a "dark peptide," i.e., a peptide that binds to its complement (e.g., NLpoly) (e.g., with low or high affinity) but produces minimal or no luminescence (see Figures 180-182). In some embodiments, high-affinity dark peptides are used in reverse complementation, or signal-gain assays to measure inhibitors. In some embodiments, low-affinity dark peptides are used to reduce the background of NLpoly11S in reagents for detection of high-affinity peptide tags (e.g., NLpep86). Exemplary dark peptides are provided in Figure 180.
[0074] In some embodiments, the peptide of the luminescent pair is a "quencher peptide," i.e., a peptide containing a quencher moiety (e.g., DAB), where the quencher absorbs light / energy generated by both the NLpoly alone (e.g., signal generated independently of the complementary NLpep) and the NLpoly-NLpep complex (e.g., signal generated as a result of complex formation). Exemplary dark-quencher peptides have suitable absorption spectra and include DAB-161 (DAB-GWRLFKK), DAB-162 (DAB-GWALFKK), DAB-163 (DAB-VTGWALFEEIL), DAB-164 (DAB-VTGYALFQEIL), DAB-165 (DAB-VTGYALFEQIL), and DAB-166 (DAB-VTGYALFEEIL), where DAB = dabcyl (475 nm quencher) + dPEG spacer.
[0075] In some embodiments, the methods described above are not limited to the design and / or optimization of non-luminescent pairs. The same steps are performed to generate pairs of elements that individually lack a given functionality (e.g., enzymatic activity) but exhibit such functionality when associated. In any such case, the strength of the interaction between the elements of the non-luminescent pair can be altered by mutation to ensure that it is insufficient to confer functionality in the absence of the interacting elements that promote the formation of a bioluminescent complex. [Example]
[0076] experiment Example 1 Preparation of peptides Peptide constructs were generated by one of three methods: annealing of 5′ phosphorylated oligonucleotides followed by ligation into pF4Ag-Barnase-HALOTAG vector (Promega Corporation; cut with SgfI and XhoI) or pFN18A (Promega Corporation; cut with SgfI and XbaI), site-directed mutagenesis using Agilent's Quik Change Lightning Multi kit, or outsourcing cloning to Gene Dynamics.
[0077] Example 2 Preparation of peptides The peptides produced in Example 1 were prepared for analysis by inoculating 2-5 ml of LB culture with a single colony of KRXE E. coli cells (Promega Corporation) transformed with the peptide-encoding plasmid and grown overnight at 37°C. The overnight culture (10 ml) was then diluted into 1 L of LB and grown for 3 hours at 37°C. The culture was then induced by adding 10 ml of 20% rhamnose to the 1 L of culture and induced for 18 hours at 25°C.
[0078] After induction, 800 ml of each culture was spun at 5000 x g for 30 minutes at 4°C. The resulting pellet was then resuspended in 80 ml of peptide lysis buffer (25 mM HEPES pH 7.4, 0.1x Passive Lysis Buffer (Promega Corporation), 1 ml / ml lysozyme, and 0.03 U / µl RQ1 DNase (Promega Corporation)) and incubated at room temperature for 15 minutes. The lysed cells were then frozen on dry ice for 15 minutes and then thawed in a room temperature bath for 15 minutes. The cells were then spun at 3500 x g for 30 minutes at 4°C. The supernatant was aliquoted into 10 ml samples, and one aliquot of 50 µl was placed in a 1.5 ml test tube.
[0079] To 50 μl of sample, 450 μl of HO and 167 μl of 4×SDS Loading Dye were added, and the samples were incubated at 95°C for 5 minutes. After heating, 5 μl of each sample was loaded onto an SDS-PAGE gel (in triplicate), and the gel was run and stained according to the manufacturer's protocol. The gel was then scanned on a Typhoon Scanner (excitation 532 nm, emission 580 nm, PMT sensitivity 400 V). The resulting bands were quantified using ImageQuant (5.2) software. The intensities of each of the three replicates were averaged, and the average intensity of NLpep53-HT was defined as 12× the concentration. The concentrations of all other peptides were compared to Pep53-HT.
[0080] Example 3 Peptide analysis All peptides generated in Examples 1-2 contained a single mutation to the peptide sequence: GVTGWRLCKRISA (SEQ ID NO: 236). All peptides were fused to the HALOTAG protein (Promega Corporation). Peptides identified as "HT-NLpep" indicate that the peptide is located at the C-terminus of the HALOTAG protein. In this case, the gene encoding the peptide contains a stop codon but no methionine to initiate translation. Peptides identified as "NLpep-HT" indicate that the peptide is located at the N-terminus of the HALOTAG protein. In this case, the peptide contains a methionine to initiate translation but no stop codon.
[0081] To determine the ability of the peptides to activate luminescence, individual colonies of KRX E. coli cells (Promega Corporation) were transformed with the plasmids encoding the peptides from Example 1, inoculated into 200 μl of minimal medium (1× M9 salts, 0.1 mM CaCl, 2 mM MgSO, 1 mM thiamine HCl, 1% gelatin, 0.2% glycerol, and 100 μl / ml ampicillin), and grown overnight at 37°C. In addition to the peptides, cultures of KRX E. coli cells expressing the wild-type (WT) fragment of residues 1-156 of NanoLuc were grown. All peptides and WT fragments were inoculated into at least three separate cultures.
[0082] After the first overnight growth, 10 μl of the culture was diluted into 190 μl of fresh minimal medium and grown again overnight at 37°C.
[0083] After a second overnight growth, 10 μl of the culture was diluted into 190 μl of autoinduction medium (minimal medium + 5% glucose and 2% rhamnose). The culture was then induced at 25° C. for approximately 18 hours.
[0084] After induction, cultures containing small peptide variants were assayed for activity. Cultures containing the WT 1-156 fragments were pooled and mixed with 10 ml of 2x Lysis Buffer (50 mM HEPES pH 7.4, 0.3x Passive Lysis Buffer, and 1 mg / ml lysozyme) and incubated at room temperature for 10 minutes. 30 μl of lysed WT 1-156 culture was then aliquoted into wells of a white, round-bottom, 96-well assay plate (Costar 3355). 20 μl of peptide culture was added to the wells of the assay plate, and the plate was incubated at room temperature for 10 minutes. After incubation, 50 μl of NANOGLO Luciferase Assay Reagent (Promega Corporation) was added, and the samples were incubated at room temperature for 10 minutes. Luminescence was measured on a GLOMAX luminometer with a 0.5-second integration.
[0085] The results (see Table 3 and Figure 1) show various mutations in the peptide (compared to SEQ ID NO: 1) that altered (e.g., increased, decreased) luminescence after complementation with the wild-type non-luminescent polypeptide. The increase in luminescence is believed to result from one (or a combination) of five major factors: affinity of the non-luminescent peptide with the non-luminescent polypeptide, expression of the peptide, intracellular solubility, intracellular stability, and bioluminescent activity, any of which may be beneficial. However, the present invention is not limited to any particular mechanism of action, and understanding the mechanism of action is not necessary to practice the present invention. Table 3 JPEG2024167207000047.jpg175162 TIFF2024167207000048.tif142161
[0086] Example 4 Preparation of non-luminescent polypeptides Error-prone PCR (epPCR) was performed using pF4Ag-NanoLuc1-156 (WT 1-156) as a template using Clontech's Diversify PCR Random Mutagenesis Kit. The resulting PCR product was digested with SgfI and XbaI and ligated into pF4Ag-Barnase (Promega Corporation), a form of the commercially available pF4A vector (Promega) containing T7 and CMV promoters and modified to contain an E. coli ribosome-binding site. After transformation into KRX E. coli cells (Promega Corporation) by heat shock at 42°C, individual colonies were used to inoculate 200 μl of culture into clear, flat-bottom 96-well plates (Costar 3370).
[0087] Example 5 Analysis of non-luminescent polypeptides To determine the luminescence of the non-luminescent polypeptide variants generated in Example 4, individual colonies of KRX E. coli cells (Promega Corporation) transformed with a plasmid containing one of the non-luminescent polypeptide variants from Example 4 were grown according to the procedure used in Example 3. Bacterial cultures were also induced according to the procedure used in Example 3.
[0088] To assay each non-luminescent polypeptide variant induced culture, 30 μl of assay lysis buffer (25 mM HEPES pH 7.4, 0.3× Passive Lysis Buffer (Promega Corporation)), 0.006 U / μl RQ1 DNase (Promega Corporation), and a 1× peptide solution containing either the peptide fragment GVTGWRLCKRISA (SEQ ID NO: 18) or GVTGWRLFKRISA (SEQ ID NO: 106) (the relative concentrations of the peptides were determined as described in Example 2, and the peptides were diluted to 1× in lysis buffer from the determined relative concentrations) were aliquoted into wells of a 96-well assay plate (Costar 3355). 20 μl of induced non-luminescent polypeptide variant culture was added to the wells of the assay plate, and the plate was incubated at room temperature for 10 minutes. After incubation, 50 μl of NANOGLO Luciferase Assay Reagent (Promega Corporation) was added, and the samples were incubated at room temperature for 10 minutes. Luminescence was measured on a GLOMAX luminometer with 0.5 second integration.
[0089] The results (Table 4 and Figure 2) show a number of point mutations that improve the luminescence of a non-luminescent polypeptide when complemented with two different peptides. As with the mutations in the peptides, these mutations in the non-luminescent polypeptide are likely to arise from a variety of factors, all of which are beneficial to the system as a whole. Table 4 JPEG2024167207000049.jpg236164 * The units in Table 4 are RLU(mutation) / RLU(WT).
[0090] Example 6 Glycine to alanine substitutions in non-luminescent polypeptides. In the following examples, glycine residues in non-luminescent polypeptides were identified that can be substituted with alanine to provide improved (e.g., greater luminescent signal) non-luminescent polypeptides. Substitutions were made singly (see Figure 3) or in combination (Figure 2). Non-luminescent polypeptides containing glycine-to-alanine substitutions were generated as described in Example 1.
[0091] Each single mutant colony was inoculated into 200 μl of minimal medium (1× M9 salts, 0.1 mM CaCl, 2 mM MgSO, 1 mM thiamine HCl, 1% gelatin, 0.2% glycerol, and 1× ampicillin) and incubated with shaking at 37°C for 20 hours. 10 μl of the culture was then added to 190 μl of fresh minimal medium and again incubated with shaking at 37°C for 20 hours. 10 μl of the second culture was then added to 190 μl of autoinduction medium (minimal medium + 5% glucose + 2% rhamnose) and incubated with shaking at 25°C for 18 hours to allow expression of the non-luminescent polypeptide.
[0092] To assay each mutant culture, 30 μl of assay lysis buffer (50 mM HEPES pH 7.5, 0.3× Passive Lysis Buffer (Promega Corporation)) and 0.006 U / μl RQ1 DNase (Promega Corporation) containing a 1:10 dilution of a non-luminescent peptide (NLpep9-HT (NLpep9 is SEQ ID NOs: 17 and 18; HT is HaloTag E. coli clarified lysate)) were added. Samples were shaken for 10 minutes at room temperature, and then 50 μl of NANOGLO Luciferase Assay Reagent (Promega Corporation) was added. Samples were incubated for 10 minutes at room temperature, and luminescence was measured on a GLOMAX luminometer with a 0.5 second integration.
[0093] To prepare NLpep9-HT E. coli clarified lysate, 5 ml of LB was inoculated with a single NLpep9-HT E. coli colony and incubated overnight at 37°C. 500 μl of the overnight culture was then diluted into 50 ml of LB and incubated at 37°C for 3 hours. 500 μl of 20% rhamnose was added and incubated at 25°C for 18 hours. The expression culture was centrifuged at 3000 x g for 30 minutes, and the cell pellet was resuspended in 5 ml of peptide lysis buffer (25 mM HEPES, pH 7.5, 0.1x Passive Lysis Buffer, 1 mg / ml lysozyme, and 0.3 U / μl RQ1 DNase) and incubated at room temperature for 10 minutes. The lysed sample was placed on dry ice for 15 minutes, thawed in a room-temperature water bath, and centrifuged at 3500 x g for 30 minutes. The supernatant was the clarified lysate.
[0094] Figures 3 and 4 show the effect of the mutations on luminescence.
[0095] Example 7 Mutation of non-luminescent peptides In the following examples, mutations were made in non-luminescent peptides based on alignment to other fatty acid binding proteins (FABPs) and selected based on high probability (frequency in FABPs) to identify mutations that retain / improve activity (e.g., NLpep2, 4, and 5) or demonstrate that the mutation is unlikely to be tolerated at that position (e.g., NLpep3). NLpep1-5 contain single mutations (see Table 1), while NLpep6-9 are a combined set of mutations in NLpep2, 4, and 5 (see Table 1). Mutants were made as described in Example 1.
[0096] Each mutant colony was inoculated into 200 μl of minimal medium and incubated with shaking at 37° C. for 20 hours. 10 μl of the culture was then added to 190 μl of fresh minimal medium and again incubated with shaking at 37° C. for 20 hours. 10 μl of the second culture was then added to 190 μl of autoinduction medium and incubated with shaking at 25° C. for 18 hours to allow expression of the non-luminescent peptide mutants.
[0097] To assay each mutant culture, 30 μl of assay lysis buffer (50 mM HEPES pH 7.5, 0.3× Passive Lysis Buffer (Promega Corporation)) and 0.006 U / μl RQ1 DNase (Promega Corporation) containing the non-luminescent polypeptide (1:10 dilution of wild-type non-luminescent polypeptide E. coli clarified lysate) were added. The samples were shaken for 10 minutes at room temperature, and then 50 μl of NANOGLO Luciferase Assay Reagent (Promega Corporation) was added. The samples were incubated for 10 minutes at room temperature, and luminescence was measured with a 0.5-second integration on a GLOMAX luminometer. Figure 1 shows the luminescence (RLU) detected for each non-luminescent peptide mutant. The results indicate various positions that can tolerate mutations without significant loss of luminescence, as well as several specific mutations that improve luminescence.
[0098] Example 8 Effect of fusion tag orientation on light emission In the following example, the luminescence produced by a non-luminescent peptide bearing an N-terminal or C-terminal HaloTag protein was compared.
[0099] Single colonies of each peptide-HT fusion were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7. Figures 6 and 7 show the luminescence (RLU) detected for each peptide-HT fusion. The results indicate mutation combinations that produce luminescence similar to that of NLpep1.
[0100] Example 9 Effect of multiple freeze-thaw cycles on non-luminescent peptides One milliliter of NLpep9-HT was frozen on dry ice for 5 minutes and then thawed in a room-temperature water bath for 5 minutes. 60 μl was then removed for assay. The freeze-thaw procedure was then repeated 10 more times. After each freeze-thaw cycle, 60 μl was removed for assay.
[0101] To assay, 20 μl of each freeze-thawed sample was mixed with 30 μl of SEQ ID NO:2 and incubated at room temperature for 10 minutes. 50 μl of NANOGLO Luciferase Assay Reagent was added and the samples were incubated at room temperature for 10 minutes. Luminescence was measured with a 0.5 second integration on a GLOMAX luminometer. The results, shown in Figure 8, demonstrate that NLpep can be subjected to multiple freeze-thaw cycles without loss of activity (luminescence).
[0102] Example 10 Identifying mutations in non-luminescent peptides In the examples below, TMR gel analysis was used to normalize the concentration of non-luminescent peptide variants to distinguish mutations that alter expression from mutations that alter luminescence (e.g., changes in luminescence may result from changes in binding affinity).
[0103] 5 ml of LB was inoculated with a single mutant peptide colony and incubated with shaking at 37° C. for 20 hours. 50 μl of the overnight culture was diluted into 5 ml of fresh LB and incubated with shaking at 37° C. for 3 hours. 50 μl of 20% rhamnose was then added and induced with shaking at 25° C. for 18 hours.
[0104] For TMR gel analysis, 79 μl of each induced culture was mixed with 10 μl of 10× Fast Break Lysis Buffer (Promega Corporation), 10 μl of a 1:100 dilution of HALOTAG TMR Ligand (Promega Corporation) non-luminescent polypeptide, and 10 μl of RQ1 DNase and incubated at room temperature for 10 minutes. 33.3 μl of 4× SDS loading buffer was added, and the samples were incubated at 95°C for 5 minutes. 15 μl of each sample was loaded onto an SDS gel and run according to the manufacturer's instructions. The gels were then scanned on a Typhoon. Each culture was diluted based on the TMR gel intensity, and concentrations were normalized. 20 μl of each diluted culture was then mixed with 30 μl of assay lysis buffer containing a non-luminescent polypeptide (1:10 dilution of SEQ ID NO:2 E. coli clarified lysate) and incubated at room temperature for 10 minutes with shaking. 50 μl of NANOGLO Luciferase Assay Reagent was added and the samples were incubated for 10 minutes at room temperature. Luminescence was measured on a GLOMAX luminometer with 0.5 second integration (see Figure 9).
[0105] Example 11 Site saturation in non-luminescent polypeptides In the following example, positions 11, 15, 18, 31, 58, 67, 106, 149, and 157 were identified as relevant sites by screening a library of random mutations in a wild-type non-luminescent polypeptide. All 20 amino acids at these positions (constructed with the 5A2 non-luminescent mutants (SEQ ID NOs: 539 and 540) generated in Example 6 to validate other mutations in the 5A2 mutant) were compared to determine the optimal amino acid at that position. Mutant non-luminescent polypeptides were generated as previously described in Example 1. Single colonies of each non-luminescent polypeptide mutant were grown according to the procedure used in Example 6. Bacterial cultures were also induced according to the procedure used in Example 6. Luminescence was assayed and detected according to the procedure used in Example 6, except that NLpep53 E. coli clarified lysate was used at a dilution of 1:11.85. Figures 10-18 show the effect of mutations on the ability to generate luminescence with and without NLpep.
[0106] Example 12 Comparison of cysteine versus proline as the first amino acid in non-luminescent peptides The following example compares the use of cysteine or proline as the first amino acid (after the required methionine) in non-luminescent peptides. Mutant non-luminescent peptides were generated as previously described in Example 1. Single colonies of each non-luminescent polypeptide variant were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7. Figure 19 shows that both cysteine and proline can be used as the first amino acid in NLpep and will generate luminescence.
[0107] Example 13 Identifying a complex set of optimal mutations for non-luminescent peptides In the following examples, optimal combination sets of mutations for non-luminescent peptides were identified. Mutant non-luminescent peptides were generated as previously described in Example 1. 1) For the non-luminescent peptide conjugate variants NLpep53, NLpep66, NLpep67, and NLpep68, single colonies of each were grown according to the procedure used in Example 10. Bacterial cultures were also induced according to the procedure used in Example 10. TMR gel analysis and luminescence were assayed and detected according to the procedure used in Example 10. The results in Figure 20 show the luminescence and E. coli expression of NLpep containing multiple mutations. 2) For the non-luminescent peptide-combined mutants NLpep53 and NLpep66-74, single colonies of each were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7. The results in Figure 21 show the luminescence of NLpep containing multiple mutations. 3) For the non-luminescent peptide conjugate variants NLpep53 and NLpep66-76, single colonies of each were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7, except that the non-luminescent polypeptide was 5A2 or 5A2+R11E (1:10 dilution of E. coli clarified lysate). The results in Figure 22 show the luminescence of NLpep containing multiple mutations with 5A2 or 5A2+R11E. These results also show lower luminescence when the NLpep mutation R11E was complemented with NLpep containing E as the ninth residue (NLpep72, 75, and 76). 4) For the non-luminescent peptide composite variants NLpep1, NLpep69, NLpep78, and NLpep79, single colonies of each were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7, except that the non-luminescent polypeptide was WT (1:10 diluted E. coli clarified lysate). The results in Figure 23 show the luminescence of NLpep containing multiple mutations.
[0108] Example 14 Composite non-luminescent polypeptide variants In the following example, to identify the optimal composite set, nine mutations from the library screen were combined into a composite clone (NLpoly1, SEQ ID NOs: 941, 942), and then one of the mutations was reverted to the original amino acid (NLpoly2-10, SEQ ID NOs: 943-960). Based on the previous results with NLpoly1-10, NLpoly11-13 (SEQ ID NOs: 961-966) was designed and tested for the same purpose. The mutant NLpoly was generated as previously described in Example 1. Single colonies of each non-luminescent polypeptide variant were grown according to the procedure used in Example 6. Bacterial cultures were also induced according to the procedure used in Example 6. Luminescence was assayed and detected according to the procedure used in Example 6, except that NLpep53 E. coli clarified lysate was used at a dilution of 1:11.85.
[0109] FIG. 24 shows the luminescence of NLpoly containing multiple mutations.
[0110] Example 15 Substrate specificity of non-luminescent polypeptide mutants In the following examples, the substrate specificity of non-luminescent polypeptide variants is investigated: Luminescence was generated from luminescent complexes formed from various non-luminescent polypeptide variants, either furimazine or coelenterazine as substrates, and various non-luminescent peptides.
[0111] HEK293 cells were plated at 100,000 cells / ml in wells of a 24-well plate containing 0.5 ml of DMEM + 10% FBS (50,000 cells / well). The cells were incubated overnight in a 37°C, 5% CO2 incubator. DNA for expression of each non-luminescent polypeptide variant was transfected in duplicate. 1 μg of plasmid DNA containing the non-luminescent polypeptide variant was mixed with OptiMEM (Life Technologies) to a final volume of 52 μl. 3.3 μl of Fugene HD (Promega Corporation) was added, and the samples were incubated at room temperature for 15 minutes. 25 μl of each sample mixture was added to two wells and incubated overnight in a 37°C, 5% CO2 incubator. After overnight incubation, the growth medium was removed, and 0.5 ml of DMEM (phenol red-free) + 0.1% Prionex was added. The cells were then frozen (however long) on dry ice and thawed before detecting luminescence.
[0112] 25-26, NLpep53 E. coli clarified lysate was used at a 1:10 dilution, and luminescence was assayed and detected according to the procedure used in Example 6, except that either furimazine or coelenterazine was used in either NanoGlo Luciferase Assay buffer or DMEM. The data show luminescence of NLpoly in NANOGLO and DMEM with either furimazine or coelenterazine as substrates, suggesting substrate specificity (furimazine vs. coelenterazine) of NLpoly in both NANOGLO and DMEM.
[0113] In Figure 27, luminescence was assayed and detected according to the procedure used in Example 6, except that E. coli clarified lysates from various non-luminescent peptides (NLpep1, NLpep9, NLpep48, NLpep53, NLpep69, or NLpep76) were used at a 1:10 dilution. In addition, either furimazine or coelenterazine was used in either NanoGlo Luciferase Assay buffer. This data demonstrates the substrate specificity of the NLpoly / NLpep pair.
[0114] In Figure 28, luminescence was assayed and detected by separately diluting the NLpep53-HT fusion 1:10 and the non-luminescent polypeptide lysate 1:10 in DMEM + 0.1% Prionex. 20 μl of the non-luminescent peptide and 20 μl of the non-luminescent polypeptide were then combined and incubated at room temperature for 10 minutes. 40 μl of NanoGlo Buffer containing 100 μM furimazine or DMEM containing 0.1% Prionex and 20 μM furimazine was then added to the sample, and luminescence was detected on a GloMax Multi. This data demonstrates the substrate specificity of NLpoly expressed in HEK293 cells.
[0115] In Figure 29, luminescence was assayed and detected by separately diluting NLpep1-HT, NLpep53-HT, NLpep69-HT, or NLpep76-HT fusions 1:10 and non-luminescent polypeptide lysates 1:10 in DMEM + 0.1% Prionex. 20 μl of non-luminescent peptide and 20 μl of non-luminescent polypeptide were then combined and incubated at room temperature for 10 minutes. 40 μl of NanoGlo buffer containing 100 μM furimazine or DMEM containing 0.1% Prionex and 20 μM furimazine was then added to the sample, and luminescence was detected on a GloMax Multi. This data shows the luminescence of NLpep expressed in mammalian cells and assayed with various NLpeps.
[0116] Example 16 Signal to background of non-luminescent polypeptide variants with furimazine or coelenterazine In the following example, the signal to background of non-luminescent polypeptide variants is examined: The luminescence generated from various non-luminescent polypeptide variants was measured with various non-luminescent peptides using either furimazine or coelenterazine as substrates.
[0117] HEK293 cells were plated at 15,000 cells / well in 100 μl of DMEM + 10% FBS in a 96-well plate. Cells were incubated overnight in a 37°C, 5% CO2 incubator. Transfection complexes were prepared by adding 0.66 μg of plasmid DNA for expression of non-luminescent polypeptide variants and non-luminescent peptide variant plasmids to a final volume of 31 μl in OptiMem. 2 μl of Fugene HD was added to each transfection complex and incubated at room temperature for 15 minutes. For each peptide / polypeptide combination, 5 μl of transfection complex was added to six 96-well plates and grown overnight in a 37°C, CO2 incubator. After overnight incubation, growth medium was removed and replaced with CO2-independent medium containing either 20 μM coelenterazine or 20 μM furimazine. Samples were incubated for 10 minutes at 37°C, and kinetics were measured over 1 hour at 37°C on a GloMax Multi+. FIG. 30 shows the substrate specificity of various NLpoly / NLpep pairs when NLpoly is expressed in mammalian cells.
[0118] Example 17 Luminescence and substrate specificity In the following examples, NLpep69 is used to examine the luminescence and substrate specificity of various non-luminescent polypeptide variants using either furimazine or coelenterazine as substrates.
[0119] CHO cells were plated at 20,000 cells / well in 100 μl of DMEM + 10% FBS in a 96-well plate. Cells were incubated overnight in a 37°C, 5% CO2 incubator. Transfection complexes were prepared by adding 0.66 μg of plasmid DNA for expression of non-luminescent polypeptide variants and non-luminescent peptide variant plasmids to a final volume of 31 μl in OptiMem. 2 μl of Fugene HD was added to each transfection complex and incubated at room temperature for 15 minutes. For each peptide / polypeptide combination, 5 μl of transfection complex was added to six 96-well plates and grown overnight in a 37°C, CO2 incubator. After overnight incubation, growth medium was removed and replaced with CO2-independent medium containing either 20 μM coelenterazine or 20 μM furimazine. Samples were incubated at 37°C for 10 minutes, and kinetics were measured over 1 hour at 37°C on a GloMax Multi+. FIG. 31 shows the substrate specificity when NLpoly is co-expressed with NLpep69 in mammalian cells.
[0120] Example 18 Luminescence and substrate specificity between live cell and lysed conditions In the following embodiments, the luminescence and substrate specificity of various non-luminescent polypeptide variants are examined using NLpep69, NLpep78, or NLpep79 under either lysed or live cell conditions, using either furimazine or coelenterazine as substrates.
[0121] HEK293 cells were plated at 15,000 cells / well in 100 μl of DMEM + 10% FBS in a 96-well plate. Cells were incubated overnight in a 37°C, 5% CO2 incubator. Transfection complexes were prepared by adding 0.66 μg of plasmid DNA for expression of non-luminescent polypeptide variants and non-luminescent peptide variants to a final volume of 31 μl in OptiMem. 2 μl of Fugene HD was added to each transfection complex and incubated at room temperature for 15 minutes. For each NLpoly-NLpep combination, 5 μl of transfection complex was added to six 96-well plates and grown overnight in a 37°C, CO2 incubator. After overnight incubation, growth medium was removed and replaced with CO2-independent medium containing either 20 μM coelenterazine or 20 μM furimazine. Samples were incubated for 10 minutes at 37°C, and kinetics were measured over 1 hour at 37°C on a GloMax Multi+. Figures 32-34 show the substrate specificity of NLpoly co-expressed with NLpep69, 78, or 79 in mammalian cells in live cell or lysed format.
[0122] Example 19 Comparison of non-luminescent polypeptide variants expressed in Escherichia coli Single colonies of each non-luminescent polypeptide were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7, except that a 1:1,000 dilution of NLpep78-HT or NLpep79-HT was used. Figure 35 shows the luminescence of NLpoly expressed in E. coli and assayed with NLpep78 or 79.
[0123] Example 20 Ability of non-luminescent polypeptide clones to produce luminescence without a complementary non-luminescent peptide Single colonies of each non-luminescent polypeptide were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in Example 7, except that no non-luminescent peptide was added to the assay buffer. Figure 36 shows the luminescence of NLpoly expressed in E. coli and assayed in the absence of NLpep.
[0124] Example 21 Substrate specificity of non-luminescent polypeptide mutants expressed in Escherichia coli Single colonies of each non-luminescent polypeptide were grown according to the procedure used in Example 7. Bacterial cultures were also induced according to the procedure used in Example 7. Luminescence was assayed and detected according to the procedure used in the Examples, except that either furimazine or coelenterazine was mixed with the NANOGLO Assay Buffer. Figure 37 shows the substrate specificity of NLpoly expressed in E. coli and assayed with NLpep78 or 79.
[0125] Example 22 NLpep78 improves the luminescence of non-luminescent polypeptide mutants Complementation of non-luminescent polypeptide variants with NLpep78-HT was demonstrated in CHO and HeLa cells.
[0126] CHO and HeLa cells (CHO: 100,000 cells plated the day before transfection; HeLa: 50,000 cells plated the day before transfection) were transfected with 5 ng of the non-luminescent polypeptide variants 5A2 or 5P or the wild-type non-luminescent polypeptide using Fugene HD in wells of a 24-well plate and incubated at 37°C overnight. After overnight incubation, the medium was replaced with phenol red-free DMEM, and the cells were frozen at -80°C for 30 minutes. The cells were then thawed and transferred to a 1.5 ml test tube. The cell lysate was then diluted 1:10 in phenol red-free DMEM, and 20 μl was mixed with NLpep78 (NLpep78-HT7 E. coli lysate diluted 1:1,000 in phenol red-free DMEM) and shaken at room temperature for 10 minutes. 40 μl of phenol red-free DMEM and 20 μM furimazine were added and luminescence was measured on the GloMax with 0.5 second integration. Figure 38 shows the luminescence of NLpoly expressed in mammalian cells and assayed with NLpep78.
[0127] Example 23 Non-luminescent polypeptide fusions and normalization of non-luminescent polypeptide concentrations To provide insight into how much benefit, e.g., in expression, solubility, and / or stability, is attributable to the concentration of the non-luminescent polypeptide and its complementarity as a fused non-luminescent polypeptide, a comparison of the original luminescence and normalized luminescence from non-luminescent polypeptides fused to either firefly luciferase (Figure 39) or click beetle red luciferase (Figure 40) was performed.
[0128] Following the procedure of Example 22, HEK293, HeLa, or CHO cells were transfected with 5 ng of 5P NLpoly-firefly luciferase fusion, 5P NLpoly-click beetle luciferase fusion, wild-type 5P-firefly luciferase fusion, or wild-type 5P-click beetle luciferase fusion. Lysates were also prepared according to Example 22. The cell lysates were then diluted 1:10 in phenol red-free DMEM, and 20 μl was mixed with NLpep78 (1:1.00 diluted in phenol red-free DMEM; E. coli lysate) and shaken at room temperature for 10 minutes. 40 μl of NanoGlo containing 20 μM furimazine or Bright-Glo (Promega Corporation) was added, and luminescence was measured on a GloMax with a 0.5 second integration. Figures 39 and 40 show the specific activity of 5P versus WT NLpoly expressed in mammalian cells and assayed with NLpep78.
[0129] Example 24 Complementation in living cells This example demonstrates complementation in live cells using either wild-type or 5P NLpoly. HeLa cells plated in wells of a 96-well plate were transfected with 0.5 ng of wild-type or 5P non-luminescent polypeptide plasmid DNA using Fugene HD and incubated overnight at 37°C. After overnight incubation, cells were transfected with 0.5 ng of NLpep78-HT plasmid DNA using Fugene HD and incubated for 3 hours at 37°C. The medium was then replaced with CO2-independent medium plus 0.1% FBS and 20 μM PBI-4377, and luminescence was measured on a GloMax with a 0.5-second integration. Figure 41 shows live-cell complementation between 5P or WT NLpoly and NLpep78.
[0130] Example 25 Complementation in live cell extracts To demonstrate complementation in live cell extracts, 0.5 μg of NLpep78-HT and 0.5 μg of non-luminescent polypeptide variant plasmid DNA were mixed with TNT Rabbit Reticulocyte Lysate Master Mix (Promega Corporation) and incubated at 30°C for 1 hour. 25 μl of cell-free expression extract was mixed with 25 μl of NanoGlo Luciferase Assay reagent and incubated at room temperature for 10 minutes. Luminescence was measured on a GloMax with a 0.5 second integration. Figure 42 shows the luminescence from the complementary NLpoly / NLpep pair expressed in a cell-free format.
[0131] Example 26 Binding affinity of non-luminescent polypeptides expressed in mammalian cells with synthetic non-luminescent peptides To demonstrate binding affinity between non-luminescent polypeptide and non-luminescent peptide pairs, non-luminescent polypeptide lysates were prepared from HeLa, HEK293, and CHO cells as previously described and diluted 1:10 in PBS + 0.1% Prionex. A 4-fold concentration of non-luminescent peptide (synthetic) was made in PBS + 0.1% Prionex. 20 μl of non-luminescent polypeptide lysate was mixed with 20 μl of non-luminescent peptide and shaken at room temperature for 10 minutes. 40 μl of NanoGlo Luciferase Assay Reagent containing furimazine or PBS + 0.1% Prionex was added and shaken at room temperature for 10 minutes. Luminescence was measured on a GloMax with a 0.5-second integration. Kd values were determined using Graphpad Prism, one-site specific binding. Figures 43 and 44 show the dissociation constants measured under various buffer conditions (PBS for complementation, then NanoGlo for detection, PBS for complementation and detection, NanoGlo for complementation and detection).
[0132] Example 27 Improved binding affinity of non-luminescent peptide variants upon cysteine to phenylalanine mutation To demonstrate the improved binding affinity of non-luminescent peptide variants with a cysteine mutated at the eighth residue of the peptide, non-luminescent polypeptide variant lysates were prepared from HeLa, HEK293, and CHO cells as previously described and diluted 1:10 in PBS + 0.1% Prionex. A four-fold concentration of non-luminescent peptide (NLpep) was made in PBS + 0.1% Prionex + 10 mM DTT. 20 μl of non-luminescent polypeptide lysate was mixed with 20 μl of non-luminescent peptide and shaken at room temperature for 10 minutes. 40 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured on a GloMax with a 0.5-second integration. Figure 45 shows that the NLpep C8F mutation significantly improves binding affinity for 5P.
[0133] Example 28 Detectable luminescence of polypeptide variants in HeLa cells in the absence of non-luminescent peptides. To demonstrate luminescence of non-luminescent polypeptides without non-luminescent peptides, HeLa cells (10,000 cells plated the day before transfection) in wells of a 96-well plate were transfected with various amounts of non-luminescent polypeptides plus pGEM-3zf Carrier DNA using Fugene HD for a total of 50 ng and incubated overnight at 37°C. After incubation, the medium was replaced with CO2-independent medium + 0.1% FBS + 20 uM furimazine, incubated for 10 minutes at 37°C, and luminescence was measured on a GloMax with a 0.5 second integration. Figure 46 shows the luminescence of NLpoly WT or 5P in live HeLa cells without NLpep after transfection with various amounts of plasmid DNA.
[0134] Example 29 Generation of additional non-luminescent polypeptide variants Additional non-luminescent polypeptide variants were generated as described below and their expression analyzed: Ile-11 (Ile at residue 11), Val-11, Tyr-11, Glu-11, Glu-157, Pro-157, Asp-157, Ser-157, Met-149, Leu-106, NLpoly11, and NLpoly12. Additional non-luminescent polypeptide variants were generated in the background of the 5A2 non-luminescent polypeptide.
[0135] A new individual colony (KRX) of each additional non-luminescent polypeptide variant was picked and grown overnight at 30°C in LB + ampicillin (100 μg / ml), then diluted 1:100 into LB + ampicillin and grown at 37°C for 2.5 hours (OD600 ~ 0.5). Rhamnose was added to a final concentration of 0.2%, and the cells were split in triplicate and grown at 25°C for approximately overnight (approximately 18 hours). Cells were lysed using 0.5X Fast Break at ambient temperature for 30 minutes, flash-frozen on dry ice, and stored at -20°C. Soluble fractions were prepared by centrifugation at 10K for 15 minutes at 4°C. Samples were assayed for luminescence on a Tecan Infinite F-500 luminometer.
[0136] Figure 49 shows the total lysate and soluble fragments of each non-luminescent polypeptide variant analyzed by SDS-PAGE. This data provides information on the expression, solubility, and stability of the additional non-luminescent polypeptide variants. The majority of the additional non-luminescent polypeptide variants produced more protein (total and soluble) than the wild-type, although in many cases the difference was small. The improvement in expression of NLpoly11 and NLpoly12 was more pronounced.
[0137] Example 30 Background luminescence of additional non-luminescent polypeptide variants The background luminescence of additional non-luminescent polypeptide variants prepared in Example 29 was measured by incubating 25 μl of non-luminescent polypeptide variant lysate with 25 μl of DMEM for 10 minutes at room temperature. 50 μl of NanoGlo Luciferase Assay Reagent was then added, and luminescence was measured at 5 and 30 minutes on a Tecan Infinite F500. NLpep53 (Pep 53) alone and DMEM (DMEM) alone served as controls. Figure 47 shows that the majority of additional non-luminescent polypeptide variants exhibited elevated background luminescence.
[0138] Example 31 Luminescence of further non-luminescent polypeptide variants after complementation Luminescence of additional non-luminescent polypeptide variants prepared in Example 28 was measured by incubating 25 μl of non-luminescent polypeptide variant lysate with 25 μl of NLpep-53 for 10 minutes at room temperature. 50 μl was then added to NanoGlo Luciferase Assay Reagent, and luminescence was measured at 5 and 30 minutes on a Tecan Infinite F500. NLpep53 (Pep 53) alone and DMEM (DMEM) alone served as controls. Figure 48 shows that the non-luminescent polypeptide variants Val-11, Glu-11, Glu-157, Pro-157, Asp-157, Ser-157, and Met-149 produced significantly more luminescence than the parent 5A2.
[0139] Example 32 Correlation between the increase in background luminescence of non-luminescent polypeptides in the absence of non-luminescent peptides and the amount of protein in the soluble fraction. Individual colonies of non-luminescent polypeptide variants 3P, 3E, 5P, 5E, 6P, and 6E were picked and grown overnight in LB + ampicillin at 30°C, diluted 1:100 in LB + ampicillin, and grown at 37°C for 2.5 hours (OD600 ~ 0.5). Rhamnose was added to a final concentration of 0.2%, and the cells were split in triplicate and grown overnight (approximately 18 hours) at 25°C. Cells were lysed using 0.5X Fast Break at ambient temperature for 30 minutes, flash-frozen on dry ice, and stored at -20°C. Soluble fractions were prepared by rapid thawing and centrifugation at 10K for 15 minutes at 4°C. Samples were assayed for luminescence on a Tecan Infinite F-500 luminometer. Figure 50A shows the total lysate and soluble fragments of each non-luminescent polypeptide variant. Figure 50B shows the background luminescence of each non-luminescent polypeptide variant. FIG. 51 shows the luminescence produced with each of the non-luminescent polypeptide variants when complemented with 10 or 100 nM of NLpep78 (NVSGWRLFKKISN) in LB medium.
[0140] Example 33 Extensions and deletions of non-luminescent polypeptides Non-luminescent polypeptide variants 5P were extended at the C-terminus by either adding residues VAT, AA, VTG, VT, VTGWR, VTGW, V, A, VA, GG, AT, GTA, ATG, or GT at the C-terminus of 5P, or deleting one to seven residues: e.g., D1 = deletion of one residue, D2 = deletion of two residues, etc. Background luminescence in E. coli lysates (Figure 52) and luminescence generated after complementation with NLpep78 (Figure 53; NVSGWRLFKKISN) or NLpep79 (Figure 54; NVTGYRLFKKISN) were measured. Figure 55 shows signal versus background for non-luminescent polypeptide 5P variants. Figure 56 provides the resulting plots of luminescence. Figure 57 shows the amount of total lysate and soluble fragments in each non-luminescent polypeptide 5P variant.
[0141] Example 34 Comparison of the 5P and I107L non-luminescent polypeptide variants Figure 58 shows the amounts of total lysate and soluble fragments of 5P and I107L (A), the luminescence generated by 5P or I107L without non-luminescent peptides or with NLpep78 or NLpep79 (B), and the improved signal-to-background of I107L over 5P (C).
[0142] Example 35 Generation of 5P non-luminescent polypeptide mutants Mutations identified in the random mutation screen for 5P non-luminescent polypeptide variants were generated as previously described. Each single 5P non-luminescent polypeptide variant colony was inoculated into 200 μl of minimal medium and incubated at 37°C for 20 hours with shaking. Ten μl of the culture was then added to 190 μl of fresh minimal medium and incubated again at 37°C for 20 hours with shaking. Ten μl of the second culture was then added to 190 μl of autoinduction medium (minimal medium + 5% glucose + 2% rhamnose) and incubated at 25°C for 18 hours with shaking to express the non-luminescent polypeptide variants. Ten μl of the expression culture of the 5P non-luminescent polypeptide variants was added to 40 μl of assay lysis buffer containing NLpep78-HT (1:386 dilution) or NLpep79-HT (1:1,000 dilution) and shaken at room temperature for 10 minutes. 50 μl of NanoGlo Assay Buffer containing 100 μM coelenterazine was added and shaken for 10 minutes at room temperature. Luminescence was measured on a GloMax with a 0.5 second integration. Figures 59-62A show background luminescence, and Figures 59-62B and C show luminescence generated after complementation with NLpep78 or NLpep79.
[0143] Example 36 Binding affinity of extended non-luminescent polypeptide mutants and deleted non-luminescent peptides Binding affinity of extended non-luminescent polypeptide variants (ie, containing additional amino acids at the C-terminus) and truncated non-luminescent peptides (ie, lacking amino acids at the N-terminus).
[0144] Lysates of E. coli expressing the nonluminescent polypeptides 5P / +V / +VT / +VTG, prepared as previously described, were diluted 1:2000 in PBS + 0.1% Prionex. 25 μl of diluted lysate was incubated with 25 μl of NLpep78, NLpep80, NLpep81, or NLpep82 (diluted to 0–500 nM in dilution buffer) at room temperature for 5 minutes. 50 μl of furimazine diluted 1X in NanoGlo Assay Buffer was added to each sample and incubated for 10 minutes at room temperature. Luminescence was measured on a GloMax Multi with a 0.5-second integration time. Figure 63 shows the binding affinity of NLpoly with an added amino acid at the C-terminus and NLpep with an amino acid deletion from the N-terminus.
[0145] Example 37 Binding affinity of non-luminescent polypeptides expressed in Escherichia coli to synthetic non-luminescent peptides Non-luminescent polypeptide LB lysates were prepared and diluted 1:100 in PBS + 0.1% Prionex. Two-fold dilutions of NLpep78 were made in PBS + 0.1% Prionex. 25 μl of diluted non-luminescent polypeptide lysate was mixed with 25 μl of each dilution of non-luminescent peptide and incubated for 3 minutes at ambient temperature. 50 μl of NanoGlo Luciferase Assay Reagent was added, incubated for 5 minutes at room temperature, and luminescence was measured on a GloMax Multi+. Figure 64 shows the Kd values calculated using one-site specific binding.
[0146] Example 38 Binding affinity of 5P non-luminescent polypeptides expressed in mammalian cells to NLpep80 or NLpep87 Lysates from CHO, HEK293T, or HeLa cells expressing NLpoly 5P were diluted 1:1000 in dilution buffer (PBS + 0.1% Prionex). 25 μl of diluted lysate was incubated with 25 μl of NLpep80 / 87 (diluted to 0-5 μM in dilution buffer) for 5 minutes at room temperature. 50 μl of furimazine (diluted to 1X in NanoGlo buffer) was added to each well, and the plate was incubated for 10 minutes at room temperature. Luminescence was then read on a GloMax Multi with a 0.5 second integration time (Figure 65).
[0147] Example 39 Binding affinity of 5P non-luminescent polypeptides expressed in Escherichia coli to NLpep80 or NLpep87. Lysate from E. coli expressing NLpoly 5P was diluted 1:2000 in dilution buffer (PBS + 0.1% Prionex). 25 μl of diluted lysate was incubated with 25 μl of NLpep80 / 87 (diluted to 0-5 μM in dilution buffer) at room temperature for 5 minutes. 50 μl of furimazine (diluted to 1X in NanoGlo buffer) was added to each well, and the plate was incubated at room temperature for 10 minutes. Luminescence was then read on a GloMax Multi with a 0.5 second integration time (Figure 66).
[0148] Example 40 Complementation between a deleted non-luminescent polypeptide and an extended non-luminescent peptide Complementation of a truncated non-luminescent polypeptide (i.e., amino acids deleted from the C-terminus) with an extended non-luminescent peptide (i.e., amino acids added to the N-terminus) was performed. NLpep-HT E. coli clarified lysate was prepared as previously described in Example 6. The amount of NLpep-HT was quantified via the HaloTag fusion. Briefly, 10 μl of clarified lysate was mixed with 10 μl of HaloTag-TMR ligand (diluted 1:100) and 80 μl of water and incubated at room temperature for 10 minutes. 33.3 μl of 4×SDS Loading Buffer was added and incubated at 95°C for 5 minutes. 15 μl was loaded onto an SDS-PAGE gel and imaged on a Typhoon. Based on the intensity from the SDS-PAGE gel, the non-luminescent peptide was diluted in PBS + 0.1% Prionex non-luminescent peptide to achieve an equivalent concentration. The non-luminescent polypeptide lysate was then diluted 1:100 in PBS + 0.1% Prionex. 20 μl of diluted non-luminescent polypeptide was mixed with 20 μl of diluted non-luminescent peptide and shaken at room temperature for 10 minutes. 40 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured using a 0.5 second integration on a GloMax. Figure 67 shows the luminescence of NLpoly, which has amino acids removed from the C-terminus, and NLpep, which has amino acids at the N-terminus.
[0149] Example 41 Binding affinity of 5P non-luminescent polypeptide expressed in HeLa cells to NLpep78 or truncated NLpep78 (NLpep80-87) 5P nonluminescent polypeptide lysates were prepared from HeLa cells as previously described and diluted 1:10 in PBS + 0.1% Prionex. Four-fold concentrations (range determined in preliminary titration experiments) of nonluminescent peptides (synthetic peptides from Peptide 2.0 (Virginia); produced at either 5, 10, or 20 mg scale; end-blocked by acetylation and amidation, confirmed by analysis of net peptide content) were prepared in PBS + 0.1% Prionex. 20 μl of 5P nonluminescent polypeptide was mixed with 20 μl of nonluminescent peptide and shaken at room temperature for 10 minutes. 40 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured on a GloMax with a 0.5-second integration. Figure 68 shows the binding affinity of 5P to truncated forms of NLpep78 and the corresponding luminescence. Removal of one amino acid from the N-terminus, C-terminus, or one amino acid from each terminus increases binding affinity. Removal of one or more amino acids from either terminus decreases affinity, but does not necessarily decrease Vmax to the same extent.
[0150] Example 42 Binding affinity of extended non-luminescent polypeptides to truncated non-luminescent peptides The binding affinity of an extended non-luminescent polypeptide (i.e., a polypeptide with two extra amino acids at the C-terminus) and a truncated non-luminescent peptide (i.e., a peptide with two amino acids removed from the N-terminus (NLpep81)) was determined.
[0151] Nonluminescent polypeptide lysates were prepared as previously described and diluted 1:100 in PBS + 0.1% Prionex. Two-fold dilutions of NLpep81 (synthetic peptide; manufactured by Peptide 2.0 (Virginia); produced at either 5, 10, or 20 mg scale; end-blocked by acetylation and amidation, confirmed by analysis of net peptide content) were prepared in PBS + 0.1% Prionex. 25 μl of nonluminescent polypeptide was mixed with 25 μl of each nonluminescent peptide dilution and shaken at room temperature for 3 minutes. 50 μl of NanoGlo Luciferase Assay reagent was added and shaken at room temperature for 5 minutes. Luminescence was measured on a GloMax Multi with a 0.5-second integration. Figure 69 shows the Kd values calculated using one-site specific binding.
[0152] Example 43 Binding affinity of extended non-luminescent polypeptides to internode non-luminescent peptides The binding affinity of an extended non-luminescent polypeptide (i.e., a polypeptide with three extra amino acids at the C-terminus) and a truncated non-luminescent peptide (i.e., a peptide with three amino acids removed from the N-terminus (NLpep82)) was determined.
[0153] Nonluminescent polypeptide lysates were prepared and diluted 1:100 in PBS + 0.1% Prionex. Two-fold dilutions of NLpep82 (synthetic peptide; manufactured by Peptide 2.0 (Virginia); produced at either 5, 10, or 20 mg scale; end-blocked by acetylation and amidation, confirmed by analysis of net peptide content) were prepared in PBS + 0.1% Prionex. 25 μl of nonluminescent polypeptide was mixed with 25 μl of each nonluminescent peptide dilution and shaken at room temperature for 3 minutes. 50 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 5 minutes. Luminescence was measured on a GloMax Multi with a 0.5-second integration. Figure 70 shows the Kd values obtained using one-site specific binding.
[0154] Example 44 Binding affinity of non-luminescent polypeptide clones expressed in E. coli to synthetic NLpep78. Non-luminescent polypeptide variants were grown in M9 minimal medium. Individual colonies were inoculated and grown overnight at 37°C. Samples were diluted 1:20 into M9 minimal medium and grown overnight at 37°C. Samples were again diluted 1:20 into M9 induction medium and grown overnight at 25°C. Samples were pooled, and 100 μl of pooled cells was lysed in 400 μl of PLB lysis buffer and incubated at room temperature for 10 minutes. The lysate was diluted 1:100 in PBS + 0.1% Prionex. Two-fold dilutions of synthetic NLpep78 were made in PBS + 0.1% Prionex. 25 μl of the non-luminescent polypeptide dilutions were mixed with 25 μl of each non-luminescent peptide dilution and incubated at room temperature for 3 minutes. 50 μl of NanoGlo Luciferase Assay Reagent was added, incubated for 5 minutes at room temperature, and luminescence was read on a GloMax Multi+. Figure 71 shows the Kd values obtained using one-site specific binding.
[0155] Example 45 Determining the effect of mutations on Km Using the diluted pooled lysates from Example 11, 25 μl of non-luminescent polypeptide diluted lysate (1:100 in PBS + 0.1% Prionex) was mixed with 25 μl of 500 nM NLpep78 per sample and incubated at room temperature for 5 minutes. Two-fold dilutions of furimazine were prepared in NanoGlo Luciferase Assay Buffer, and 50 μl of the non-luminescent peptide and non-luminescent polypeptide samples were mixed with 50 μl of the NanoGlo / furimazine dilution. After 5 minutes of incubation, luminescence was measured at room temperature. Figure 72 shows the calculated Km obtained using the Michaelis-Menten assay.
[0156] Example 46 Proof of complementarity of the three components To demonstrate tertiary complementation using two non-luminescent polypeptides, NLpep and NLpoly5P, lysates were prepared: NLpoly5P-B9 (5P with residues 147-157 deleted) and NLpep B9-HT (HT7 fused to the N-terminus with Met+ residues 147-157).
[0157] A) Titration of NLpoly 5P-B9 + NLpoly B9 with NLpep78 NLpoly 5P-B9 + NLpoly B9 was titrated with NLpep78. 20 μl of 5P-B9 (undiluted) was mixed with 20 μl of peptide B9-HT (undiluted). Dilutions of NLpep78 (synthetic peptide, highest concentration = 100 μM) were made in PBS + 0.1% Prionex. 20 μl of NLpep78 was added to 40 μl of the 5P-B9 + peptide B9-HT mixture and shaken at room temperature for 10 minutes. 60 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured on a GloMax Multi with a 0.5 second integration.
[0158] B) Titration of NLpoly 5P-B9 + NLpep78 with NLpepB9-HT 20 μl of NLpoly 5P-B9 (undiluted) was mixed with 20 μl of NLpep78 (100 μM). Dilutions of peptide B9-HT (highest concentration = undiluted) were made in PBS + 0.1% Prionex. 20 μl of peptide B9-HT was added to 40 μl of the 5P-B9 + NLpep78 mixture and shaken at room temperature for 10 minutes. 60 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured on a GloMax Multi with a 0.5 second integration.
[0159] Figure 73 shows the feasibility of a ternary system consisting of two different NLpeps and a truncated NLpoly. Because all three components are non-luminescent without the other two, this system can be configured by fusing each NLpep (synthetically or genetically) to a binding moiety and a truncated NLpoly used at high concentrations to produce light only if there is an interaction between the binding moieties, or by fusing each of the three components to a binding moiety to produce light only when the ternary complex forms.
[0160] Example 47 Complementation with NLpep88 (NLpep78 containing glycine instead of arginine as the sixth residue) NLpep88-HT and 5P E. coli clarified lysates were prepared as previously described. Serial dilutions of NLpep88-HT lysate were made in PBS + 0.1% Prionex. 20 μl of 5P lysate was mixed with 20 μl of NLpep88-HT lysate and shaken at room temperature for 10 minutes. 40 μl of NanoGlo Luciferase Assay Reagent was added and shaken at room temperature for 10 minutes. Luminescence was measured with a 0.5-second integration on a GloMax Multi. Figure 74 demonstrates the importance of the arginine residue at position 6 of NLpep. While low concentrations of NLpep88 did not increase luminescence over 5P alone, high concentrations of NLpep increased luminescence, suggesting a catalytically impaired complex, not a lack of interaction between 5P and NLpep88.
[0161] Example 48 Subcellular localization of NLpep78 and 79 as N-terminal fusions to HaloTag U2OS cells were plated and left to recover overnight at 37°C. Cells were then transfected with HaloTag DNA constructs alone or HaloTag-NanoLuc peptide DNA constructs (all under the control of the CMV promoter): P1-HT, P78-HT, or P79-HT were diluted 1:10 in carrier DNA (pSI) using FuGENE HD and incubated for 24 hours at 37°C. Cells were then labeled with the HaloTag-TMR ligand using the manufacturer's standard rapid labeling protocol and imaged. Figure 75 shows that NLpep78 and 79 do not alter the subcellular localization of the HaloTag protein.
[0162] Example 49 Subcellular localization of non-luminescent polypeptides (WT and 5P) U2OS cells were plated and left to recover overnight at 37°C. Cells were either maintained as untransfected controls or transfected with NanoLuc DNA constructs: FL, NLpoly(wild-type), or NLpoly(5P) were diluted 1:10 in carrier DNA (pSI) using FuGENE HD and incubated for 24 hours at room temperature. Cells were fixed and then processed for ICC. ICC was performed using a 1:5000 GS(PRO) primary antibody overnight at 4°C, followed by an Alexa488 goat anti-rabbit secondary antibody. Figure 76 shows that both NLpolyWT and NLpoly5P were uniformly localized within the cells.
[0163] Example 50 Non-luminescent polypeptides demonstrate the ease and rapid detection of non-luminescent peptides conjugated to proteins of interest. 99 μl of NLpep53-HT E. coli clarified lysate was mixed with 24.75 μl of 4×SDS loading buffer. Serial 1:10 dilutions of the lysate-loading buffer mixture were made and incubated at 95°C for 5 minutes. 15 μl was loaded onto an SDS-PAGE gel. After the gel was completed, it was transferred to PVDF using iBlot and washed with 10 mL of room temperature NLpoly L149M E. coli clarified lysate for 30 minutes. The membrane was then placed on a LAS4000 imager and 2 mL of NanoGlo® Luciferase Assay Reagent was added. A 60-second exposure was performed (Figure 77).
[0164] Example 51 Site saturation at positions 31, 46, 108, 144, and 157 of non-luminescent polypeptides related to 5P Mutants with single amino acid changes were constructed in NLpoly5P (pF4Ag vector background) at sites according to Table 5 below, in which the native residue was actually different for each of the 19 alternative amino acids in a total of 95 mutants. Table 5 TIFF2024167207000050.tif108170
[0165] Individual colonies were grown in LB+amp and incubated overnight at 30°C. A 5P control was also included. The overnight cultures were used to inoculate fresh LB+amp (1:100), and these cultures were grown at 37°C for 2 hours and 45 minutes. Rhamnose was added to 0.2%, and the cultures were left to grow / induce overnight at 25°C. After 18 hours of induction, cells were lysed using 0.5X FastBreak (30 minutes at ambient temperature), flash-frozen on dry ice, and stored at -20°C. After rapid thawing, samples were assayed in the absence and presence of Pep87 (also known as NLpep87).
[0166] For (-) peptide reactions, 30 μL of lysate was incubated with 30 μL of PBS (pH 7.5) for 10 minutes, followed by the addition of 60 μL of NanoGlo® Luciferase Assay Reagent (Promega Corporation). Luminescence was measured after 5 minutes. For (+) peptide reactions, 30 μL of lysate was incubated with 30 μL of 8 nM Pep87. After 10 minutes, 60 μL of NanoGlo® Luciferase Assay Reagent was added, and luminescence was measured at 5 minutes.
[0167] The luminescence (RLU) data for the (-) peptide samples were normalized to the 5P control readings, and these results are presented in Figure 78. The luminescence (RLU) data for the (+) peptide samples were also normalized to 5P, but then also normalized to the values in Figure 76 to represent signal to background (S / B; Figure 79).
[0168] Example 52 Use of high affinity between NLpoly and NLpep for protein purification / pull-down MAGNEHALOTAG beads (Promega Corporation; G728A) were equilibrated as follows. a) 1 mL of beads was placed on a magnet for approximately 30 seconds and the buffer was removed; b) The beads were removed from the magnet, resuspended in 1 mL of PBS + 0.1% Prionex, and shaken at room temperature for 5 minutes; c) Steps a) and b) were repeated two more times. NLpep78-HaloTag (E. coli clarified lysate) was bound to MagneHaloTag beads by resuspending the beads in 1 mL of NLpep78-HT clarified lysate, shaking for 1 hour at room temperature, and placing on a magnet for approximately 30 seconds. The lysate (flow-through fraction) was removed and saved for analysis. NLpoly 8S (E. coli clarified lysate) was bound to the NLpep78-conjugated MagneHaloTag beads from the above step by resuspending the beads in 1.5 mL of 8S lysate, shaking for 1 hour at room temperature, and placing on a magnet for approximately 30 seconds. The lysate (flow-through) was removed and saved for analysis. The beads were resuspended in 1 mL of PBS + 0.1% Prionex, shaken for 5 minutes at room temperature, placed on a magnet for approximately 30 seconds, and the PBS (wash) was removed. The beads were washed three more times.
[0169] To elute the bound peptides / polypeptides, the beads were resuspended in 500 μL of 1×SDS buffer and shaken at room temperature for 5 minutes. The beads were then placed on a magnet for approximately 30 seconds; the SDS buffer (elution) was removed and saved for analysis. The elution was repeated once more.
[0170] The samples were then analyzed by gel. 37.5 uL of the sample (excluding the elution) was mixed with 12.5 uL of 4x SDS buffer and incubated at 95°C for 5 minutes. 5 uL was loaded onto a Novex 4-20% Tris-Glycine gel and run at approximately 180V for approximately 50 minutes. The gel was stained with SimplyBlue Safe Stain and imaged on a LAS4000 imager.
[0171] Figure 94 shows that the affinity between NLpoly and NLpep is sufficient to allow purification from E. coli lysate. Because NLpoly8S is purified from E. coli lysate, it is reasonable to expect that proteins fused to NLpoly8S (or other variants described herein) can be purified in a similar manner. In this example, NLpep is immobilized and used to purify NLpoly, but it is also reasonable to expect similar results when NLpoly is immobilized.
[0172] Example 53 Kinetics of NLpoly / NLpep binding A 2x concentrate of synthetic NLpep was prepared and diluted 9 times 2.7x (10 concentrations) in PBS + 0.1% Prionex. Final concentrations used in the assay ranged from 30µM to 3.9nM. WT NLpoly (E. coli clarified lysate; 1:10,000) or 11S (1:10,000,000) was diluted in NanoGlo + 100µM Flamadin (Fz). 50µL of NLpep was placed into wells of a white 96-well assay plate. 50µL of NLpoly / NanoGlo / Fz was injected into the wells using the injector on the GloMax® Multi+ instrument, and luminescence was measured every 3 seconds for 5 minutes. Data were analyzed using Graphpad Prism JPEG2024167207000051.jpg440 by adapting it obs Then, k on and k off of JPEG2024167207000052.jpg5170. Figure 95 shows the association and dissociation rate constants for the binding of NLpoly and NLpep.
[0173] Example 54 NLpoly / NLpep substrate affinity NLpoly was diluted in PBS + 0.1% Prionex as follows: WT: 1:10 5 , 5P:1:10 7, and 11S:1:10 8 NLpep was diluted in PBS + 0.1% Prionex as follows: 30 uM for WT NLpoly experiments or 3 uM for NLpoly 5P and 11S experiments. 50 uL of NLpoly / NLpep was incubated at room temperature for 5 minutes, and 50 uL of NanoGlo+Fz (100 uM-1.2 uM range, 2X) was added and incubated at room temperature for 10 minutes. Luminescence was measured on a GloMax® Multi+ with a 0.5 second integration. Km was obtained using Graphpad Prism, Michaelis-Menten best fit values. Figure 96 shows the Km values for various NLpoly / NLpep pairs.
[0174] Example 55 Effect of substrate on NLpoly / NLpep affinity 11S (E. coli clarified lysate) 1:10 in PBS + 0.1% Prionex 7 Synthetic NLpep79 was serially diluted (1:2) from 800 nM to 0.39 nM (2X). 20 uL of 11S + 20 uL of NLpep79 were then mixed and incubated at room temperature for 5 minutes. 40 uL of NanoGlo + 5 uM or 50 uM Fz was added and incubated at room temperature for an additional 5 minutes. Luminescence was measured on a GloMax® Multi+ with a 0.5 second integration. Kd was obtained using Graphpad prism, a value for one-site specific binding. Figure 97 shows that saturating concentrations of furimazine increase the affinity of 11S for NLpep79.
[0175] Example 56 NLpoly 5A2:NLpep Km NLpoly 5A2 1:10 in PBS + 0.1% Prionex 5NLpep (WT, NLpep 78, or NLpep 79) was diluted to 30 uM in PBS + 0.1% Prionex. 50 uL of NLpoly / NLpep was incubated at room temperature for 5 minutes, and 50 uL of NanoGlo+Fz (100 uM-1.2 uM range, 2X) was added and incubated at room temperature for 10 minutes. Luminescence was measured on a GloMax® Multi+ with a 0.5 second integration. Km was obtained using Graphpad Prism, Michaelis-Menten best fit values. Figure 98 shows the Km values for NLpoly5A2, and NLpep WT, 78, and 79.
[0176] Example 57 Emission of NLpoly without NLpep E. coli clarified lysates were prepared as previously described for NLpoly WT, 5A2, 5P, 8S, and 11S. 50 μL of each lysate was mixed with 50 μL of NanoGlo +Fz and incubated at room temperature for 5 minutes. Luminescence was measured on a GloMax® Multi+ with a 0.5-second integration. Figure 99 shows that the ability of NLpoly to generate luminescence in the absence of NLpep gradually increased throughout the evolution process, resulting in approximately 500-fold higher luminescence for 11S than for WT NLpoly.
[0177] Example 58 Improving luminescence in Escherichia coli through evolutionary processes A single NLpoly colony of WT, 5A2, 5P, 8S, or 11S was inoculated into 200 μL of minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of the overnight culture was diluted into 190 μL of fresh minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of this overnight culture was diluted into 190 μL of autoinduction medium (previously described) and grown on a shaker for 18 hours at 25°C. The autoinduction culture was diluted 50-fold (4 μL in 196 μL of assay lysis buffer), and 10 μL of the expression culture was added to 40 μL of assay lysis buffer containing NLpep (synthetic; 1 nM; WT, NLpep78, NL79, or NLpep80) and shaken at room temperature for 10 minutes. 50 μL of NanoGlo+Fz was added, and the sample was shaken at room temperature for 5 minutes. Luminescence was measured on a GloMax luminometer with 0.5 second integration. Figure 100 shows the improvement in luminescence from E. coli-derived NLpoly over the evolutionary process, with an overall improvement of approximately 10 5 Improvement was observed (NLpolyWT:NLpepWT to NLpoly11S:NLpep80).
[0178] Example 59 Improving luminescence in HeLa cells through an evolutionary process 50 ng of plasmid DNA expressing NLpoly WT, 5A2, 5P, 8S, or 11S was transfected into HeLa cells using Fugene HD in wells of a 12-well plate. Cells were then incubated overnight at 37°C / 5% CO2. The medium was replaced with 500 μL of phenol red-free DMEM, and the cells were frozen at -80°C for >30 minutes. Cells were thawed and transferred to 1.5 ml tubes. NLpep WT, NLpep78, NLpep79, or NLpep80 (synthetic) was diluted to 10 nM in PBS + 0.1% Prionex, and 25 μL was mixed with 25 μL of each NLpoly cell lysate. Samples were shaken for 10 minutes at room temperature, then 50 μL of NanoGlo + 100 μM Fz was added and incubated for 5 minutes at room temperature. Luminescence was measured on a GloMax luminometer with 0.5 second integration. Figure 101 shows the improvement in luminescence from NLpoly expressed in HeLa over the evolutionary process, with an overall improvement of approximately 10 5Improvement was observed (NLpolyWT:NLpepWT to NLpoly11S:NLpep80).
[0179] Example 60 Improving luminescence in HEK293 cells through an evolutionary process 50 ng of plasmid DNA expressing NLpoly WT, 5A2, 5P, 8S, or 11S was transfected into HEK293 cells in wells of a 12-well plate using Fugene HD. Cells were then incubated overnight at 37°C / 5% CO2. The medium was replaced with 500 μL of phenol red-free DMEM, and the cells were frozen at -80°C for >30 minutes. Cells were thawed and transferred to 1.5 ml test tubes. NLpep WT, NLpep78, NLpep79, or NLpep 80 (synthetic) was diluted to 10 nM in PBS + 0.1% Prionex, and 25 μL was mixed with 25 μL of each NLpoly cell lysate. Samples were shaken for 10 minutes at room temperature, then 50 μL of NanoGlo + 100 μM Fz was added and incubated for 5 minutes at room temperature. Luminescence was measured on a Luminescence GloMax luminometer with 0.5 second integration. Figure 102 shows the improvement in luminescence from NLpoly expressed in HEK293 over the evolutionary process, with an overall improvement of approximately 10 4 Improvement was observed (NLpolyWT:NLpepWT to NLpoly11S:NLpep80).
[0180] Example 61 Improving binding affinity through evolutionary processes NLpoly WT, 5A2, 5P, 8S, or 11S (E. coli clarified lysates) were diluted in PBS + 0.1% Prionex as follows: WT 1:10 4; 5A2 1:105;5P 1:10 6 ;8S 1:10 7 ; and 11S 1:10 7NLpepWT, NLpep78, NLpep79, or NLpep80 (synthetic) were diluted 4x in PBS + 0.1% Prionex. 25uL of NLpoly was mixed with 25uL of NLpep and incubated at room temperature for 10 minutes. 50uL of NanoGlo+ 100uM Fz was added and incubated at room temperature for 5 minutes. Luminescence was measured on a GloMax Multi+ with 0.5 seconds integration. Kd was determined using Graphpad Prism, a best fit value for one-site specific binding. Figure 103 shows the 100% Kd increase compared to wild type. 4 K is the fold improved affinity of the tested variant (starting affinity: NLpolyWT:NLpepWT, Kd ~ 10 uM). d <1 nM (NLpoly11S:NLpep86 or NLpoly11S:NLpep80).
[0181] Example 62 NLpoly luminescence A single NLpoly mutant colony was inoculated into 200 μL of minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of the overnight culture was diluted into 190 μL of fresh minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of this overnight culture was then diluted into 190 μL of autoinduction medium (previously described) and grown on a shaker for 18 hours at 25°C. 10 μL of this expression culture was mixed with 40 μL of assay lysis buffer (previously described) without NLpep or NLpep78-HT (1:3,860 dilution) or NLpep79-HT (1:10,000 dilution) and shaken at room temperature for 10 minutes. 50 μL of NanoGlo+Fz was added and shaken again for 10 minutes at room temperature. Luminescence was measured on a GloMax® luminometer with a 0.5-second integration. Figures 105 to 107 show the luminescence of various NLpoly in the absence of NLpep.
[0182] Example 63 Solubility of NLpoly mutants A single NLpoly mutant colony (see Figure 143) was inoculated into 5 mL LB cultures and grown overnight at 37°C with shaking. The overnight cultures were diluted 1:100 into fresh LB and incubated at 37°C with shaking for 3 hours. Rhamnose was added to the cultures to 0.2% and incubated at 25°C with shaking overnight. 900 μl of these overnight cultures were mixed with 100 μl of 10X FastBreak Lysis Buffer (Promega Corporation) and incubated at room temperature for 15 minutes. A 75 μl aliquot (total) was removed from each culture and saved for analysis. The remaining culture from each sample was centrifuged at 14,000× rpm in a tabletop microcentrifuge for 15 minutes at 4°C. A 75 μl aliquot of the supernatant (soluble) was removed from each sample and saved for analysis. 25 μl of 4X SDS buffer was added to the saved aliquots and incubated at 95°C for 5 minutes. 5 ul of each sample was loaded onto a 4-20% Tris-Glycine SDS gel and run at approximately 190V for approximately 50 minutes. The gel was stained with SimplyBlue Safe Stain and imaged on an LAS4000. Figure 143 shows a protein gel of the total lysate of the NLpoly mutant and the soluble fraction of the same lysate.
[0183] Example 64 Dissociation constant NLpoly mutant lysate (see Figure 144; prepared as previously described) was diluted 1:10 in PBS + 0.1% Prionex. A 4x concentrate of NLpep78 (synthetic NLpep78) was made in PBS + 0.1% Prionex. 20uL of NLpoly mutant lysate was mixed with 20uL of NLpep and shaken at room temperature for 10 minutes. 40uL of NanoGlo / Fz was added and shaken at room temperature for 10 minutes. Luminescence was measured with 0.5 seconds integration on a GloMax® luminometer. Kd was determined using Graphpad Prism, a best fit value for one-site specific binding. Figure 144 shows the dissociation constant of NLpep78 with various NLpolys.
[0184] Example 65 Comparison of luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 HEK293T cells (400,000 cells) were reverse transfected with 1 μg of pF4A Ag FKBP or 1 μg of pF4A Ag FRB expressing N- or C-terminal fusions of NLpoly5P and / or NLpep80 / 87 using FuGENE HD at a 1:4 DNA to FuGENE HD ratio. 24 h posttransfection, cells were trypsinized and replated at a density of 10,000 cells per well in opaque 96-well assay plates. 24 h after plating, cells were washed with PBS and then incubated with or without 20 nM rapamycin in phenol red-free OptiMEMI for 15, 60, or 120 min. 10 μM furimazine substrate, with or without 20 nM rapamycin in OptiMEM, was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. Figures 108 (15 min induction), 109 (60 min induction), and 110 (120 min induction) show the overall increase in induction over time, with the combination of NLpoly5P and NLpep80 producing the most luminescence. Individual components contribute minimally to the signal.
[0185] Example 66 Comparison of luminescence generated by cells expressing different combinations of FRB and FKBP fused to NLpoly5P and NLpep80 / 87 Similar to Example 65, this example tested all eight possible combinations of FRB and FKBP fused to NLpoly / NLpep and used less total DNA. HEK293T cells (400,000 cells) were reverse transfected with a total of 0.001 μg of pF4A Ag FRB-NLpoly5P and 0.001 μg of pF4A Ag FKBP-NLpep80 / NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA per transfection. Twenty-four hours after transfection, 10,000 cells were replated in opaque 96-well assay plates and incubated for an additional 24 hours. Cells were washed with PBS and then incubated for 2 hours in phenol red-free OptiMEMI containing 0 or 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) containing 0 or 50 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 minutes at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figure 111 shows that the NLpep80 combination produced the highest luminescence, and all structures responded to rapamycin treatment.
[0186] Example 67 Comparison of luminescence generated by FRB or FKBP fusions expressed in the absence of binding partners HEK293T cells (400,000 cells) were reverse transfected with a total of 0.001 μg of pF4A Ag FRB-NLpoly5P or pF4A Ag FKBP-NLpep80 / NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA in each transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI containing 0 or 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) containing 0 or 50 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. Figure 112 shows that the individual components produce low basal levels of luminescence that are insensitive to rapamycin treatment.
[0187] Example 68 Comparison of luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 / 87 DNA HEK293T cells (400,000 cells) were reverse transfected with 2, 0.2, 0.02, or 0.002 μg total of pF4A Ag FRB-NLpoly5P and pF4A Ag FKBP-NLpep80 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to achieve a total DNA of 2 μg per transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 20 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 20 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figure 113 shows that transfection with less DNA reduces overall luminescence but increases the fold induction.
[0188] Example 69 Comparison of luminescence generated by cells transfected with various amounts of FRB-NLpoly5P or FKBP-NLpep80 / 87 DNA in the absence of binding partners HEK293T cells (400,000 cells) were reverse transfected with 2, 0.2, 0.02, or 0.002 μg total of pF4A Ag FRB-NLpoly5P or pF4A Ag FKBP-NLpep80 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to achieve a total DNA of 2 μg per transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 20 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 20 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figure 114 shows that lower DNA levels do not alter the overall luminescence of cells transfected with individual components.
[0189] Example 70 Comparison of luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 / 87 DNA HEK293T cells (400,000 cells) were reverse transfected with 0.2, 0.02, 0.002, or 0.0002 μg total of pF4A Ag FRB-NLpoly5P and pF4A Ag FKBP-NLpep80 / NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to achieve 2 μg total DNA per transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 50 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figure 115 shows luminescence above background, demonstrating that rapamycin induction can be achieved at DNA levels down to 2.5 pg, as determined in Examples 69 and 71.
[0190] Example 71 Comparison of luminescence generated by cells transfected with various amounts of FRB-NLpoly5P or FKBP-NLpep80 / 87 DNA in the absence of binding partners HEK293T cells (400,000 cells) were reverse transfected with 0.2, 0.02, 0.002, or 0.0002 μg total of pF4A Ag FRB-NLpoly5P or pF4A Ag FKBP-NLpep80 / NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to achieve 2 μg total DNA in each transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 50 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on the GloMax Multi with an integration time of 0.5 seconds. Figure 116 shows that there was no significant change in the luminescence generated by the individual components when less DNA was used.
[0191] Example 72 Comparison of luminescence generated by cells transfected with various amounts of FRB-NLpoly5P and FKBP-NLpep80 or FKBP-NLpep87 DNA after treatment with rapamycin for different lengths of time. HEK293T cells (400,000 cells) were reverse transfected with 2, 0.2, 0.02, or 0.002 μg total of pF4A Ag FRB-NLpoly5P and pF4A Ag FKBP-NLpep80 or FKBP-NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to achieve a total DNA of 2 μg per transfection. 24 hours post-transfection, 10,000 cells were replated in opaque 96-well assay plates and incubated for an additional 24 hours. Cells were washed with PBS and incubated in phenol red-free OptiMEMI with or without 20 nM rapamycin for 5, 15, 30, 60, or 120 minutes. 10 μM furimazine substrate (final concentration on cells) with or without 20 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 minutes at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figures 117 and 118 show the decrease in luminescence with less DNA and the increase in rapamycin induction over time.
[0192] Example 73 Comparison of luminescence generated by cells expressing different combinations of FRB-NLpoly5P or FRB-NLpoly5A2 and FKBP-NLpep80 / 87 / 95 / 96 / 97 In this example, assays were performed in both 2-day and 3-day formats. For the 2-day assay, 20,000 HEK293T cells were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly5P or FRB-NLpoly5A2 and pF4A Ag FKBP-NLpep80 / 87 / 95 / 96 / 97 in an opaque 96-well assay plate using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA in each transfection. 24 hours post-transfection, cells were washed with PBS and then incubated for 2 hours in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) in OptiMEMI with or without 50 nM rapamycin was added directly to each well and incubated for 5 minutes at room temperature. Luminescence was then measured on a GloMax Multi with an integration time of 0.5 seconds.
[0193] For the 3-day assay, 400,000 HEK293T cells were reverse transfected with a total of 0.002 μg of pF4A Ag FRB-NLpoly5P and pF4A Ag FKBP-NLpep80 / 87 / 95 / 96 / 97 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA in each transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 50 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 second integration time. Figures 119 and 120 show similar levels of luminescence in both the 2-day and 3-day assays. Assays performed with NLpoly5A2 showed higher rapamycin induction compared to NLpoly5P, and assays performed with NLpoly5A2 and NLpep96 showed the highest rapamycin induction of all combinations tested.
[0194] Example 73 Comparison of luminescence generated by cells expressing different combinations of FRB-NLpoly5A2 or FRB-NLpoly11S and FKBP-NLpep101 / 104 / 105 / 106 / 107 / 108 / 109 / 110 HEK293T cells (20,000 cells) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly5A2 / 11S and pF4A Ag FKBP-NLpep101 / 104 / 105 / 106 / 107 / 108 / 109 / 110 in opaque 96-well assay plates using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA per transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) in OptiMEMI with or without 50 nM rapamycin was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with an integration time of 0.5 seconds. Figure 121 shows that of the combinations tested, NLpep101 and NLpoly11S showed the highest rapamycin induction and one of the strongest rapamycin-specific luminescence signals.
[0195] Example 74 Comparison of luminescence generated by cells transfected with different combinations of FRB-NLpoly5A2 or FRB-NLpoly11S and FKBP-NLpep87 / 96 / 98 / 99 / 100 / 101 / 102 / 103 HEK293T cells (20,000 cells) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly5A2 / 11S and pF4A Ag FKBP-NLpep87 / 96 / 98 / 99 / 100 / 101 / 102 / 103 in opaque 96-well assay plates using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg of total DNA per transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 2 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) in OptiMEMI with or without 50 nM rapamycin was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with an integration time of 0.5 seconds. Figure 122 shows that the combination of NLpoly11S and NLpep101 results in the highest induction while maintaining a high level of specific luminescence.
[0196] Example 75 Comparison of luminescence generated by cells transfected with different levels of FRB-NLpoly11S and FKBP-NLpep87 / 101 / 102 / 107 DNA HEK293T cells (20,000 cells) were reverse transfected with 0.01, 0.1, 1, or 10 ng total of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep87 / 101 / 102 / 107 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 50 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. Figure 123 shows that NLpoly11S and NLpep101 produce the lowest overall luminescence in untreated samples at all DNA levels tested, and that this combination maintains relatively high levels of luminescence in rapamycin-treated samples.
[0197] Example 76 Comparison of luminescence generated by cells transfected with different levels of FRB-NLpoly5A2 and FKBP-NLpep87 / 101 / 102 / 107 DNA HEK293T cells (20,000 cells) were reverse transfected with 0.01, 0.1, 1, or 10 ng total of pF4A Ag FRB-NLpoly5A2 and pF4A Ag FKBP-NLpep87 / 101 / 102 / 107 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) with or without 50 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. FIG. 124 shows that NLpoly5A2 produces higher luminescence in untreated samples than NLpoly11S shown in Example 75.
[0198] Example 77 Rapamycin dose-response curve showing luminescence of cells expressing FRB-NLpoly5P and FKBP-NLpep80 / 87 DNA. HEK293T cells (400,000 cells) were reverse transfected with a total of 0.001 μg of pF4A Ag FRB-NLpoly5P and 0.001 μg of pF4A Ag FKBP-NLpep80 / NLpep87 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to each well to achieve a total DNA concentration of 1 μg per transfection. 24 h post-transfection, 10,000 cells were replated in an opaque 96-well assay plate and incubated for an additional 24 h. Cells were washed with PBS and incubated for 2 h in phenol red-free OptiMEM containing 0–500 nM rapamycin. 10 μM furimazine substrate (final concentration on cells) containing 0–500 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with an integration time of 0.5 seconds. Kd was calculated using GraphPad Prism version 5.00 for Windows. Figure 125 shows the rapamycin-specific increase in luminescence.
[0199] Example 78 Rapamycin dose-response curve showing luminescence of cells expressing FRB-NLpoly5A2 and FKBP-NLpep87 / 101 DNA. HEK293T cells (20,000 cells) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly5A2 / 11S and pF4A Ag FKBP-NLpep87 / 101 using FuGENE HD at a DNA to FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve a total DNA concentration of 1 μg per transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI containing 0–1 μM rapamycin. 10 μM furimazine substrate (final concentration on cells) containing 0–1 μM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. Figure 126 shows the sigmoidal dose response to rapamycin using the combinations NLpoly5A2 / NLpep101 and NLpoly11S / NLpep101. Combinations including NLpep87 show increased luminescence with rapamycin, but the collected data points deviate further from the sigmoidal curve.
[0200] Example 79 Comparison of luminescence generated by cells expressing FRB-11S and FKBP-101 and treated with the substrates PBI-4377 or furimazine HEK293T cells (20,000 cells) were reverse transfected with 0.1 / 1 / 10 ng total of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA per transfection. 24 h posttransfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI containing 0 or 50 nM rapamycin. 10 μM furimazine or PBI-4377 substrate (final concentration on cells) containing 0 or 50 nM rapamycin in OptiMEM was added directly to each well and incubated for 5 min at room temperature. Luminescence was then measured on a GloMax Multi with a 0.5 s integration time. Figure 127 shows the increase in luminescence and fold induction with the PBI-4377 substrate compared to the furimazine substrate.
[0201] Example 80 Time course of cells expressing FRB-NLpoly11S / 5A2 and FKBP-NLpep87 / 101 in the presence or absence of rapamycin HEK293T cells (20,000 cells) were reverse transfected with 0.1 ng total of pF4A Ag FRB-NLpoly11S / 5A2 and pF4A Ag FKBP-NLpep87 / 101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 50 nM rapamycin and 10 μM furimazine was added manually or via instrument injection. Luminescence was measured immediately on the GloMax Multi with a 0.5-second integration time. Figures 128 and 129 show that of all combinations tested, NLpoly11S and NLpep101 had the lowest luminescence at time 0, plateaued more quickly, and had the greatest dynamic range.
[0202] Example 81 Luminescence generated by FRB-NLpoly11S and FKBP-NLpep101 measured with two different instruments HEK293T cells (20,000 cells) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve a total DNA concentration of 1 μg per transfection. 24 h posttransfection, cells were washed with PBS and then treated with phenol red-free OptiMEMI containing 0 or 50 nM rapamycin and 10 μM furimazine for 20 min. 10 μM furimazine (final concentration on cells) in OptiMEMI containing 0 or 50 nM rapamycin was added and incubated for an additional 5 min. Luminescence was immediately measured using a 0.5-second integration time on a GloMax Multi and a 450 nM bandpass filter on a Varioskan Flash. Figure 130 shows that rapamycin-specific induction of FRB-NLpoly11S and FKBP-NLpep101 can be measured on different instruments.
[0203] Example 82 Images showing luminescence of cells expressing FRB-NLpoly11S and FKBP-NLpep101 at various times after rapamycin treatment. HeLa cells (500,000 cells) were reverse transfected with 1 μg of pF4 Ag FRB-NLpoly11S and 1 μg of pF4 Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. Cells were transfected in 35 mm glass-bottom culture dishes (MatTek #p35gc-1.5-14-C). 24 h posttransfection, cells were washed with PBS and then incubated with 10 μM furimazine in OptiMEM for 5 minutes. 50 nM rapamycin in OptiMEM was added to the cells, and luminescence images were acquired at 10-second intervals using an LV200 microscope for a total of 20 minutes. The instrument was maintained at 37°C, with a 60X objective, a gain of 200, and an exposure time of 600 ms. FIG. 131 shows that an increase in cellular luminescence can be detected in cells expressing FRB-NLpoly11S and FKBP-NLpep101 after treatment with rapamycin.
[0204] Example 83 Quantification of signals generated by individual cells expressing FRB-NLpoly11S and FKBP-NLpep101 at various times after rapamycin treatment HeLa cells (500,000 cells) were reverse transfected with 1 μg of pF4 Ag FRB-NLpoly11S and 1 μg of pF4 Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. Cells were transfected in 35 mm glass-bottom culture dishes (MatTek #p35gc-1.5-14-C). 24 h posttransfection, cells were washed with PBS and then incubated with 10 μM furimazine in OptiMEM for 5 minutes. 50 nM rapamycin in OptiMEM was added to the cells, and luminescence images were acquired at 10-second intervals using an LV200 microscope for a total of 20 minutes. The instrument was maintained at 37°C, with a 60X objective, a gain of 200, and an exposure time of 600 ms. The signal intensity of every cell within the field of view was analyzed over the entire period using Image J software. Figure 132 shows that the signal generated by individual cells can be measured and that the increase in signal from each cell parallels the increase observed in the 96-well plate assay shown in Figures 128 and 129.
[0205] Example 84 Comparison of luminescence in different cell lines expressing FRB-NLpoly11S and FKBP-NLpep101 HEK293T, HeLa, or U2-OS cells (20,000 cells) were reverse transfected with a total of 0.1 ng pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in opaque 96-well assay plates. pGEM-3Zf(+) DNA was added to achieve a total DNA content of 1 μg per transfection. 24 h posttransfection, cells were washed with PBS and then treated with phenol red-free OptiMEMI containing 0 or 50 nM rapamycin and 10 μM furimazine for 20 min. 10 μM furimazine (final concentration on cells) in OptiMEMI containing 0 or 50 nM rapamycin was added and incubated for an additional 5 min. Luminescence was immediately measured on a GloMax Multi with a 0.5 s integration time. FIG. 133 shows that similar levels of luminescence were generated in the absence and presence of rapamycin in three different cell lines transfected with FRB-NLpoly11S and FKBP-NLpep101.
[0206] Example 85 Comparison of luminescence generated by cells expressing FRB-NLpoly11S and FKBP-NLpep101 after treatment with the rapamycin-competitive inhibitor FK506. HEK293T cells (20,000 cells) were reverse transfected with 0.1 ng total of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 20 nM rapamycin was added for 20 minutes. FK506 inhibitor in OptiMEM was added to the cells at a final concentration of 5 μM and incubated for 3 or 5 hours. Furimazine in OptiMEM was added to a final concentration on the cells of 10 μM. Luminescence was immediately measured on a GloMax Multi with a 0.5 second integration time. Figure 134 shows the decrease in rapamycin-induced luminescence after treatment with the competitive inhibitor FK506.
[0207] Example 86 Luminescence generated by cells expressing FRB-NLpoly11S and FKBP-NLpep101 after treatment with the rapamycin-competitive inhibitor FK506. HEK293T cells (20,000 cells) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve a total DNA of 1 μg per transfection. 24 h posttransfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 20 nM rapamycin was added for 2.5 h. FK506 inhibitor in OptiMEM was added to cells via syringe at a final concentration of 0, 1, or 10 μM in 10 μM OptiMEM. Luminescence was measured every 10 min for 4 h with a 0.5 s integration time on a GloMax Multi set at 37°C. Figure 135 shows that by 200 seconds, the FK506 inhibitor is able to reduce luminescence to near the level of untreated cells.
[0208] Example 87 Luminescence generated by cells transfected with different combinations of V2R-NLpoly5A2 or V2R-NLpoly11S and NLpep87 / 101-ARRB2 in the presence or absence of the V2R agonist AVP HEK293T cells (20,000 cells) were reverse transfected with 0.1, 1, or 10 ng total of pF4A Ag V2R-NLpoly11S and pF4A Ag ARRB2-NLpep87 / 101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in an opaque 96-well assay plate. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 1 μM AVP and 10 μM furimazine was added for 25 minutes. Luminescence was then measured on a GloMax Multi with a 0.5-second integration time. Figure 136 shows that V2R-NLpoly11S and NLpep101 produced the highest AVP-specific increase in luminescence. The combination with NLpep87 showed no significant response to AVP.
[0209] Example 88 Time course showing luminescence generated by cells transfected with V2R-NLpoly5A2 or V2R-NLpoly11S and NLpep87 / 101-ARRB2 after treatment with AVP HEK293T cells (20,000 cells) were reverse transfected with 0.1 or 1 ng total of pF4A Ag V2R-NLpoly11S or 1 ng total of pF4A Ag V2R-NLpoly5A2 and pF4A Ag ARRB2-NLpep87 / 101 in opaque 96-well assay plates using FuGENE HD at a DNA to FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 hours post-transfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 1 μM AVP and 10 μM furimazine was added manually (Figure 137) or via instrument injection (Figure 138). Luminescence was then measured every 5 minutes for 25 minutes at room temperature (Figures 137 and 138) or 37°C (Figure 139) on a GloMax Multi with a 0.5 second integration time. Figures 137 and 138 show a time-dependent increase in AVP-induced luminescence (starting to peak at 600 seconds) for V2R-NLpoly11S and NLpep101-ARRB2. The combination of V2R-NLpoly5A2 and NLpep87 does not show a significant increase in luminescence over time. Figure 139 shows that at 37°C, all tested combinations of NLpoly11S and NLpep101 show a time-dependent increase in AVP-induced luminescence of 200 seconds on average.
[0210] Example 89 Comparison of luminescence in different cell lines expressing V2R-NLpoly11S and NLpep101-ARRB2 HEK293T, HeLa, or U2-OS cells (20,000 cells) were reverse transfected with 1 ng total of pF4A Ag V2R-NLpoly11S and pF4A Ag ARRB2-NLpep87 / 101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:8 in opaque 96-well assay plates. pGEM-3Zf(+) DNA was added to achieve 1 μg total DNA in each transfection. 24 h posttransfection, cells were washed with PBS, and then phenol red-free OptiMEMI containing 0 or 1 μM AVP was added for 20 minutes. Furimazine in OptiMEM was then added to a final concentration of 10 μM on the cells, and luminescence was measured using a GloMax Multi with a 0.5-second integration time.
[0211] Figure 140 shows similar luminescence levels in three different cell lines expressing V2R-NLpoly11S and NLpep101-ARRB2 in the presence and absence of AVP.
[0212] Example 90 Luminescence of cells expressing V2R-NLpoly11S and NLpep101-ARRB2 at various times after AVP treatment HeLa cells (500,000 cells) were reverse transfected with 1 μg of pF4 Ag V2R-NLpoly11S and 1 μg of pF4 Ag ARRB2-NLpep101 using FuGENE HD at a DNA-to-FuGENE ratio of 1:4. Cells were transfected in 35 mm glass-bottom culture dishes (MatTek #p35gc-1.5-14-C). 24 h posttransfection, cells were washed with PBS and then incubated with 10 μM furimazine in OptiMEM for 5 minutes. 1 μM AVP in OptiMEM was added to the cells, and luminescence images were acquired at 15-second intervals using an LV200 microscope for a total of 30 minutes. The instrument was maintained at 37°C, with a 60X or 150X objective, a gain of 600, and exposure times of 1 second or 2 seconds. Figures 141 and 142 show that image processing allows detection of increased luminescence and puncta formation in individual cells after treatment with AVP.
[0213] Example 91 Dissociation constant of NLpep NLpoly 5PE E. coli clarified lysate (prepared as previously described) was diluted 1:1,000 in PBS + 0.1% Prionex. A 4x concentration of NLpep78-HT (E. coli clarified lysate prepared as previously described) was made in PBS + 0.1% Prionex. 20 μL of NLpoly 5P was mixed with 20 μL of NLpep78 and shaken at room temperature for 10 minutes. 40 μL of NanoGlo / Fz was added and shaken at room temperature for 10 minutes. Luminescence was measured with 0.5 second integration on a GloMax luminometer. Kd was determined using Graphpad Prism, a best-fit value for one-site specific binding. Figure 80 compares the dissociation constants for NLpep consisting of either one or two repeating units of NLpep78.
[0214] Example 92 Affinity of NLpoly 5A2 and NLpep86 NLpoly 5A2 lysate (prepared as previously described after transfecting CHO cells) was diluted 1:10 in PBS + 0.1% Prionex. A 4x concentrate of NLpep86 (synthetic NLpep) was made in PBS + 0.1% Prionex. 20uL of NLpoly was mixed with 20uL of NLpep and shaken at room temperature for 10 minutes. 40uL of NanoGlo / Fz was added and shaken at room temperature for 10 minutes. Luminescence was measured with 0.5 seconds integration on a GloMax luminometer. Kd was determined using Graphpad Prism, a best fit value for one-site specific binding. Figure 81 shows the affinity of NLpoly 5A2 with NLpep86.
[0215] Example 93 Luminescence of NLpoly mutants Single colonies of various NLpolypeptides were individually inoculated into 200 μL of minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of the overnight culture was diluted into 190 μL of fresh minimal medium and grown on a shaker for 20 hours at 37°C. 10 μL of this overnight culture was diluted into 190 μL of autoinduction medium (previously described) and grown on a shaker for 18 hours at 25°C. 10 μL of the expression culture was mixed with 40 μL of assay lysis buffer (previously described) containing no NLpep or NLpep78-HT (1:3,860 dilution) or NLpep79-HT (1:10,000 dilution). The mixture was shaken at room temperature for 10 minutes, and 50 μL of NanoGlo+Fz was added and shaken again for 10 minutes at room temperature. Luminescence was measured on a GloMax luminometer with a 0.5-second integration. Figure 82 shows the luminescence from the NLpoly mutants without NLpep or with NLpep78 or NLpep79. The results show that the NLpoly mutant 11S (12S-51) has improved luminescence compared to the other mutants.
[0216] Example 94 Dissociation constants and Vmax values of NLpoly using 96 mutants of NLpep NLpep was synthesized in an array format by New England Peptide (peptides blocked at the N-terminus by acetylation and the C-terminus by amidation; peptides in the array were synthesized at approximately 1 mg scale) (Table 6). Each peptide was lyophilized in three separate plates. Each well from one of the three plates of peptides was dissolved in 100 uL of nanopure water, and the A260 was measured and used to calculate the concentration using the extinction coefficient of each peptide. The concentration was then adjusted based on the purity of the peptide, and nanopure water was added to obtain a final concentration of 750 uM.
[0217] Peptides were diluted to 12.66 μM (4X) in PBS + 0.1% Prionex and then serially diluted seven times in 0.5 log steps (total of eight concentrations) (3.162-fold dilutions). NLpoly 5P, 8S, 5A2, or 11S were diluted in PBS + 0.1% Prionex as follows: 5P 1:2,000; 8S 1:10,000; 11S 1:150,000; 5A2 1:1,000. 25 μL of each NLpep + 25 μL of each NLpoly was mixed and incubated at room temperature for 30 minutes. 50 μL of NanoGlo + 100 μM Fz was added and incubated at room temperature for 30 minutes. Luminescence was measured on a GloMax Multi+ with a 0.5-second integration. Kd / Vmax was determined using Graphpad Prism, a best-fit value for one-site specific binding. Figures 83-90 show the dissociation constants and Vmax values from NLpoly for 96 mutant NLpep. The results suggest specific mutations in NLpep that exhibit lower binding affinity without loss of Vmax. Table 6. Peptide array 1 JPEG2024167207000053.jpg178163 JPEG2024167207000054.jpg176168 JPEG2024167207000055.jpg176170
[0218] Example 95 Solubility of NLpoly mutants A single NLpoly5A2, 12S, 11S, 12S-75, 12S-107, or 5P-B9 colony was inoculated into 5 mL LB cultures and incubated overnight at 37°C with shaking. The overnight cultures were diluted 1:100 into fresh LB and incubated for 3 hours at 37°C with shaking. Rhamnose was added to the cultures to 0.2% and incubated overnight at 25°C with shaking. 900 μL of these overnight cultures were mixed with 100 μL of 10X FastBreak Lysis Buffer (Promega Corporation) and incubated at room temperature for 15 minutes. A 75 μL aliquot (total) was removed from each culture and saved for analysis. The remaining culture from each sample was centrifuged at 14,000× rpm in a tabletop microcentrifuge for 15 minutes at 4°C. A 75 μL aliquot of the supernatant (soluble) was removed from each sample and saved for analysis. 25uL of 4x SDS buffer was added to the pooled aliquots and incubated at 95°C for 5 minutes. 5uL of each sample was loaded onto a 4-20% Tris-Glycine SDS gel and run at approximately 190V for approximately 50 minutes. The gel was stained with SimplyBlue Safe Stain and imaged on an LAS4000. Figure 91 shows a protein gel of the total lysates of the NLpoly variants and the soluble fractions of the same lysates. With the exception of 5A2, all variants showed a proportion of NLpoly in the soluble fraction.
[0219] Example 96 Solubility and dissociation constants of NLpoly variants A single NLpoly colony (listed in Figure 92) was inoculated into a 5 mL LB culture and incubated overnight at 37°C with shaking. The overnight culture was diluted 1:100 into fresh LB and incubated for 3 hours at 37°C with shaking. Rhamnose was added to the culture to 0.2% and incubated overnight at 25°C with shaking. 900 μl of these overnight cultures were mixed with 100 μl of 10X FastBreak Lysis Buffer (Promega Corporation) and incubated at room temperature for 15 minutes. A 75 μl aliquot (total) was removed from each culture and saved for analysis. The remaining culture from each sample was centrifuged at 14,000× rpm in a tabletop microcentrifuge for 15 minutes at 4°C. A 75 μl aliquot of the supernatant (soluble) was removed from each sample and saved for analysis. 25 μl of 4X SDS buffer was added to the saved aliquot and incubated at 95°C for 5 minutes. 5 ul of each sample was loaded onto a 4-20% Tris-Glycine SDS gel and run at approximately 190V for approximately 50 minutes. The gel was stained with SimplyBlue Safe Stain and imaged on an LAS4000. Figure 92 shows protein gels of total lysates of NLpoly variants and the soluble fractions of the same lysates, as well as a table containing the dissociation constants of the same variants.
[0220] Example 97 Substrate specificity of NLpoly5P and 11S when using NLpep79 E. coli clarified lysates for NLpoly5P or 11S were prepared as previously described. The NLpoly lysates were then serially diluted 10-fold in PBS + 0.1% Prionex. 25 μL of NLpoly and 25 μL of synthetic NLpep79 (400 nM, 4X) were mixed and incubated at room temperature for 10 minutes. 50 μL of NanoGlo + 100 μM Fz was added, incubated at room temperature for 10 minutes, and luminescence was measured with a 0.5-second integration on a GloMax Multi+. Figure 93 shows the substrate specificity of 5P and 11S with NLpep79, demonstrating that 11S has superior specificity for furimazine over 5P.
[0221] Example 98 Solubility of NLpoly variants from different stages of evolution A single NLpoly WT, 5A2, 5P, 8S, or 11S colony was inoculated into 5 mL LB cultures and incubated overnight at 37°C with shaking. The overnight cultures were diluted 1:100 into fresh LB and incubated for 3 hours at 37°C with shaking. Rhamnose was added to the cultures to 0.2% and incubated overnight at 25°C with shaking. 900 μL of these overnight cultures were mixed with 100 μL of 10X FastBreak Lysis Buffer (Promega Corporation) and incubated at room temperature for 15 minutes. A 75 μL aliquot (total) was removed from each culture and saved for analysis. The remaining culture from each sample was centrifuged at 14,000 rpm in a tabletop microcentrifuge for 15 minutes at 4°C. A 75 μL aliquot of the supernatant (soluble) was removed from each sample and saved for analysis. 25 μL of 4X SDS buffer was added to the saved aliquots and incubated at 95°C for 5 minutes. Five microliters of each sample was loaded onto a 4-20% Tris-glycine SDS gel and run at approximately 190 V for approximately 50 minutes. The gel was stained with SimplyBlue Safe Stain and imaged on an LAS4000. Figure 104 shows a protein gel of the total lysate of NLpoly mutants from various stages of the evolution process and the soluble fraction of the same lysate. These results demonstrate that the solubility of NLpoly increased dramatically during the evolution process.
[0222] Example 99 Chemical labeling of proteins The non-luminescent peptides (NLpeps) of the present invention can be used to chemically label proteins. The NLpeps of the present invention can be synthesized to contain reactive groups, such as biotin, succinimidyl ester, maleimide, etc., and can be attached (e.g., conjugated, linked, labeled, etc.) to proteins, such as antibodies. The NLpep-labeled protein, e.g., NLpep-antibody, can then be used in various applications, such as ELISA. The interaction / binding of the NLpep-labeled protein, e.g., NLpep-antibody, with its target / binding partner is detected by adding the NLpoly and NanoGlo® assay reagents of the present invention. The luminescence generated by the interaction of the NLpep-labeled protein with the NLpoly will correlate with the interaction of the NL-labeled protein with its target / binding partner. This concept allows multiple NLpeps to be attached to a single protein molecule, thereby resulting in multiple NLpep-labeled protein / NLpoly interactions that cause signal amplification.
[0223] Example 100 Detection of post-translational protein modifications using HaloTag-NLpep by Western blot Some proteins can be post-translationally modified by AMPylation or ADP-ribosylation. In AMPylation, AMP is added to a target protein via a phosphodiester bond using ATP as the donor molecule. Similarly, in ADP-ribosylation, an ADP-ribose moiety is added to a target protein via a phosphodiester bond using NAD+ as the donor molecule. It has been shown that the N6 position of both ATP and NAD+ can be used to tag linkers without affecting post-modification events. When N6-modified chloroalkane-ATP or -NAD+ is used to perform the AMPylation or ADP-ribosylation reaction, the target protein is modified to contain the chloroalkane-ATP or -NAD+.
[0224] N6-modified ATP / NAD has been used in combination with click chemistry to develop an in-gel fluorescence-based detection system. Detection of these post-translational modifications by Western blot techniques requires antibodies, which are often not specific or available. An alternative approach may be to combine the properties of HaloTag® technology with the high luminescence of NanoLuc® luciferase (NL). Using either cell lysates or purified proteins, target proteins can be post-translationally modified with chloroalkane-ATP (for AMP) or chloroalkane-NAD+ (for ADP-ribosylation). The samples can then be resolved by SDS-PAGE and transferred to a PVDF membrane. After blocking, the blot can be incubated with HaloTag-NLpep. HaloTag binds to post-translationally modified proteins. In a next step, NLpoly and furimazine can be added to the blot for bioluminescence detection. This detection method is an alternative to chemiluminescence-based techniques for Western blot detection. Chemiluminescence-based techniques may involve incubation of a HaloTag-Protein G fusion (as a primary) and in the next step any secondary antibody linked to HRP may be used after the ECL reaction.
[0225] Example 101 Post-translational modification assays Post-translational modifications (PTMs) of proteins are central to all aspects of biological regulation. PTMs amplify the diverse functions of the proteome by covalently attaching functional groups to proteins. These modifications, including phosphorylation, methylation, acetylation, glycosylation, ubiquitination, nitrosylation, and lipidation, influence many aspects of normal cell biology and pathogenesis. More specifically, PTMs associated with histones are of paramount importance. Epigenetic covalent modifications of histone proteins profoundly influence gene transcriptional regulation and cellular activity. Examples of post-translational modification enzymes include, but are not limited to, kinases / phosphatases, histone methyltransferases (HMTs) / demethylases (HDMTs), histone acetyltransferases / deacetylases, glycosyltransferases / glucanases, and ADP-ribosyltransferases. Under normal physiological conditions, the regulation of PTM enzymes is tightly regulated. However, under pathological conditions, the activity of these enzymes can be dysregulated and disruption of the intracellular networks governed by these enzymes leads to many diseases, including cancer and inflammation.
[0226] The non-luminescent peptides (NLpeps) and non-luminescent polypeptides (NLpolys) of the invention can be used to determine the activity of PTM enzymes by monitoring changes in covalent group transfer (e.g., phosphoryl, acetyl) to specific peptide substrates linked to the NLpeps of the invention. NLpeps are linked to small PTM enzyme-specific peptides by peptide synthesis and used as substrates for the PTM enzymes.
[0227] A) PTM transferase assay (HAT) Once the PTM enzymatic reaction occurs, the unmodified peptide (NLpep; control) can be degraded using an aminopeptidase. Because aminopeptidase activity is known to be affected by PTM, the modified (acetylated) peptide (NLpep-PTM enzyme substrate) is degraded at a very slow rate or not at all. Once the aminopeptidase reaction is complete, NLpoly is added along with the NanoGlo® assay reagent containing furimazine. Luminescence is generated from samples in which PTM has occurred via the interaction between NLpep and NLpoly. If PTM does not occur, NLpep is degraded and no interaction occurs between NLpep and NLpoly, resulting in no luminescence. This concept is illustrated for general transferase enzymes in Figure 197 and for H3K4 / 9 acetyltransferase in Figure 145.
[0228] The reaction is carried out under optimal enzymatic reaction conditions using a histone peptide substrate linked to an NLpep of the present invention and Acetyl-CoA or SAM as the acetyl or methyl group donor. A buffer containing an aminopeptidase or a mixture of aminopeptidases is added to specifically degrade all unmodified substrates. A buffer containing an NLpoly of the present invention and an aminopeptidase inhibitor is added. NanoGlo® assay reagent is added, and luminescence is detected. The luminescence generated is proportional to the amount of undegraded NLpep present and therefore correlates with the amount of methylated or acetylated substrate, thereby indicating the amount of methyltransferase or acetyltransferase activity. This assay can also be applied to PTMs such as phosphorylation, glycosylation, ubiquitination, nitrosylation, and lipidation.
[0229] B) PTM hydrolase assay (HDMT) A similar concept to A) can be used for histone demethylases (HDMTs). However, instead of aminopeptidases, PTM-specific antibodies can be used to inhibit activity. The NLpep of the present invention can be linked to a small methylated peptide by peptide synthesis and used as a substrate for the hydrolase. After the hydrolase reaction is complete, an anti-methyl antibody can be added to the reaction. This antibody specifically binds to the methylated peptide (control). The peptide product generated by the HDMT does not bind to the antibody. The NLpoly of the present invention can then be added. If the antibody does not interfere with the interaction of the NLpep and NLpoly, no luminescence is generated. If hydrolysis of the PTM by the demethylase occurs, the NLpep and NLpoly interact and luminescence is generated. This concept is illustrated for the general hydrolase enzyme concept in Figure 198 and for the H3K4 / 9 demethylase in Figure 146.
[0230] The concept of aminopeptidase degradation of unmodified substrates can also be used in hydrolase assays, although the resulting assay results in a loss of signal rather than a gain of signal. The reaction is performed under optimal enzyme reaction conditions using a modified (methylated or acetylated) histone peptide substrate linked to an NLpep of the present invention. A buffer containing an antibody capable of recognizing methyl or acetyl groups is added. A buffer containing an NLpep of the present invention is added. The NLpep interacts with NLpep that is not bound to the antibody. NanoGlo® assay reagent is added, and luminescence is detected. The luminescence generated is proportional to the amount of NLpep that is not bound to the antibody and therefore correlates with the amount of demethylated or deacetylated substrate, thereby indicating the amount of demethylase or deacetylase activity. Both hydrolase assay concepts can also be applied to PTM hydrolases, such as phosphatases, glucanases, and deubiquitinases.
[0231] In another version of these concepts, the introduction or hydrolysis of a PTM on the peptide-NLpep is sufficient alone to reduce or enhance the interaction between NLpep and NLpoly, thus reducing or increasing the luminescent signal without the need for an aminopeptidase or antibody.
[0232] The method of the present invention was used to assay the representative transferase tyrosine kinase SRC using the following NLpep-SRC substrate peptide: YIYGAFKRRGGVTGWRLCERILA. The SRC enzyme was titrated into 10 μl of reaction buffer A (40 mM Tris 7.5, 20 mM MgCl2, and 0.1 mg / ml BSA) in the presence of 150 μM ATP and 2.5 μM NLpep-Src substrate and incubated at 23°C for 1 hour. After incubation, 10 μl of amino-peptidase M (APM) reagent (40 mM Tris 7.5, 0.1 mg / ml BSA, and 50 mU APM) was added, mixed on an orbital shaker for 2 minutes, and then incubated at 37°C for 2 hours. 30 μl of NLpoly reagent was added to the sample, and the sample was incubated at room temperature. The NLpoly reagent contained the NLpoly fragment and aminopeptidase inhibitor. After 30 minutes, 50 μl of NanoGlo® assay reagent was added, and luminescence was recorded on a luminometer after 3 minutes. An increase in SRC kinase enzyme activity was found to correlate with an increase in luminescence above background (Figure 199). Only background activity was observed in the absence of SRC, demonstrating that the unphosphorylated NLpep-SRC substrate peptide is digested and does not result in light production by the NLpoly fragment, thus demonstrating the use of the methods of the present invention to monitor the activity of transferase enzymes such as kinases.
[0233] Example 102 Detection of specific RNAs of interest (non-coding RNA or mRNA) in mammalian cells, cell lysates, or clinical samples The non-luminescent peptides (NLpeps) and polypeptides (NLpolys) of the present invention can be tethered to RNA-binding domains (RBDs) with engineered sequence specificity. The specificity of the RBD can be precisely altered by altering specific amino acids that confer base specificity to the RBD. One example of such an RBD is the human pumilio domain (referred to herein as PUM). The RNA recognition code of PUM is fairly well established. PUM consists of eight tandem repeats (each repeat consisting of 34 amino acids that fold into a tightly packed domain consisting of an α-helical structure). Conserved amino acids from the center of each repeat make specific contacts with individual bases within the RNA recognition sequence (consisting of eight bases). The sequence specificity of PUM can be precisely altered by altering (by site-directed mutagenesis) the conserved amino acids involved in base recognition within the RNA recognition sequence. For intracellular detection of specific RNAs, PUM domains (PUM1 and PUM2) with customized sequence specificity for target RNAs can be tethered to the NLpep and NLpoly of the present invention (e.g., genetically engineered fusion proteins) and expressed in mammalian cells. PUM1 and PUM2 are designed to recognize eight nucleotide sequences in close proximity to each other (separated by several base pairs, experimentally determined) in the target RNA. Optimal interaction of PUM1 and PUM2 with their target sequences is ensured by introducing a flexible linker (the sequence and length of the linker are experimentally determined) separating the PUMs from the non-luminescent peptide and polypeptide. Binding of PUM1 and PUM2 to their target sequences brings the NLpep and NLpoly into close proximity in an orientation that results in the formation of a functional complex capable of generating a bioluminescent signal under our specific assay conditions. Due to the unstable interaction of the NLpep and NLpoly pairs that make up the complex, a functional bioluminescent complex is not formed in the absence of the RNA target.
[0234] A similar strategy can be used for in vitro detection of RNA in clinical samples. NLpep-PUM fusion proteins with customized RNA specificity can be expressed from an appropriate protein expression system (such as E. coli or a mammalian protein expression system) and purified. The purified components can be added to a biological sample along with appropriate substrates and assay components to generate a bioluminescent signal.
[0235] Example 103 DNA oligo-based detection of specific RNAs (non-coding RNAs or mRNAs) in clinical samples or mammalian cell lysates The non-luminescent peptides (NLpeps) and non-luminescent polypeptides (NLpoly) of the present invention can be attached to oligonucleotides complementary to target RNAs using appropriate linkers (amino acids or nucleotides). Functional assembly of a bioluminescent complex occurs only when sequence-specific hybridization of DNA oligos with their target RNA brings the NLpeps and NLpolys into close proximity in an ideal conformation optimal for generating a bioluminescent signal under assay conditions. Detection can also be achieved through a three-component complementation system comprising two NLpeps and a third NLpoly. For example, two NLpep-DNA conjugates are mixed with the target RNA. Functional assembly of the bioluminescent complex is then achieved by adding a third NLpoly. Thus, if a detectable signal is generated under specific assay conditions using clinical samples or cell lysates, the presence of the target RNA in such samples is inferred. Such assays are useful for detecting RNA derived from infectious agents (viral RNA) and specific RNA biomarkers (associated with many pathologies, such as various forms of cancer, liver disease, and heart disease), and may provide new avenues for the diagnosis and prognosis of many pathologies.
[0236] Example 104 In-vivo imaging Biotechnology-derived products (biologics), including antibodies, peptides, and proteins, hold great promise as therapeutic agents. Unlike small molecule drugs, biologics are large molecules with secondary and tertiary structures and often contain post-translational modifications. The internalization, intracellular trafficking, biodistribution, pharmacokinetics and pharmacodynamics (PK / PD), and immunogenicity of biologics are significantly different from those of small molecule drugs, creating a need for new tools to "track" these antibodies in vivo. Traditional chemical labeling using enzyme reporters (e.g., HRP, luciferase) or small fluorescent tags can significantly alter the therapeutic value of biologics and is not ideal for in vivo imaging with biologics. Radioisotope labeling for PET-based imaging is also inconvenient.
[0237] The NLpoly and NLpep described herein provide a novel solution for in vivo imaging of biologics. NLpep can be genetically encoded into biotherapeutics without any synthetic steps. Genetic encoding allows precise control of the amount and location of peptide per biomolecule, minimizing any perturbation to its therapeutic value. For imaging, NLpoly can be injected into animals along with a substrate, such as furimazine. Upon interaction between NLpep-biologic and NLpoly, luminescence is generated. Alternatively, transgenic animals expressing NLpoly can be used as a model system.
[0238] Example 105 BRET use This concept essentially measures three moieties combined: two of the NLpoly and / or NLpep moieties form a complex, and a third moiety, either fluorescent or bioluminescent, provides the energy transfer component. If the complex formed is bioluminescent, both bioluminescence and energy transfer (i.e., BRET) can be measured. If the complex formed is fluorescent, the magnitude of energy transfer can be measured if the third component is a bioluminescent molecule.
[0239] A) This example shows a fluorescent dye bound to NLpep. Alternatively, a fluorescent protein may be fused: for example, a fusion protein (made from a genetic construct) with NLpoly or NLpep. NLpolyWT E. coli clarified lysate was prepared as previously described. 40 μL of NLpolyWT lysate was mixed with 10 μL of PBI-4730 (NLpep1) or PBI-4877 (NLpep1-TMR) and incubated at room temperature for 10 min. 50 μL of 100 μM furimazine in 50 mM HEPES (pH 7.4) was added and incubated at room temperature for 30 min. Luminescence was measured over a range of 400–700 nm on a TECAN M1000.
[0240] Figure 147 shows the highly efficient energy transfer from the NLPoly / NLPep complex (donor) to TMR (acceptor) and the corresponding red shift in the wavelength of the emitted light.
[0241] B) This example demonstrates the use of BRET in detection, such as detecting small molecule concentration or enzyme activity. Because energy transfer is strongly distance-dependent, the magnitude of energy transfer is often related to the conformation of the system. For example, insertion of a calcium-chelating polypeptide can be used to measure calcium concentration by modifying energy transfer.
[0242] Enzymes that also change distance by causing a conformational change in the sensor as described above or by cleaving the sensor from the fluorescent moiety can be measured by the system described herein. NLpoly or NLpep bound to a fluorescent moiety results in energy transfer when the NLpoly and NLpep interact. One example of this is a peptide sensor engineered such that the NLpep is conjugated to a fluorescent TOM dye via a DEVD linker (caspase-3 cleavage site). Energy transfer is observed upon exposure to NLpoly. Upon exposure to caspase-3, energy transfer is eliminated, but emission at 460 nm remains.
[0243] NLpoly 5A2 and NL-HT (NanoLuc fused to HaloTag) were purified. 20 μL of 8 pM NL-HT was mixed with 20 μL of 100 nM PBI-3781 (see, e.g., U.S. Patent Application No. 13 / 682,589, incorporated herein by reference in its entirety) and incubated at room temperature for 10 minutes. 40 μL of NanoGlo + 100 μM furimazine was added, and luminescence was measured over a range of 300-800 nm on a TECAN M1000.
[0244] 20 uL of 33 ng / uL NLpoly 5A2 was mixed with 20 uL of approximately 500 uM PBI-5074 (TOM-NCT-NLpep). 40 uL of NanoGlo + 100 uM furimazine was added and emission was measured over 300-800 nm on a TECAN M1000.
[0245] Figure 148 shows the energy transfer from the NLPoly / NLPep complex (donor) to the TOM dye (acceptor) and the corresponding red shift in the wavelength of the emitted light.
[0246] C) ternary interaction Energy transfer via NLpoly and NLpep can also be used to measure three interacting molecules. One example is a GPCR labeled with NLpoly and a GPCR-interacting protein labeled with NLpep, which form a bioluminescent complex upon interaction. This allows for the measurement of two-component interactions. When a small molecule GPCR ligand bearing a fluorescent moiety suitable for energy transfer interacts with this system, energy transfer occurs. Thus, two-component protein-protein interactions and drug-protein-protein ternary interactions can be measured in the same experiment. Furthermore, only the fluorescent moiety can elicit a signal when interacting with the protein pair, eliminating any signal from the ligand interacting with the inactive protein (Figure 149).
[0247] Example 106 6-Tetramethylrhodamine-PEG3-NH2: To a solution of 6-tetramethylrhodamine succidimyl ester (0.25 g, 0.5 mmol) in DMF (5 mL) was added 1-Boc-4,7,10-trioxatridecane-1,13-diamine (0.15 g, 0.5 mmol), followed by diisopropylethylamine (0.25 mL, 1.4 mmol). After stirring for 16 h, the reaction was analyzed by HPLC to confirm complete consumption of 6-tetramethylrhodamine succidimyl ester. The reaction was concentrated to a pink film and dissolved in a combination of triisopropylsilane (0.2 mL) and trifluoroacetic acid (4 mL). The pink solution was stirred for 2 h, after which analytical HPLC confirmed complete consumption of the starting material. The reaction was concentrated to dryness to give crude 6-tetramethylrhodamine-PEG3-NH2 as a pink film.
[0248] H-GVTGWRLCERILA-PEG-TMR(PBI-4877): The fully protected peptide Boc-GVTGWRLCERILA was synthesized by standard solid-phase peptide synthesis using Fmoc technology and then cleaved from the resin using dichloroacetic acid to release the fully protected peptide as a white solid. To a solution of 6-tetramethylrhodamine-PEG3-NH2 (0.05 g, 0.08 mmol) in DMF (1.5 mL) was added Boc-GVTGWRLCERILA-OH (0.2 g, 0.07 mmol), 1-hydroxyazabenzotriazole (11 mg, 0.08 mmol), 1-ethyl-3-(3-diethylaminopropyl)carbodiimide (15 mg, 0.08 mmol), and diisopropylethylamine (0.28 mL, 0.16 mmol). After stirring for 30 minutes, the reaction was concentrated, and the resulting crude product was partitioned between CHCl and water. The layers were separated, and the organic layer was washed with water and brine, dried over sodium sulfate, and concentrated. The resulting pink solid was dissolved in a combination of triisopropylsilane (0.2 mL) and trifluoroacetic acid (4 mL). After stirring for 3 hours, the reaction was concentrated, and the resulting pink film was purified by reverse-phase HPLC using a gradient of ACN in 0.1% aqueous TFA to give PBI 4877 as a pink powder: MS (M+) calculated 2088.5, found 2089.1.
[0249] TOM-DEVDGVTGWRLCERILA-OH(PBI-5074): The fully protected peptide H-DEVDGVTGWRLCERILA was synthesized on resin by standard solid-phase peptide synthesis using Fmoc technology. While still on the resin, a solution of 6-TOM (PBI-3739) succidimidyl ester was added to react with the free N-terminus. The peptide was then cleaved from the resin and fully deprotected using trifluoroacetic acid (TFA), yielding a blue solid. The solid was purified by reverse-phase HPLC using a gradient of ACN in 0.1% aqueous TFA to yield PBI 5074 as a blue powder: MS (M+Z / 2) calculated 1238.9, found 1238.8.
[0250] Example 107 Comparison of complementation between synthetic, N-terminally fused, and C-terminally fused NLPep78 NLpep78-HaloTag (78-HT) and HaloTag-NLPep78 (HT-78) fusions were quantified using GST-HaloTag fusion (GST-HT) as a control by labeling E. coli lysates with the HaloTag-TMR® ligand, separated by SDS-PAGE, and scanned on a Typhoon. A standard curve was then generated using known concentrations of GST-HT standards, and the band intensities of 78-HT and HT-78 were used to determine their concentrations.
[0251] E. coli lysate containing NLpoly11S was diluted 1:10 in PBS pH 7 + 0.1% Prionex 7 Serial dilutions of 78-HT, HT-78, and synthetic NLpep78 were made in PBS pH 7 + 0.1% Prionex. 20 uL of NLpoly11S and 20 uL of one of the NLPeps were mixed and incubated at ambient temperature for 5 minutes. 40 uL of NanoGlo® reagent (Promega Corporation) + 100 uM Fz was added, and the sample was incubated at ambient temperature for 5 minutes. Luminescence was measured on a GlomaxMulti+ using 0.5 second integration. Data were fitted to one-site specific binding using GraphPad Prism, and Bmax and Kd were determined.
[0252] The results (Figure 150) compare the binding of NLpoly11S to synthetic NLPep78 and NLPep78 at the N- or C-terminus of the fusion partner (HaloTag). Binding affinity was found not to change significantly, but Bmax was reduced when NLPep78 was at the C-terminus.
[0253] Example 108 Complementation comparison between synthetic, N-terminally fused, and C-terminally fused NLPep79 NLpep79-HaloTag (79-HT) and HaloTag-NLPep79 (HT-79) fusions were quantified by labeling E. coli lysates with the HaloTag-TMR ligand, using a GST-HaloTag® fusion (GST-HT) as a control, separating them by SDS-PAGE, and scanning them on a Typhoon. A standard curve was then generated using GST-HT standards of known concentration, and the band intensities of 79-HT and HT-79 were used to determine their concentrations.
[0254] E. coli lysate containing NLpoly11S was diluted 1:10 in PBS pH 7 + 0.1% Prionex 7 Serial dilutions of 79-HT, HT-79, and synthetic NLpep79 were made in PBS pH 7 + 0.1% Prionex. 20 μL NLpoly11S and 20 μL of one of the NLPeps were mixed and incubated at ambient temperature for 5 minutes. 40 μL NanoGlo® Reagent (Promega Corporation) + 100 μM Fz was added, and the sample was incubated at ambient temperature for 5 minutes. Luminescence was measured using a GlomaxMulti+ with a 0.5 second integration. Data were fitted to one-site specific binding using GraphPad Prism to determine Bmax and Kd.
[0255] The results (Figure 151) compare the binding of NLpoly11S to synthetic NLPep79 as well as to NLPep79 at the N- or C-terminus of the fusion partner (HaloTag). Binding affinity was not found to change significantly, but Bmax was reduced when NLPep79 was at the C-terminus.
[0256] Example 109 Spectral scanning of NLpoly11S with NLPep86 compared to PBI-4877 (NLPep1-fluorophore) Purified NLpoly11S was diluted to 1 nM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. NLPep86 or PBI-4877 was diluted to 40 μM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. 25 μL NLpoly11S and 25 μL NLPep86 or PBI-4877 were mixed and then incubated at ambient temperature for 10 minutes. 50 μL buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT) + 100 μM Fz was then added. Emission was measured on a Tecan Infinite M1000 as follows: 300–800 nm, 5 nm intervals, bandwidth 10 nm, gain 127, integration 0.5 seconds, z-position 22,000 μm.
[0257] The results demonstrate that NLPep can be conjugated to small molecules such as fluorescent dyes and retain their interaction with NLpoly11S, resulting in light emission (Figure 152), which also demonstrates efficient energy transfer and the ability to alter the emission spectrum.
[0258] Example 110 Spectral scanning of NLpoly11S with NLPep86 compared to PBI-5434 (fluorophore-NLPep1) Purified NLpoly11S was diluted to 1 nM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. NLPep86 or PBI-5434 was diluted to 40 μM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. 25 μL NLpoly11S and 25 μL NLPep86 or PBI-5434 were mixed and then incubated at ambient temperature for 10 minutes. 50 μL buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT) + 100 μM Fz was then added. Emission was measured on a Tecan Infinite M1000 as follows: 300–800 nm, 5 nm intervals, bandwidth 10 nm, gain 127, integration 0.5 seconds, z-position 22,000 μm.
[0259] The results demonstrate that NLPep can be conjugated to small molecules such as fluorescent dyes and retain their interaction with 11S, resulting in light emission (Figure 153). This, combined with the results with PBI-4877 in Example 109, also suggests that the termini and / or linker length used for conjugation can significantly affect energy transfer.
[0260] Example 111 Spectral scanning of NLpoly11S with NLPep86 compared to PBI-5436 (fluorophore-NLPep1) Purified NLpoly11S was diluted to 1 nM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. NLPep86 or PBI-5436 was diluted to 40 μM in PBS pH 7 + 0.01% Prionex + 1 mM DTT. 25 μL NLpoly11S and 25 μL NLPep86 or PBI-5436 were mixed and then incubated at ambient temperature for 10 minutes. 50 μL buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT) + 100 μM Fz was then added. Emission was measured on a Tecan Infinite M1000 as follows: 300–800 nm, 5 nm intervals, bandwidth 10 nm, gain 127, integration 0.5 seconds, z-position 22,000 μm.
[0261] The results demonstrate that NLPep can be conjugated to small molecules such as fluorescent dyes and retain their interaction with 11S, resulting in light emission (Figure 154), which also demonstrates efficient energy transfer and the ability to alter the emission spectrum.
[0262] Example 112 Comparison of Km values for 11S with various NLPep in affinity buffer Purified NLpoly11S was diluted to 40 pM in PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol (affinity buffer) or NanoGlo assay reagent (Promega Corporation). NLPep (NLpep 86, 78, 99, 101, 104, 128, and 114) was diluted to 400 μM (NLPep to 1 mM) in affinity buffer or NanoGlo assay reagent. 300 μL NLpoly11S and 300 μL NLPep were mixed and incubated at ambient temperature for 30 minutes. 50 μL was then added to the wells of a white 96-well plate. 50 μl affinity buffer + 2xFz (12.5 μM, 7 x 2 dilutions) or 50 μl NanoGlo + 2xFz (100 μM, 7 x 2 dilutions) was added to each well and luminescence was measured using a Glomax Multi+ with 0.5 second integration. Km was determined using GraphPad Prism, Michaelis Menten.
[0263] The results demonstrate substrate binding to complexes between NLpoly11S and various NLPeps in affinity buffer (Figure 155) or NanoGlo assay buffer (Figure 156). The determined Km values do not vary significantly for the NLPeps shown.
[0264] Example 113 NLPep1 binding affinity to NLpoly11S at different concentrations of furimazine Purified NLpoly156 and NLpoly11S were brought to 40 pM in affinity buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol). Synthetic NLPep1 (WT) was diluted in affinity buffer to 560 μM for NLpoly156 or 80 μM for NLpoly11S, followed by 3-fold serial dilutions to create eight concentrations. 350 μL NLPep1 and 350 μL NLPoly156 or 11S were mixed and then incubated at ambient temperature for 30 minutes. 50 μL was then aliquoted into wells of a white 96-well assay plate. Fz was added to affinity buffer to give concentrations of 40, 20, 10, 5, 2.5, and 1.25 μM, and 50 μL Fz / affinity buffer was added to each well and incubated at ambient temperature for 2 minutes. Luminescence was measured with a Glomax Multi+ using 0.5 second integration. Kd at each concentration of Fz was calculated using GraphPad Prism and one-site specific binding.
[0265] The results (Figure 157) show the change in affinity (NLPoly / NLPep) as the concentration of Fz increases.
[0266] Example 114 Furimazine Km values for NLpoly156 / NLPep1 and NLpoly11S / NLPep1 at different concentrations of NLPep1 Purified NLpoly156 and NLpoly11S were diluted to 40 pM in affinity buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol). Synthetic NLPep1 (WT) was diluted in affinity buffer to 560 μM for NLpoly156 or 80 μM for NLpoly11S, followed by 3-fold serial dilutions to create eight concentrations. 50 μL was then aliquoted into wells of a white 96-well assay plate. Fz was added to affinity buffer to yield concentrations of 40, 20, 10, 5, 2.5, and 1.25 μM, and 50 μL Fz / affinity buffer was added to each well and incubated for 2 minutes at ambient temperature. Luminescence was measured using a Glomax Multi+ with a 0.5-second integration. Kd values at each concentration of NLPep1 were calculated using GraphPad Prism and one-site specific binding.
[0267] The results (Figure 158) show the change in affinity (NLPoly / NLPep) as the concentration of NLPep1 increases.
[0268] Example 115 Comparison of maximum activity for NLPoly156 / NLPep1, NLPoly11S / NLPep1, and NanoLuc® luciferase Purified NLPoly156, NLPoly11S, or NanoLuc® luciferase (Nluc) was diluted to 40 pM in affinity buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol). Synthetic NLPep1 (WT) was diluted in affinity buffer to 560 μM for NLPoly156 or 80 μM for NLPoly11S, followed by 3-fold serial dilutions to create eight concentrations. 350 μL NLPep1 (or affinity buffer) and 350 μL NLPoly (or Nluc) were mixed and then incubated at ambient temperature for 30 minutes. 50 μL was then aliquoted into wells of a white 96-well assay plate. Fz was added to affinity buffer to concentrations of 40, 20, 10, 5, 2.5, and 1.25 μM, and 50 μL Fz / affinity buffer was added to each well and incubated for 2 minutes at ambient temperature. Luminescence was measured using a Glomax Multi+ with a 0.5-second integration. Using GraphPad Prism and the Michaelis-Menton equation, Vmax was calculated for each concentration of NLPep (Vmax values calculated for each concentration of NLPep1 were input into the one-site specific binding equation to calculate Bmax). Using GraphPad Prism and the one-site specific binding equation, Bmax was calculated for each concentration of Fz (Bmax values calculated for each concentration of Fz were input into the Michaelis-Menton equation to calculate Vmax).
[0269] The results (Figure 159) demonstrate the maximal activity of NLPoly156 or NLPoly11S versus NanoLuc luciferase when activated by NLPep1.
[0270] Example 116 Luminescence values resulting from titration of NLpoly11S with various NLPep Purified NLPoly11S was diluted to 40 pM in PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol (affinity buffer). Synthetic NLPep (NLPep86, 78, 79, 99, 101, 104, 114, 128, or wild-type) was diluted in affinity buffer as follows: NLPep86 = 60 nM, NLPep78 = 280 nM, NLPep79 = 800 nM, NLPep99 = 4 μM, NLPep101 = 34 μM, NLPep104 = 20 μM, NLPep128 = 4 μM, NLPep114 = 4.48 mM, and NLPepWT = 20 μM. 25 μL of NLPoly11S and 25 μL of one NLPep were mixed and then incubated at ambient temperature for 30 min. 50 μl affinity buffer + 20 μM Fz was then added to each mixture and luminescence was measured using a 0.5 second integration on a GlomaxMulti+. Bmax and Kd values were determined using GraphPad Prism and one-site specific binding.
[0271] The results (Figure 160) demonstrate an approximately 100,000-fold range of affinities using NLPoly11S and various NLPeps. Minimal loss of Bmax was observed between high and low affinity NLPeps.
[0272] Example 117 Western blot of NLPoly156, NLPoly11S, and NanoLuc® luciferase after transfection into HEK293T cells On day 1, a transfection mixture was made with 2 ng NLPoly156, NLPoly11S, or NanoLuc® luciferase (Nluc) DNA, 1 ug pGEM3Zf(+) carrier DNA, 4 ul Fugene HD (Promega Corporation), and phenol red-free OptiMEM (up to 100 ul) and incubated at room temperature for 10 minutes. The transfection mixture was then transferred to one well of a 6-well plate, and 2 ml of HEK293T cells were added at 400,000 cells / ml (800,000 cells total). The cells were incubated overnight at 37°C.
[0273] On day 2, cells were washed with phenol red-free DMEM, 500 μL of phenol red-free DMEM was added to each well, and the cells were frozen at -70°C for at least 30 minutes. The cells were then thawed, 500 μL transferred to a microfuge tube, and 20 μL mixed with 80 μL of 1.25x SDS loading buffer and incubated at 95°C for 5 minutes. 10 μL was loaded onto a 10% Bis-Tris NuPAGE gel with MES running buffer. Proteins were transferred to PVDF using iBlot, and the membrane was washed in methanol. The membrane was then blocked in TBST + 5% BSA at ambient temperature for 1 hour, washed three times in TBST, and then incubated overnight at 4°C with 10 mL TBST + 2 μL rabbit anti-Nluc polyclonal antibody + 2 μL rabbit anti-β-actin polyclonal antibody (Abcam #ab8227).
[0274] On day 3, the membrane was washed three times in TBST, incubated with 10 mL TBST + 2 μL anti-rabbit HRP-conjugated antibody for 1 h at ambient temperature, washed three times again with TBST, and incubated with 12 mL ECL Western blotting substrate for 1 min. Chemiluminescence was imaged on a LAS 4000 Image Quant.
[0275] The results (Figure 161) show the expression levels of NLPoly compared to full-length NanoLuc® luciferase. NLPoly156 is not as expressed as NanoLuc® luciferase (Nluc), while NLPoly11S is expressed similarly to Nluc.
[0276] Example 118 Determining the effect of NLPoly11S / NLPep114 affinity on the interaction between .BETA.-lactamase (SME) and .BETA.-lactamase inhibitory protein (BLIP) and comparing affinity values measured through 11S / 114 and .BETA.-lactamase activity Protein purification pF1K-signal-6H-SME, pF1K-signal-6H-SME-11S, pF1K-signal-6H-BLIPY50A, and pF1K-signal-6H-BLIPy50A-114 (Promega Flexi vectors for T7 promoter-based expression of recombinant proteins in E. coli; signal refers to the native signal peptide for either SME or BLIP) were expressed in the periplasm of KRX cells induced with rhamnose for 18–20 h at 25°C. Cells were pelleted, resuspended in B-Per lysis reagent (Pierce, 1 / 50 culture volume), and incubated at ambient temperature for 15 min. The lysate was then diluted by adding 1.5 volumes of 20 mM Tris pH 8 + 500 mM NaCl and centrifuged at 12,000 × g for 10 min. The supernatant was transferred to a clean tube, 1 mL RQ1 DNase (Promega Corporation) was added, and the mixture was centrifuged again at 12,000 × g for 10 minutes. The supernatant was purified on a HisTALON column (Clontech) with 25 mM Tris pH 8 and 500 mM NaCl loading buffer and eluted with 25 mM Tris pH 8, 500 mM NaCl, and 50 mM imidazole. The eluted protein was dialyzed into 25 mM Tris pH 7.5 and 25 mM NaCl and purified on a HiTrap Q FF column (GE Healthcare) with 25 mM Tris pH 7.5 and 25 mM NaCl loading buffer and eluted with 25 mM Tris pH 7.5 and 125 mM NaCl. The ionic strength was adjusted to a final concentration of 150 mM NaCl and concentrated using a VivaSpin concentrator.
[0277] Assay BLIPY50A and BLIPY50A-114 were diluted to 312.5 nM in affinity buffer (PBS pH 7, 0.01% Prionex, 0.005% Tergitol, 1 mM DTT) and then serially diluted 1.5-fold. SME and SME-11S were diluted to 0.2 nM in affinity buffer. 11.11 μL SME and 88.89 μL BLIP were mixed and then incubated at ambient temperature for 2 hours. 90 μL of the mixture was transferred to a clear 96-well plate containing 10 μL of 100 μM nitrocefin (Calbiochem, in affinity buffer). 90 μL of SME-11S / BLIPY50A-114 was transferred to a white 96-well plate containing 10 μL of 100 μM Fz (in affinity buffer). Absorbance (nitrocefin) was measured at 486 nm every 15 seconds for 30 minutes, and emission (Fz) was measured every 2 minutes for 30 minutes.
[0278] For nitrocefin, initial rates were fitted using Excel. Initial rates versus BLIP concentration were plotted. Ki was fitted using E_Free=[E]-(E_0]+[I_0]+K_app-√(([E_0]+[I_0]+K_app)^2-(4[E_0][I_0]))) / 2 and K_app=K_i(1+([S]) / K_M). For Fz, Kd was fitted using RLU=(Bmax×[BLIP-114]) / ([BLIP-114]+K_D).
[0279] The results (Figure 162) compare the affinity of the protein interaction (β-lactamase SME and its inhibitor BLIPY50A) as unfused proteins with the affinity when NLPoly and NLPep are fused to them, and demonstrate that the affinity between NLPoly11S and NLPep114 does not result in an increased apparent affinity for the SME / BLIPY50A interaction. This also demonstrates the use of NLPoly11S and NLPep114 to measure equilibrium binding constants for protein interactions, and that the affinity measured through NLPoly11S and NLPep114 is consistent with the affinity measured by the activity of the target protein (SME).
[0280] Example 119 Comparison of luminescence generated by cells expressing different combinations of FRB-NLPoly11S and FKBP-NLPep101 and 111–136 HEK293T cells (20,000) were reverse transfected with a total of 1 ng pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep101 or 111-136 plasmid DNA into wells of an opaque 96-well assay plate using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to bring the total DNA in each transfection to 1 μg. 24 h post-transfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration) with or without 50 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then read using a GloMax Multi with a 0.5 s integration time.
[0281] Figure 163 demonstrates that of the combinations tested, NLpoly11S with NLpep114 exhibits the greatest rapamycin induction and one of the strongest rapamycin-specific luminescence signals.
[0282] Example 120 Comparison of luminescence generated by cells expressing different combinations of FRB-NLpoly11S and FKBP-NLpep114 and 137–143 HEK293T cells (20,000) were reverse transfected with a total of 1 ng pF4A AgFRB-NLpoly11S and pF4A AgFKBP-NLpep114 or 137-143 plasmid DNA in wells of an opaque 96-well assay plate using FuGENE HD at a DNA-to-FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to bring the total DNA in each transfection to 1 μg. 24 h post-transfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI with or without 50 nM rapamycin. 10 μM furimazine substrate (final concentration) with or without 50 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then read using a GloMax Multi with a 0.5 s integration time.
[0283] Figure 164 demonstrates that of the combinations tested, NLpoly11S with NLpep114 exhibits the greatest rapamycin induction and one of the strongest rapamycin-specific luminescence signals.
[0284] Example 121 Rapamycin dose-response curves for cells expressing FRB-NLpoly11S and FKBP-NLpep78 / 79 / 99 / 101 / 104 / 114 / 128 HEK293T cells (20,000) were reverse transfected with a total of 0.1 ng pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep78 / 79 / 99 / 101 / 104 / 128 plasmid DNA in wells of an opaque 96-well assay plate using FuGENE HD at a DNA to FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to bring the total DNA to 1 μg in each transfection. 24 h post-transfection, cells were washed with PBS and then incubated for 1.5 h in phenol red-free OptiMEMI containing 0-300 nM rapamycin. 10 μM furimazine substrate (final concentration) containing 0-300 nM rapamycin in OptiMEMI was added directly to each well and incubated for 5 min at room temperature. Luminescence was then read using a GloMax Multi with a 0.5 s integration time. Data were fitted to a sigmoidal curve using Graphpad Prism and EC50 values calculated.
[0285] Figure 165 shows the sigmoidal dose response to rapamycin for NLpoly11S with NLpep78 / 79 / 99 / 101 / 104 / 114 / 128. Of the combinations plotted, NLpoly11S with NLpep114 shows the largest dynamic range.
[0286] Example 122 Response of cells expressing FRB-NLpoly11S and FKBP-78 / 79 / 99 / 101 / 104 / 114 / 128 to the rapamycin-competitive inhibitor FK506 HEK293T cells (20,000) were reverse transfected with a total of 0.1 ng of pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep78 / 79 / 99 / 101 / 104 / 114 / 128 plasmid DNA in wells of an opaque 96-well assay plate using FuGENE HD at a DNA to FuGENE ratio of 1:8. pGEM-3Zf(+) DNA was added to bring the total DNA to 1 μg per transfection. 24 h post-transfection, cells were washed with PBS and then phenol red-free OptiMEM containing 10 nM rapamycin was added for 2 h. FK506 inhibitor in OptiMEM was added to cells at final concentrations of 0–50 μM and incubated for 3 h. Furimazine in OptiMEM was added to cells to a final concentration of 10 μM on cells. Luminescence was read immediately on a GloMax Multi using a 0.5 second integration time. Data were fitted to a sigmoidal curve using Graphpad Prism and IC50 values were calculated.
[0287] Figure 166 demonstrates dose-dependent reduction of rapamycin-induced signaling of FRB-NLpoly11S and FKBP-78 / 79 / 99 / 101 / 104 / 114 / 128 by the rapamycin-competitive inhibitor FK506.
[0288] Example 123 Comparison of luminescence generated by cells transfected with FRB-NLpoly11S and FKBP-NLpep114 at different ratios HEK293T cells (20,000) were reverse transfected with 1 ng pF4A Ag FKBP-NLpep114 plasmid DNA and 0.01, 0.1, 1, 10, or 100 ng pF4A Ag FKBP-NLpep114 plasmid DNA in wells of an opaque 96-well assay plate using FuGENE HD at a DNA to FuGENE ratio of 1:8. HEK293T cells (20,000) were also reverse transfected with 1 ng pF4A Ag FKBP-NLpep114 and 0.01, 0.1, 1, 10, or 100 ng pF4A Ag FRB-NLpoly11S. In both cases, pGEM-3Zf(+) DNA was added to bring the total DNA in each transfection to 1 μg. Twenty-four hours after transfection, cells were washed with PBS and then incubated in phenol red-free OptiMEMI with or without 50 nM rapamycin for 1.5 hours. 10 μM furimazine substrate (final concentration) in OptiMEMI with or without 50 nM rapamycin was added directly to each well and incubated for 5 minutes at room temperature. Luminescence was then read on a GloMax Multi using a 0.5 second integration time.
[0289] Figure 167 demonstrates that although a 1:1 DNA ratio produced the greatest rapamycin induction, significant induction was observed at all DNA ratios tested.
[0290] Example 124 Comparison of luminescence generated by cells expressing NLpoly11S / NLpep114 fusions of FRB / FKBP in different orientations and with different linker lengths. HEK293T cells (20,000) were transfected into wells of a 96-well plate with vectors expressing combinations of N- and C-terminal fusions of pF4Ag NLpoly11S and pF4Ag NLpep114 with FRB or FKBP. In these constructs, NLpoly11S / NLpep114 was separated from their fusion partners by either a 4, 10, or 15 serine / glycine linker. 0.1 ng of NLpoly11S and NLpep114 DNA was transfected at a DNA to FugeneHD ratio of 1:8 per well. 24 hours after transfection, cells were washed with PBS and then incubated for 2 hours in phenol red-free OptiMEMI with or without 50 nM rapamycin in OptiMEMI. 10 μM furimazine substrate was then added, followed by a 5 minute incubation at room temperature and the plate was read using a GloMax Multi with a 0.5 second integration time.
[0291] Figure 168 illustrates the rapamycin-specific increase in RLU regardless of fusion orientation or linker length.
[0292] Example 125 Comparison of rapamycin dose-response curves and time courses generated by FRB-NLpoly11S / FKBP-NLpep114 and split firefly complementation systems HEK293T cells (800,000) were transfected into wells of a 6-well assay plate with a total of 20 ng pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep114 or 750 ng pF4A Ag N-Fluc(1-398)-FRB and FKBP-C-Fluc(394-544) using FuGENE HD at a DNA to FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to bring the total DNA in each transfection to 1 μg. 24 hours after transfection, 20,000 cells were replated into wells of an opaque 96-well assay plate and incubated for an additional 24 hours.
[0293] For dose-response experiments (Figure 169A), NLpoly11S / NLpep114-expressing cells were treated with 0-1 μM rapamycin in phenol red-free OptiMEMI for 3 hours, followed by a 5-minute incubation with 10 μM furimazine before luminescence recording with a GloMax Multi. Cells expressing N-Fluc(1-398) / C-Fluc(394-544) were incubated with 0-1 μM rapamycin in phenol red-free OptiMEMI for 2 hours, followed by an additional 1-hour incubation in the presence of 4 mM D-luciferin before luminescence recording with a GloMax Multi.
[0294] For time course experiments (Figure 169B), NLpoly11S / NLpep114-expressing cells were treated with 0 or 50 nM rapamycin in phenol red-free OptiMEMI added via a GloMax Multi injector, and luminescence was immediately measured. Cells expressing N-Flu(1-398) / C-Flu(394-544) were treated with 4 mM D-luciferin in phenol red-free OptiMEMI for 1 hour, followed by injection of 0 or 50 nM rapamycin via the injector and measurement of luminescence with GloMax Multi. Curves were fitted using GraphPad Prism 6 software. Figures 169A-B demonstrate that both the NLpoly11S / NLpep114 and split firefly complementation systems respond in a rapamycin-dependent manner, generating sigmoidal dose-response curves and similar EC50 values. The NLpoly11S / NLpep114 system exhibits faster association kinetics and a higher maximal signal.
[0295] Example 126 Comparison of dose-response curves and time courses of FK506 produced by FRB-NLpoly11S / FKBP-NLpep114 and split firefly complementation systems HEK293T cells (800,000) were transfected into wells of a 6-well assay plate with a total of 20 ng pF4A Ag FRB-NLpoly11S and pF4A Ag FKBP-NLpep114 or 750 ng pF4A Ag N-Fluc(1-398)-FRB and FKBP-C-Fluc(394-544) using FuGENE HD at a DNA to FuGENE ratio of 1:4. pGEM-3Zf(+) DNA was added to bring the total DNA in each transfection to 1 μg. 24 hours after transfection, 20,000 cells were replated into wells of an opaque 96-well assay plate and incubated for an additional 24 hours. Cells were then treated with 0 or 20 nM rapamycin in phenol red-free OptiMEMI for 3 hours.
[0296] For the FK506 dose-response experiment (Figure 170A), cells were incubated with 0-100 μM FK506 inhibitor in phenol red-free OptiMEMI for 5 hours, treated with 10 μM furimazine, and then read in luminescence mode with a 0.5 second integration time on the GloMax Multi. For the time course experiment (Figure 170B), cells were treated with 10 μM FK506 in phenol red-free OptiMEMI containing 10 μM furimazine, and luminescence was read immediately on the GloMax Multi.
[0297] Figures 170A-B demonstrate that the NLpoly11S / NLpep114 and split firefly complementation systems exhibit a dose-dependent decrease in light output after treatment with the FK506 inhibitor. The loss of signal in the NLpoly11S / NLpep114 system begins at an earlier time point, is more rapid, and is more complete than in the split firefly system.
[0298] Example 127 Western blot showing the expression levels of FKBP-NLpep114 and FKBP-Fluc(394-544) HEK293T cells (200,000) were transfected with 0–30 ng of pF4Ag NLpep114-FKBP or pF4Ag FKBP-Fluc(394-544) DNA using Fugene HD at a DNA to Fugene ratio of 1:8. Forty-eight hours after transfection, cells were harvested with 1X SDS gel loading buffer. Samples were resolved on a 4–10% Tris-HCl SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blocked for 1 hour in 5% BSA in TBST and then incubated overnight with anti-FKBP (Abcam #ab2918). Secondary antibody incubation with horseradish peroxidase-conjugated donkey anti-rabbit IgG was performed for 1 hour, and then the blot was developed using ECL Western blotting substrate (Promega Corporation) and an Image Quant LAS 4000 system.
[0299] Figure 171 demonstrates similar expression levels of FKBP-NLpep114 and FKBP-Fluc(394-544) at equivalent levels of transfected DNA.
[0300] Example 128 Dose- and time-specific inhibition of NLpoly11S-BRD4 and histone H3.3-NLpep114 interactions by IBET-151 HEK293T cells (20,000) were transfected with 10 ng of pF4Ag histone H3.3-NLpep114 and NLpoly11S-NLpoly11S in wells of a 96-well white assay plate using Fugene HD at a DNA to Fugene ratio of 1:8.
[0301] For dose-response experiments (Figure 172A), cells were treated with 0-10 μM IBET-151 in phenol red-free OptiMEMI for 4 hours at 37°C, followed by treatment with 10 μM furimazine for 5 minutes before reading luminescence on a GloMax Multi.
[0302] For time course experiments (Figure 172B), cells were pre-incubated with 10 μM furimazine for 5 minutes, treated with 0-500 nM IBET-151, and immediately placed in GloMax Multi for luminescence measurements every 5 minutes.
[0303] Figures 172A-B demonstrate that upon treatment with the BRD4 inhibitor IBET-151, a dose-dependent decrease in luminescence occurs within 3 hours of treatment, consistent with literature reports.
[0304] Example 129 RAS / CRAF, BRAF / BRAF, and CRAF / BRAF dimerization in response to GDC0879 HEK293T cells (20,000) were co-transfected with pF4Ag NLpoly11S-BRAF, NLpoly11S-CRAF, NLpep114-KRAS, or NLpep114-BRAF in combination with 0.1 ng of DNA per well and Fugene HD at a 1:4 ratio in a 96-well assay plate. 24 hours after transfection, cells were treated with 0-10 μM of the BRAF inhibitor GDC0879 in phenol red-free OptiMEMI for 4 hours. Furimazine substrate in phenol red-free OptiMEMI was added to 10 μM, and luminescence was immediately read on a GloMax Multi with a 0.5 second integration time.
[0305] Figure 173 demonstrates a dose-dependent increase in RAS / CRAF, BRAF / BRAF, and CRAF / BRAF dimerization in response to the BRAF inhibitor GDC0879.
[0306] Example 130 Twelve synthetic peptides (Figure 180) were tested for their ability to structurally complement three different versions of NLpoly11S (i.e., 11S, 11S-amino acid 157, 11S-amino acid 156 and 157). Stock solutions of NLpoly were made up to 35 nM in NanoGlo reagent, and stock solutions of NLpep were made up to 12.5 nM in PBS pH 7.2. Equal volumes were mixed, and samples were measured for luminescence on a Tecan Infinite F500 reader (100 ms integration time; 10 min time point) (Figure 200).
[0307] Example 131 Spontaneously interacting peptide NLpep86 Purified NLPoly11S was diluted to 40 pM in PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol (affinity buffer). Synthetic NLPep (NLPep86, WT, 114) was diluted in affinity buffer as follows: NLPep86 = 60 nM, NLPep114 = 4.48 mM, and NLPepWT = 20 μM. 25 μL NLPoly11S and 25 μL NLPep were mixed and then incubated at ambient temperature for 30 min. 50 μL affinity buffer + 20 μM Fz was then added to each mixture, and luminescence was measured using a GlomaxMulti+ with a 0.5-second integration. Bmax and Kd values were determined using GraphPad Prism and one-site specific binding.
[0308] Figure 174 demonstrates a 100,000-fold range of affinities using NLPoly11S and various NLPeps. Pep86 is an example of a spontaneously interacting peptide (with LSP11S), while Pep114 is shown as a low-affinity interacting peptide for reference.
[0309] Example 132 In vitro titration of high affinity peptides Purified NLpoly11S (HaloTag purified / E. coli expressed, pFN18K) and synthetic peptide NLpep86 (derived from peptide 2.0) were titrated in the linear dynamic range from 3.3 fM to 100 nM high-affinity NLpep86 using 33 nM NLpoly11S in Nano-Glo® assay buffer. For a 30 kDa protein, this corresponds to an LOD of 10 fg.
[0310] Figure 176 demonstrates the broad linear range and ability to detect high affinity peptide tags (NLpep86) at femtomolar concentrations, which is comparable to the most sensitive Western blot (WB) plus enhanced chemiluminescence (ECL) kits.
[0311] Example 133 Western blot-like utility of NLpoly and NLpep Titration of HaloTag(HT7)-NLpep 80(80) or NLpep80-HaloTag(HT7) was performed on an SDS page gel. HaloTag® protein was imaged using a Typhoon scanner with HaloTag-TMR ligand (Promega Corporation). Samples were transferred to membranes and blotted onto the membrane using PBS pH 7 + 0.1% Prionex + NLpoly11S (1:1,000 diluted E. coli lysate). NanoGlo / Fz was then added to the membrane, which was then imaged using an Image Quant.
[0312] Figure 177 demonstrates the sensitivity of using NLpoly11S to detect proteins tagged with high affinity NLPep. Figure 177 also compares detection using NLPep / NLPoly with detection using fluorescently labeled HaloTag.
[0313] Example 134 Stability of NLpoly11S reagent 100 nM NLpoly11S was incubated in NanoGlo assay buffer (Promega Corporation) + 100 μM furimazine and assayed with an equal volume of diluted NLpep 86. As a control, an equal volume of diluted NanoLuc® luciferase (Promega Corporation) was assayed using NanoGlo assay buffer + 100 μM furimazine.
[0314] The results (Figure 178) demonstrate that the NLpoly11S reagent (containing Fz) has similar stability compared to the commercial NanoGlo® assay reagent (also containing Fz).
[0315] Example 135 Titration of DNA for high affinity NLpep78-HT7 fusion HEK293 cells (200,000 / ml) were reverse transfected with 10-fold dilutions of DNA (starting at 100 ng) from the high-affinity peptide NLpep78 fused to the HaloTag® protein (HT7). 100 μl of each transfection was plated in triplicate into wells of a 96-well plate. 24 hours after transfection, 100 μl NanoGlo® Assay Buffer containing 100 nM NLpoly11S and 100 μl furimazine was added and mixed. Luminescence was measured 10 minutes after reagent addition using a GloMax luminometer.
[0316] The results (Figure 179) demonstrate a broad linear range similar to that of Example 131 / Figure 27. This is essentially a similar experiment to that performed in Example 131, except that this example uses peptides (fused to HaloTag) recombinantly expressed in mammalian cells.
[0317] Example 136 Preliminary results (array peptides) In Figure 183A, 50 nM NLpoly11S was mixed with 7.5 μM NLpep114 and 37.5 μM dark peptide (DP) candidate (Q-162, A-162, K-162, or E-162). NanoGlo® Assay Reagent (Promega Corporation) was added and incubated for 5 minutes. Luminescence was detected. In Figure 183B, 50 nM NLpoly11S in assay buffer (PBS pH 7 + 0.01% Prionex + 1 mM DTT + 0.005% Tergitol) was mixed with 7.5 μM NLpep114 (also in assay buffer) and varying amounts of dark peptide (DP) candidate Q-162 or K-162 (also in assay buffer). NanoGlo® Assay Reagent (Promega Corporation) was added and incubated for 5 minutes. Luminescence was detected with a Tecan Infinite F500 reader using a 100 ms integration time and a 5 minute time point.
[0318] Panel A shows that each of the peptide candidates (at 7.5 μM) can inhibit binding between NLpoly11S and NLpep114, as indicated by less bioluminescence. Note that these "dark" peptides do generate some luminescence, thus increasing the signal compared to no peptide at all.
[0319] Panel B shows that for the Lys-162 and Gln-162 peptides, inhibition is dose-dependent.
[0320] Example 137 High purity (>95%) dark peptides In Figure 184A, 5 nM NLpoly11S was mixed with 500 nM NLpep114 and varying amounts of the dark peptide (DP) candidates Q-162 or A-162 (n=3). NanoGlo® Assay Reagent (Promega Corporation) was added and incubated for 5 minutes. Luminescence was detected.
[0321] In Figure 184B, 5 nM NLpoly11S in assay buffer was mixed with varying amounts of dark peptide (DP) candidate Q-162 or A-162 (without NLpep114) (n=3) in assay buffer. NanoGlo® Assay Reagent (Promega Corporation) was added and incubated for 5 minutes. Luminescence was detected.
[0322] The results (Figures 184A and B) confirm those from Example 135, but are more reliable here because the peptide is purer. These results also suggest that the Ala peptide is the most potent inhibitor of the dark peptide variants tested.
[0323] Example 138 Inhibition of circularly permuted NanoLuc® luciferase by dark peptides To determine whether the "high affinity / low activity" NLpep (also known as the dark peptide) can compete with the intramolecular interactions (i.e., protein folding) between NanoLuc® luciferase (Nluc) residues 1-156 and 157-169 in the context of circularly permuted Nluc (CP Nluc). JPEG2024167207000058.jpg30167
[0324] Recombinant CP-Nluc was prepared as a soluble fraction of a 5x concentrated E. coli lysate (T7 promoter, overnight expression). A 10,000-fold dilution of CP-Nluc in assay buffer (PBS pH 7 / 0.01% Prionex / 1 mM DTT / 0.005% Tergitol) was used. Synthetically derived dark peptides were prepared over a range of concentrations, also in assay buffer. Reactions were set up using 30 μL of CP-Nluc and 60 μL of dark peptide and assayed by adding 90 μL of NanoGlo® Assay Reagent (Promega Corporation). Luminescence was measured (5 min) using a Tecan Infinite F500 reader (100 ms integration). Three replicates were used for the dark peptide samples. Two replicates were used for the buffer control (acetic acid from peptide stock solution).
[0325] Figure 185 demonstrates the dose-response of dark peptide with CP Nluc. Figure 186 demonstrates the time course of dark peptide (56 μM peptide) with CP Nluc.
[0326] The results show that both dark peptides, especially the Ala162 version, can significantly inhibit the generation of luminescence by CP Nluc (Ala162>2 log, Gln162>1 log), demonstrating the utility of the CP Nluc approach over reverse complementation.
[0327] Example 139 Intracellular dark peptides In this example, the following constructs were used: - 4 dark peptide vectors: pF4Ag+FKBP-dark peptides Ala-162, Leu-162, Gln-162 and Val-162 - Two non-dark peptide vectors: pFc5K2 FKBP-NLpep114 (low affinity peptide) and pFc5K2 FKBP-NLpep80 (high affinity peptide) -One NLpoly vector: pFc5K2 FRB-NLpoly11S All constructs included a CMV promoter for mammalian cell expression. All fusion constructs contained a 10 aa Gly-Ser flexible linker.
[0328] Serial dilutions of the dark peptide constructs Ala-162 (A), Leu-162 (L), Gln-162 (Q), and Val-162 (V) were made in OptiMem and also contained carrier DNA (pGEM-3Z).
[0329] For transfections containing only NLpoly11S, 20 μl of diluted dark peptide was mixed with 20 μl NLpoly11S, 60 μl OptiMem, and 8 μl Fugene. For transfections containing NLpoly11S and NLpep114 or NLpep80, 20 μl of diluted dark peptide was mixed with 20 μl NLpoly11S (10 ng / μl), 20 μl NLpep114 or NLpep80 (10 ng / μl), 40 μl OptiMem, and 8 μl Fugene. All were incubated at room temperature for 15 minutes. Five μl of each transfection in triplicate was added to wells of two 96-well plates (one with rapamycin and one without). 100 μl of HEK293T at 200,000 cells / ml in DMEM+10% FBS was then added to the wells and the transfected cells were incubated overnight at 37°C.
[0330] The medium was then removed from the cells and the cells were washed with 200 μl DPBS. 50 μl of 50 nM rapamycin was added and the cells were incubated at 37° C. for 1 hour. 20 μl of 5 mM furimazine was diluted in 5 ml phenol red-free OptiMEMI + 50 nM rapamycin and 50 μl was added directly to the cells and incubated for 5 minutes in GloMax Multi+. Luminescence was measured by GloMax.
[0331] Figure 187 demonstrates that the dark peptide, when fused to FKBP, can reduce the background signal of NLpoly11S (i.e., FRB-NLpoly11S). Collectively, Figures 188-190 demonstrate that the dark peptide, when fused to FKBP, 1) competes with the folding of full-length NanoLuc (i.e., FRB-NanoLuc or NanoLuc-FRB) and 2) competes with both low-affinity and high-affinity peptides (also FKBP fusions) for binding to NLpoly11S (i.e., FRB-NLpoly11S), resulting in a reduction in the total luminescence generated and detected in live cells.
[0332] Example 140 Virology Applications In addition to enabling the measurement of viral titers, spontaneously interacting NLpep also allows for the study of viral (e.g., influenza) reassortment, which refers to the formation of new "hybrid" viruses from dual infections, e.g., H1N1, H5N1, and H3N2 (H is hemagglutinin and N is neuraminidase) in birds, humans, pigs, and chickens (most commonly in pigs).
[0333] Due to its segmented nature, the influenza genome can be easily shuffled within host cells infected with more than one virus. When cells are infected with influenza viruses from different species, reassortment can result in progeny viruses containing genes from strains that normally infect birds and genes from strains that normally infect humans, leading to the creation of new strains not previously seen in most hosts. Furthermore, at least 16 different subtypes and nine different neuraminidase subtypes have been characterized, allowing for many different combinations of capsid proteins. Of these subtypes, three hemagglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes (N1 and N2) have caused persistent epidemics in human populations. Birds are the host for all influenza A subtypes and the original reservoir from which new HA subtypes are introduced into humans (Palese, 2004).
[0334] An application of this system to detect reassortment is that the two spontaneously interacting components of NLpep are put into different virus particles, or the large component in the cell and the small component in the virus, and the presence of both components (e.g., present in the cell) is detected by luminescence.
[0335] Example 141 Validation of the use of spontaneously interacting NLpep86 as an epitope tag for proteins degraded by the proteasome During development of embodiments of the present invention, experiments were performed to validate the use of NLpep86 as a tag to monitor the expression levels of proteins degraded by the proteasome. To do this, NLpep86 was fused to firefly luciferase mutants that were similarly fused to one or more of either the PEST, CL1, or ubiquitin sequences (pBC21, 22, 24-29). Each of these constructs is expected to undergo varying degrees of proteasome-mediated turnover following expression from a mutant CMV promoter (d1CMV).
[0336] Constructs pBC21, 22, 24-29, expressing untagged firefly luciferase or untagged firefly luciferase fused to a PEST sequence, and control constructs (ATG082 and ATG083) were transiently transfected into HELA cells plated at 10,000 cells per well in 96-well plates using 100 μL of DMEM + 10% FBS. The following day, 10 μL of transfection mixture (920 μL OptiMEM I + 5 μg of each construct + 15 μL Fugene HD) was added to each well, and the cells were incubated at 37°C for 48 hours in an incubator containing 5% CO2. Protein expression levels were quantified in replicate wells for each construct by detecting firefly luciferase activity or by adding a detection reagent containing NLpoly11S (purified NLpoly11S added to NanoGlo®). In each case, good correlation was observed between the NLpep86 and Fluc signals, suggesting that NLpep86 detection can be used to monitor fusion protein expression levels of proteins that are degraded by the proteasome. BC21 MVSGWRLFKKIS-GGSGGGGSGG-Fluc (high affinity) BC22 MVSGWRLFKKIS-GGSGGGGSGG-FlucP (high affinity) BC24 pFC15A / MVSGWRLFKKIS-GGSGGGGSGG-Fluc-CL1 BC25 MVSGWRLFKKIS-GGSGGGGSGG-Fluc-PEST12opt (high affinity) BC26 MVSGWRLFKKIS-GGSGGGGSGG-Fluc-CP (high affinity) BC27 UBQ G76V-VGKLGRQDP-Fluc(EDAKNIKK..)-GGSGGGGSGG-VSGWRLFKKIS(High affinity) BC28 UBQ-RGKLGRQDP-Fluc(EDAKNIKK..)-GGSGGGGSGG-VSGWRLFKKIS(high affinity) BC29 UBQ-LGKLGRQDP-Fluc(EDAKNIKK..)-GGSGGGGSGG-VSGWRLFKKIS(high affinity) ATG083 D1 FlucP, pF4Ag CMV Luc2-PEST ATG082 D1Fluc, pF4Ag CMV Luc2 After 48 hours of incubation, 100 μL NanoGlo® NLpep11S reagent (90 μl NLpoly11S in 50 ml NanoGlo® Assay Reagent) was added to each well and incubated for 3 minutes with shaking. Luminescence was then read on a GloMax luminometer (0.5 seconds / well).
[0337] The results in Figure 191 demonstrate that the signals from Fluc and NLpep86 appear to mirror each other in terms of relative brightness and have similar RLUs. BC21, BC25, and BC29 are the brightest constructs in the BC series and appeared to be the brightest in this experiment, while BC24, 26, and 27 were the least bright, as expected from the engineered destabilization.
[0338] Example 142 This example demonstrates that a known peptide can be used as a linker between the same or different complementary NLpep and NLpoly11S (e.g., NLpep78(2X)).
[0339] HEK293T cells (20,000) were transfected with a mixture containing 20 μL of NLpep78-HaloTag(HT) or NLpep78(2x)-HT DNA, 80 μL of phenol-free Opimex, and 8 μL of FugeneHD. Cells were grown overnight at 37°C and assayed at 24 hours using NanoGlo® Assay Reagent (Promega Corporation) containing 33 nM purified NLpoly11S.
[0340] The results (Figure 192) demonstrate that tandem binding peptides can be used and that they may be sufficient as linkers.
[0341] Example 143 Comparison of the specific activities of wild-type Oplophorus luciferase residues 1-156, NLpoly11S, and NanoLuc in HEK293T lysates Each clone was inserted into the pFN21A HaloTag® CMV Flexi® vector (Promega G2821), and lysates were prepared as follows: 3 ml of HEK293T cells diluted to a concentration of 200,000 cells / ml (600,000 cells total) were plated into each well of a 6-well plate and grown overnight at 37°C in a CO2 incubator. The next day, transfection complexes for each DNA were prepared by combining 6.6 μg of DNA...
Claims
1. A peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity with SEQ ID NO:2, characterized in that when the peptide is contacted with a polypeptide consisting of SEQ ID NO:440, in the presence of a substrate, a detectable bioluminescent signal is produced.
2. The peptide of claim 1, wherein when the peptide associates with the polypeptide consisting of SEQ ID NO:440, in the presence of a substrate, the detectable bioluminescent signal is produced.
3. 2. The peptide of claim 1, wherein the peptide exhibits enhanced one or more traits compared to the peptide of SEQ ID NO:2, the traits being selected from affinity for the polypeptide of SEQ ID NO:440, expression, intracellular solubility, intracellular stability, and bioluminescent activity when combined with the polypeptide of SEQ ID NO:
440.
4. 2. The peptide of claim 1, wherein the amino acid sequence is selected from the peptides in Table 1.
5. 2. The peptide of claim 1, wherein the amino acid sequence is synthetic, contains unnatural amino acids, or is a peptidomimetic.
6. A nucleic acid comprising a sequence encoding the peptide according to claim 1.
7. A fusion polypeptide comprising the peptide of claim 1 and a first interacting polypeptide, wherein the first interacting polypeptide is configured to form a complex with the second interacting polypeptide when the first interacting polypeptide and a second interacting polypeptide come into contact with each other.
8. A nucleic acid comprising a sequence encoding the fusion polypeptide according to claim 7.
9. (a) a fusion polypeptide according to claim 7; (b) a second fusion polypeptide; and wherein the second fusion polypeptide comprises: (i) the second interacting polypeptide; and (ii) a complementary polypeptide that emits a detectable bioluminescent signal in the presence of a substrate when associated with a peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:2; the first fusion polypeptide and the second fusion polypeptide are associated with each other, A bioluminescent complex, characterized in that a peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity with SEQ ID NO: 440 is associated with the complementary polypeptide.
10. A polypeptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:440, wherein when the polypeptide is contacted with a peptide consisting of SEQ ID NO:2, in the presence of a substrate, a detectable bioluminescent signal is produced.
11. 10. The polypeptide of claim 9, wherein the polypeptide exhibits enhanced one or more traits compared to the polypeptide of SEQ ID NO:440, the traits being selected from affinity for the peptide of SEQ ID NO:2, expression, intracellular solubility, intracellular stability, and bioluminescent activity when combined with the peptide of SEQ ID NO:
2.
12. 11. The polypeptide of claim 10, wherein the amino acid sequence is selected from one of the polypeptide sequences in Table 2.
13. The polypeptide of claim 10, wherein the detectable bioluminescent signal is generated in the presence of a substrate when the polypeptide associates with the peptide consisting of SEQ ID NO:
2.
14. 11. The polypeptide of claim 10, wherein the amino acid sequence is synthetic, contains unnatural amino acids, or is a peptidomimetic.
15. A nucleic acid comprising a sequence encoding the polypeptide according to claim 10.
16. A fusion polypeptide comprising the polypeptide of claim 10 and a first interacting polypeptide, wherein the first interacting polypeptide is configured to form a complex with the second interacting polypeptide when the first interacting polypeptide and a second interacting polypeptide are contacted.
17. (a) a fusion polypeptide according to claim 16; (b) a second fusion polypeptide; and wherein the second fusion polypeptide comprises: i) said second interacting polypeptide; and ii) a complementary peptide that, when associated with each other, causes a polypeptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity with SEQ ID NO:2 to emit a detectable bioluminescent signal in the presence of a substrate; the first fusion polypeptide and the second fusion polypeptide are associated with each other, A bioluminescent complex, characterized in that a polypeptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:440 is associated with said complementary polypeptide.
18. (a) a peptide comprising a peptide amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO:2; (b) a polypeptide comprising a polypeptide amino acid sequence having less than 100% and more than 40% sequence identity to SEQ ID NO: 440; A bioluminescent complex comprising the above-mentioned, wherein the bioluminescent complex exhibits detectable luminescence.
19. 20. The bioluminescent complex of claim 18, wherein the peptide amino acid sequence and the polypeptide amino acid sequence are associated.
20. 20. The bioluminescent conjugate of claim 18, wherein the peptide amino acid sequence is selected from the peptide sequences in Table 1.
21. 20. The bioluminescent complex of claim 18, wherein the polypeptide amino acid sequence is selected from the polypeptide sequences in Table 2.
22. 20. The bioluminescent complex of claim 19, wherein the peptide amino acid sequence is attached to a first interacting element that is in association with a second interacting element.
23. 23. The bioluminescent complex of claim 22, wherein the polypeptide amino acid sequence is attached to the second interacting element.
24. 24. The bioluminescent complex of claim 23, wherein the polypeptide amino acid sequence and the peptide amino acid sequence are incapable of associating in the absence of association of the first and second interacting elements.
25. (a) a first amino acid sequence that is not a fragment of an existing protein; (b) a second amino acid sequence that is not a fragment of an existing protein; and A bioluminescent complex comprising: The bioluminescent complex exhibits detectable luminescence, and the first amino acid sequence and the second amino acid sequence associate, and the bioluminescent complex, when the first amino acid sequence and the second amino acid sequence associate, emits a detectable bioluminescent signal in the presence of a substrate.
26. (c) a third amino acid sequence comprising a first member of an interacting pair, the third amino acid sequence being covalently linked to the first amino acid sequence; (d) a fourth amino acid sequence comprising a second member of an interacting pair, the fourth amino acid sequence being covalently linked to the second amino acid sequence; 26. The bioluminescent complex of claim 25, further comprising:
27. 27. The bioluminescent complex of claim 26, wherein the non-covalent interaction between the first amino acid sequence and the second amino acid sequence is not sufficient to cause the first amino acid sequence to associate with the second amino acid sequence in the absence of a non-covalent interaction between the first and second members of the interacting pair.
28. 27. The bioluminescent complex of claim 26, wherein the first polypeptide chain comprises the first amino acid sequence and the third amino acid sequence, and the second polypeptide chain comprises the second amino acid sequence and the fourth amino acid sequence.
29. 30. The bioluminescent complex of claim 28, wherein the first polypeptide chain and the second polypeptide chain are expressed intracellularly.
30. (a) a non-emissive pair; (b) an interaction pair; A bioluminescent complex comprising: each non-luminescent member of said non-luminescent pair is not a fragment of an existing protein, A bioluminescent complex, characterized in that each interacting member of said interacting pair is covalently bound to one of said non-luminescent members of said non-luminescent pair.
31. 1. A method for detecting a stable interaction between a first amino acid sequence and a second amino acid sequence, comprising: (a) attaching the first amino acid sequence to a third amino acid sequence and the second amino acid sequence to a fourth amino acid sequence, wherein the third and fourth amino acid sequences are not fragments of an existing protein, a stable complex of the third and fourth amino acid sequences emits a detectable bioluminescent signal in the presence of a substrate, and non-covalent interactions between the third and fourth amino acid sequences are not sufficient to form a complex of the third and fourth amino acid sequences in the absence of additional stabilizing and / or aggregating forces, and the stable interaction between the first amino acid sequence and the second amino acid sequence provides the additional stabilizing and / or aggregating forces to generate a stable complex of the third and fourth amino acid sequences; (b) positioning the first, second, third, and fourth amino acid sequences of step (a) under conditions that allow a stable interaction between the first amino acid sequence and the second amino acid sequence to occur; (c) detecting the bioluminescent signal emitted in the presence of a substrate by the stable complex of the third and fourth amino acid sequences in the presence of a substrate, wherein detection of the bioluminescent signal indicates a stable interaction between the first amino acid sequence and the second amino acid sequence; A method comprising:
32. 32. The method of claim 31 , wherein attaching the first amino acid sequence to the third amino acid sequence and the second amino acid sequence to the fourth amino acid sequence comprises forming a first fusion protein comprising the first amino acid sequence and the third amino acid sequence, and forming a second fusion protein comprising the second amino acid sequence and the fourth amino acid sequence.
33. 33. The method of claim 32, wherein the first fusion protein and the second fusion protein further comprise linkers between the first and third amino acid sequences and between the second and fourth amino acid sequences, respectively.
34. 33. The method of claim 32, wherein the first fusion protein is expressed from a first nucleic acid sequence encoding the first and third amino acid sequences, and the second fusion protein is expressed from a second nucleic acid sequence encoding the second and fourth amino acid sequences.
35. 35. The method of claim 34, wherein a single vector comprises the first nucleic acid sequence and the second nucleic acid sequence.
36. 35. The method of claim 34, wherein the first nucleic acid sequence and the second nucleic acid sequence are on separate vectors.
37. 35. The method of claim 34, wherein steps (a) and (b) comprise expressing the first and second fusion proteins in a cell.
38. 1. A method for optimizing a non-emissive pair, comprising: (a) aligning the sequences of three or more related proteins; (b) determining a consensus sequence of the related proteins; (c) providing first and second fragments of three or more related proteins, the fragments being individually substantially non-luminescent but luminescent when the fragments stably interact; (d) mutating each of the first and second fragments at one or more positions, wherein the mutations change the sequences of the fragments to be more similar to corresponding portions of a consensus sequence, and wherein the mutations result in a non-emissive pair that is not a fragment of an existing protein; (e) testing the non-emissive pair for the absence of luminescence when unassociated and for luminescence when the non-emissive pair is stably associated; A method comprising:
39. The method of claim 38, wherein the non-luminescent pair exhibits one or more enhanced traits compared to the first and second fragments, the traits being selected from increased affinity for reconstitution, decreased affinity for reconstitution, enhanced expression, increased intracellular solubility, increased intracellular stability, and increased intensity of reconstituted luminescence.
40. A detection reagent comprising: (a) a polypeptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity with SEQ ID NO:440, wherein when the polypeptide is contacted with a peptide consisting of SEQ ID NO:2, in the presence of a substrate, a detectable bioluminescent signal is generated; and (b) a substrate for a bioluminescent complex generated by the polypeptide and the peptide consisting of SEQ ID NO:
2.
41. A detection reagent comprising: (a) a peptide comprising an amino acid sequence having less than 100% and more than 40% sequence identity with SEQ ID NO:2, wherein when the peptide is contacted with a polypeptide consisting of SEQ ID NO:440, in the presence of a substrate, a detectable bioluminescent signal is generated; and (b) a substrate for a bioluminescent complex generated by the peptide and the polypeptide consisting of SEQ ID NO:440.
Citation Information
Patent Citations
New luciferase and photoprotein
JP2002320482A
Novel coelenterazine substrates and methods of use
WO2012061529A1
Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
WO2012061530A2
